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Summary
The studies described in this thesis investigated the haemodynamic response to 
initiation of therapy with a number of angiotensin converting enzyme inhibitor agents in 
patients with heart failure. The studies were designed to: (i) define differences among agents 
in terms of the haemodynamic response to initiation of therapy (ii) investigate possible 
mechanisms for observed differences among agents in this regard (iii) investigate the 
relationship between plasma concentration of ACE inhibitor agent and the blood pressure 
response, and (iv) investigate the relationship between baseline clinical and physiological 
variables and the blood pressure response.
Differences were observed among ACE inhibitor agents in terms of the blood pressure 
response to initiation of therapy. While similar blood pressure responses were observed to 
single oral doses of the ester prodrug ACE inhibitors enalapril and quinapril, the blood 
pressure response to oral perindopril did not differ from that seen with placebo.
Two possible mechanisms, steric hindrance and ’’slow, tight binding", for the observed 
differences were explored using assay of both plasma ACE inhibition and relative 
concentrations of angiotensin I and angiotensin II. No evidence for either mechanism was 
gained from these studies.
Using pharmacodynamic/pharmacokinetic modelling a direct linear relationship 
between the pharmacodynamic effect and plasma drug concentration was derived. Marked 
interindividual variability was apparent in the blood pressure response to oral initiation of ACE 
inhibitor therapy. The blood response was more consistent when interindividual 
pharmacokinetic differences were minimised by intravenous dosing.
No consistent relationship could be identified between any single baseline physiological 
variable and the blood pressure response. The strongest relationship was with baseline mean
16
arterial blood pressure. Forward stepwise regression analysis was used to identify the best 
combinations of predictive variables. The best of these, containing the variables, mean arterial 
pressure, plasma renin activity, 1/creatinine concentration, age and the ACE inhibitor agent, 
could explain approximately 25% of the variability in blood pressure response.
In conclusion, differences in the individual blood pressure responses to initiation of 
ACE inhibitor therapy in CHF appear to be largely dependent upon interindividual 
pharmacokinetic differences. Accurate prediction of the blood pressure response to initiation 
of therapy is not possible using readily available laboratory and clinical criteria.
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CHAPTER 1
INTRODUCTION
The recognition of the therapeutic benefits of vasodilatation in general and the 
angiotensin converting enzyme (ACE) inhibitors in particular in congestive heart failure 
(CHF) represents one of the major medical advances of the second half of the 20th 
century. The burgeoning costs of health care has over the same period seen the advent of 
the practice of evidence based medicine, ie the application of the results of large 
randomised controlled clinical trials to the everyday practice of medicine. In this regard the 
case for the use of angiotensin converting enzyme inhibitors is established beyond doubt.
In spite of the evidence of their benefit in CHF, large numbers of patients who might 
benefit are currently not prescribed an ACE inhibitor.
A number of case reports and the results of one controlled study have led to 
physicians concerns of the potential harm they may do by initiating therapy with these 
agents including first-dose hypotension. However the true extent of the phenomenon and 
its origins are unclear. The available evidence suggests that the name "first-dose" 
hypotension is inappropriate and that the blood pressure response to a given agent is 
consistent within the one individual.
The studies described here explore apparent differences among ACE inhibitor 
agents in terms of the blood pressure response to initiation of therapy in patients with 
stable CHF. A series of studies in elderly patients with CHF are described. The possible 
mechanisms of the inter-agent differences are investigated via comparison of the 
haemodynamic and neurohormonal profiles to initiation of therapy with a number of 
agents administered orally or intravenously. The potential use of a specific assay of
18
circulating levels of angiotensin peptides for the assessment of the level of activity of the 
renin angiotensin system is explored.
Much has been made of the possible predictive factors of the extent of the blood 
presure fall in response to ACE inhibition. A systematic analysis of the relationship of a 
large number of routinely available clinical and laboratory parameters on the one hand, and 
the blood pressure response on the other, in a population of patients with mild to moderate 
CHF is described.
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CHAPTER 2
THE PATHOPHYSIOLOGY AND THERAPY OF CONGESTIVE 
HEART FAILURE
2.1 BACKGROUND
Of all the advances in medical therapy in the latter half of the 20th century, those in 
the field of the treatment of heart disease are as remarkable as any. Effective 
pharmacological treatments have altered the prognosis for both the patient with 
hypertension and the patient with ischaemic heart disease. The prolonged life expectancy 
of patients in these categories has however been accompanied by a growing awareness of 
the long-term sequelae of both hypertension and ischaemic heart disease, and in particular 
the syndrome of congestive heart failure.
Congestive heart failure (CHF) can be considered as a condition in which the heart 
fails to fulfil its role as a pump and cardiac output is insufficient to meet the metabolic 
needs of the body. The characteristic symptoms of CHF are fatigue, dyspnoea at rest or on 
exertion, accompanied by reduced exercise tolerance, and oedema (Poole-Wilson 1988). 
The accompanying signs are varied and include peripheral oedema, pulmonary oedema 
(detected clinically or radiologically), added heart sounds and cardiomegaly. Thus 
"congestive heart failure" is not simply a diagnosis but a constellation of symptoms and 
signs, a syndrome attributable to ventricular dysfunction of whatever aetiology. The 
relationship of the signs and symptoms of heart failure to underlying disturbances of 
central or peripheral perfusion, tissue metabolism and neurohormonal response is not clear 
(Editorial 1989). There is no doubt however as to the relentlessly progressive nature of
20
the condition and its accompanying morbidity and mortality (Schocken et al 1992). 
Congestive heart failure is an increasingly common condition which affects approximately 
1% of the population of Western society. An estimated further 2% of the population have 
the precursor of overt CHF, namely asymptomatic left ventricular dysfunction. Much of 
the current interest in CHF stems from the increasing awareness of the prevalence of the 
condition, and in particular the dramatic improvements in both symptoms and survival 
which are brought to the condition by vasodilator therapy in general and the angiotensin 
converting enzyme (ACE) inhibitors in particular.
2.2 THE EPIDEMIOLOGY AND DIAGNOSIS OF HEART FAILURE
2.2.1 Epidemiology
Congestive heart failure is one of the most common conditions leading to 
hospital admission in industrialised society. Estimates of the overall mortality from the 
condition are difficult to establish. Accurate diagnosis of the condition is difficult, partly as 
a result of the relatively non-specific nature of the symptoms, especially in the presence of 
concomitant pulmonary disease (Wheeldon et al 1993).
The increasing prevalence of CHF is at least partly due to the improvement in 
treatment of and survival from coronary artery disease and hypertension, and to a lesser 
extent the decreasing prevalence of valvular heart diseases. In contrast to the figures 
relating to myocardial infarction, heart failure is a growing cause of morbidity and 
mortality in most industrialised nations. In the U.S.A. the prevalence of the condition is 
put at 2.5-3 million cases with approximately 400,000 new cases annually.
The incidence of CHF is age related. In the large scale Framingham Heart Study 
study 0.3% of subjects were thought to have heart failure at admission. Over 34 years of
21
follow-up, the prevalence rate was 0.8% at 50-59 years of age compared to 9% for those 
aged over 80 years (Kannel & Belanger 1991). Under 65 years of age more men than 
women develop the condition, a pattern which is reversed for those over 75 years of age, 
in whom the rate has been estimated to be as high as 40 new cases per 1000 population 
per year (Van De Lisdonk et al 1990). The incidence increases with age: 2.8 % in those 
over 65 years, 0.06 % in those less than 65 and up to 10% in elderly subjects (Sutton 
1990, Parameshwar et al 1992, Wheeldon et al 1993). In urban areas of the U.K. a 
prevalence in the population as a whole of 0.4-2% has been reported. Studies from 
Sweden have reported prevalence rates of 2% at age 50 to 13% at 67 years of age 
(Eriksson et al 1989) and between 11% and 17% in those aged 70-75 years (Landahl et al 
1984). Similar figures have been reported from Finland, with a marked predominance of 
men in the age range 45-74 years (Remes et al 1992).
In keeping with the increased prevalence of the condition, hospitalisation rates for 
heart failure have increased in a number of industrialised societies. In the U.S.A. in 1990 
heart failure was the primary diagnosis at hospital discharge for more than 750,000 
admissions (Graves 1992). In the U.K. there are approximately 120,000 hospital 
admissions per year, representing 5% of all adult medical and geriatric admissions (Sutton 
1990, McMurray & Dargie 1992). The hospitalisation rate for heart failure in the U.S.A. 
rose from 82/100,000 in 1970 to 281/100,000 in 1990 (Ghali et al 1990). The increase in 
rate was entirely attributable to an increase in those over 55 years of age. Similar trends 
have been observed in studies in Sweden (Eriksson et al 1991) and the U.K. (Sutton 
1990). Most recently, data from the Netherlands has confirmed the increasing rate of 
hospital admissions for CHF, the total number of patients discharged with a principal 
diagnosis of heart failure increasing from 7377 in 1980 to 13022 in 1993 (Reitsma et al
22
1996).
2.2.2. The diagnosis of heart failure
The identification and appropriate treatment of patients with CHF remains 
problematic. Difficulties exist with the interpretation of the clinical (Ghali et al 1991) and 
radiological (Chakko et al 1991) manifestations of CHF. Many of the symptoms of CHF 
may be ascribable to coexisting conditions often present in the largely elderly population 
with heart failure. Few studies have attempted to address the value of various signs and 
symptoms in the diagnosis of CHF. Table 2.1 shows the relative sensitivity and specificity 
o f the common signs and symptoms of CHF in predicting the presence of the syndrome, as 
found in a series of 1300 patients undergoing cardiac catheterisation. The sensitivity of 
both symptoms and physical signs is low and although physical signs have high specificity, 
any one sign has low sensitivity (Harlan et al 1977). Thus although the presence of signs is 
often diagnostic, their absence is of little value in excluding CHF. In a large primary care 
study in the Netherlands, the presence of oedema was predictive of CHF in only 11% of 
those aged 65-74 and 27% for those > 75 years (Grundmeijer et al 1996).
In the U.K. the majority of contacts between patients with CHF and medical staff is 
with general practitioners (Wheeldon et al 1993). In this setting only half of those patients 
prescribed loop diuretics fulfil diagnostic criteria for heart failure (Clarke et al 1994). In 
the context of the proven benefits of the angiotensin converting enzyme (ACE) inhibitors 
in CHF, these agents are prescribed for less than one in five of the patients correctly 
identified as having the condition (Clarke et al 1994). Thus in spite of increasing 
awareness of CHF as a major health issue it seems that present investigation and treatment 
of the condition is inadequate.
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Table 2.1
The predictive value of symptoms and physical signs for the presence of CHF (LVEF < 40%) 
in 1306 patients undergoing cardiac catheterisation.
Sensitivity (%) Specificity (%) Positive predictive value (%)
Medical history
Dyspnoea 66 52 23
Orthopnoea 21 81 2
Nocturnal dyspnoea 33 76 26
History of oedema 23 80 22
Physical signs
Tachycardia 7 99 6
Rales 13 91 27
Oedema 10 93 3
Added heart sound 31 95 61
Elevated JVP 10 97 2
Cardiomegaly 62 67 32
(Chest X Ray)
Given the clinical difficulty of clinical diagnosis of CHF in many cases, diagnostic 
investigations are of paramount importance in the identification of patients with CHF. 
Electrocardiographic and radiological investigations have an important but limited role in 
this respect. At the present time there is no serological test or tests for the diagnosis of 
CHF. The assay of one of a number of recently identified peptide compounds such as B- 
type natriuretic peptide (Struthers 1993), various atrial natriuretic peptide fragments 
(Kelly et al 1995) or adrenomedullin (Richards et al 1996) may lead to the development of 
a screening test for CHF. Until such a test becomes available, echocardiography will 
continue to have a pivotal role in the identification of the patient with CHF and is at 
present the most appropriate initial investigation of patients with suspected heart failure. In 
spite of the fact that approximately three out of four patients with CHF are referred to 
hospital either acutely or electively, only around one third of these undergo echo­
cardiography (Clarke et al 1994). In this context it is of note that the greatest increase in 
the demand for echocardiography services has been in the area of the assessment of left 
ventricular function after myocardial infarction (Gupta et al 1995).
2.2.3 The economic importance of heart failure
Heart failure is the cause of approximately 10 % of acute hospital admissions of 
those over 65 years of age in the U.K. (McMurray & McDevitt 1990). With such 
numbers and the chronic nature of the condition with relapses requiring intermittent 
hospitalisation, CHF represents an important drain on health care resources. It is estimated 
that for each hospital admission there are 14 general practice consultations (Wheeldon et 
al 1993). The cost of CHF to the National Health Service in the U.K. has been put at 
approximately £360 million for the year 1990/91, more than 1% of the N.H.S. budget
24
(McMurray et al 1993). Almost 60% of this total was taken up by the cost of emergency 
and elective hospital admissions of patients. Similar figures have been reported for other 
European countries such as the Netherlands (Koopmanschap et al 1992).
As already discussed, CHF is a condition with a poor prognosis characterised by 
steady progression of disease interspersed with acute exacerbations. It has been estimated 
that one major determinant of the cost of CHF to the NHS is how and by whom ACE 
inhibitor therapy is initiated. Hart & McMurray have estimated that ACE inhibition 
commenced by the General Practitioner without admission of the patient to hospital results 
in a lifetime cost saving of £11 per patient treated. Initiation in hospital results in an 
estimated cost per life-year gained of £747 (Hart & McMurray 1993). However this latter 
figure still compares very favourably with that accrued from other common procedures 
(Hay et al 1991, Hart et al 1993). At a time when Health Service resources are becoming 
more scarce, the accurate diagnosis of a condition as prevalent as CHF, and its optimum 
management, has become a priority for all health care professionals. For the same reasons, 
prevention of the condition and identification at an early stage are now prime aims and 
further research into the patho-physiological mechanisms involved in CHF and potential 
therapeutic strategies are easily justifiable.
2.3 THE AETIOLOGY OF HEART FAILURE
Very few studies of therapy in CHF have stratified predisposing illness, which may 
have variable prognoses (Packer 1988). The underlying diagnoses from the Framingham 
Heart Study and the SOLVD registry are shown in Table 2.2.
Initial epidemiological studies identified chronic hypertension as the major 
predisposing risk-factor for heart failure with over three quarters of the patients in the
25
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Framingham population having been diagnosed as suffering from hypertensive heart 
disease (Kannel 1989). The risk of developing heart failure was related more strongly to 
systolic than diastolic blood pressure. Other community based studies have found 
hypertension to be a rather less common cause of CHF (Eriksson et al 1988, Parameshwar 
et al 1992, Remes et al 1992). Even within the Framingham study (Table 2.2) a significant 
proportion of this population had intercurrent ischaemic heart disease and the latter is now 
the most common condition predisposing to chronic CHF in industrialised society.
In the Studies of Left Ventricular Dysfunction (SOLVD) registry, ischaemic heart 
disease was the main underlying disease, being the predisposing factor to CHF in 74% of 
patients with an ejection fraction of < 0.45 in comparison to only 4% with 
hypertensive heart disease (Bangdiwala et al 1992). Data from U.K. studies have yielded 
broadly similar results (Sutton 1990). Valvular heart disease and cardiomyopathies 
represent a small proportion of the overall CHF population.
The presence of ischaemic heart disease, in particular a history of myocardial 
infarction is a powerful risk factor for the development of CHF (Kannel 1989). 
Hypertension with ECG evidence of left ventricular hypertrophy confers a markedly 
elevated risk (Kannel et al 1994). Diabetes appears to be a relatively greater risk factor for 
females (Ho et al 1993a). In the presence of any of the underlying aetiological conditions, 
the presence of cardiomegaly, left ventricular hypertrophy or diabetes mellitus increases 
the likelihood of developing heart failure.
2.4 PROGNOSIS
2.4.1 Morbidity and mortality
As noted above the rates of hospitalisation of patients with heart failure are
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high. One year after diagnosis, 40% of heart failure patients on the SOLVD registry had 
been hospitalised at least once. Approximately half of these admissions were for worsening 
heart failure; a further 25% were for other cardiovascular causes such as myocardial 
infarction, cardiac surgery, unstable angina, thromboembolic event and arrhythmia; the 
remainder were for non-cardiovascular reasons. Mortality from heart failure appears to be 
on the increase, even allowing for the increasing numbers of elderly people in the 
population. Heart failure was listed as the primary or a contributory factor on 230,000 
death certificates in the U.S.A. in 1988, double the number in 1970. The increase in death 
rates from heart failure has been seen in both sexes (Yusuf et al 1989). In the Framingham 
study only 25% of men and 38% of women with heart failure were alive 5 years after 
diagnosis (Ho et al 1993b). Similar figures have been reported from other studies 
(Eriksson et al 1991). The annual mortality rate among heart failure patients is 
approximately 10% (Kannel 1989) and is over 60% in those with the most severe disease 
(CONSENSUS Trial Group 1987); the one year mortality in patients with NYHAIV 
symptoms is approximately 50% compared to a similar rate at 3-5 years in mild heart 
failure (McKee et al 1971, Cohn et al 1986). More recent data suggests that the age- 
adjusted, in-hospital mortality has fallen in recent years (Reitsma et al 1996).
2.4.2 Mode of death in CHF
It is not simply the presence of left ventricular dysfunction which confers the 
increased mortality risk in CHF. From the SOLVD prevention trial it is estimated that, 
among patients with impaired left ventricular dysfunction, the development of overt heart 
failure increases the risk of death 5-fold compared to patients with similar left ventricular 
function but no clinical evidence of heart failure (The SOLVD investigators 1992).
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However it is important to note that asymptomatic left ventricular dysfunction carries an 
annual mortality of 3-4% and will progress to symptomatic disease in the majority of 
patients. Recent studies, in particular the prevention arm of SOLVD, indicate that 
substantial benefits in terms of development of symptomatic disease, reduced mortality 
and morbidity can be obtained by ACE inhibitor treatment in asymptomatic CHF (The 
SOLVD Investigators 1992). Mortality in CHF patients results from both cardiovascular 
and non-cardiovascular events (The SOLVD investigators 1991). The proportion of 
deaths attributable to cardiovascular causes increases as left ventricular ejection fraction 
falls (The SOLVD investigators 1991). The rate of mortality in CHF appears to be fairly 
consistent irrespective of the aetiology of the condition (Burgraff and Parker 1975, Cohn 
1982, Demakis and Proskey 1974) although information from large prospective studies is 
sparse in this regard.
The presence of CHF is a powerful predictor of sudden cardiac death which 
becomes increasingly common with greater severity of disease: half of patients with 
ejection fraction < 30% will die suddenly, presumably from cardiac arrhythmia, within 
three years (Packer 1985). Half of the deaths in patients with heart failure in the 
Framingham study were "sudden" (Kannel et al 1988). The reason or reasons for the 
increased risk of sudden death in CHF is not clear but a number of mechanisms related to 
myocardial structure, drug therapy, electrolyte disturbance and neurohormonal activation 
have been proposed (Packer 1987). Although the arrhythmic nature of these deaths is 
difficult to establish in most cases, there is no doubt that the incidence of ventricular 
dysrhythmia is increased in CHF. The electrophysiological changes associated with 
myocardial remodelling predispose to dysrhythmia (Hansen et al 1990). In patients with 
CHF, the incidence of rhythm disorders is increased in patients with ventricular dilatation
28
(Sogaard et al 1994). Further to this, data from a substudy of the SOLVD trial indicate 
that once left ventricular ejection fraction is reduced below 35%, the occurrence of 
ventricular dysrhythmia correlates directly with ventricular size (Koilpillai et al 1996).
2.4.3 Indicators of prognosis
Upwards of 40 variables have been identified as prognostic indicators in CHF. The 
occurrence of cardiac arrhythmias confers a worse prognosis (Middlekauf et al 1991). 
Neurohormonal criteria pertaining to increased activity of the sympathetic nervous system 
(Cohn et al 1984, Rector et al 1987), and the renin angiotensin system (Rockman et al
1989) and factors relating to electrolyte imbalance such as hypo- natraemia (Lee and 
Packer 1986) are of relevance.
Of clinical criteria, the New York Heart Association (NYHA) functional class is 
directly related to sudden death in CHF, death being much more likely for those in 
functional class IV (McKee et al 1971, Swedberg 1987, Wilson et al 1983). As the NYHA 
classification system depends upon exercise capacity for stratification, it is not 
surprising that this too is also a good predictor of prognosis in CHF, as is left ventricular 
ejection fraction (Cohn et al 1987, Gradman et al 1989). However the relationship 
between systolic dysfunction and exercise capacity is unclear for any individual patient 
(Higginbotham et al 1983, Meiler et al 1987). Plasma noradrenaline levels (Cohn et al 
1984, Swedberg et al 1990) and plasma renin activity are powerful predictors of mortality 
in severe CHF (Lee & Packer 1986). As noted above, the activity of both the sympathetic 
nervous system and renin-angiotensin system is increased in CHF. Catecholamines may be 
directly arrhythmogenic or may contribute to electrolyte disturbances in CHF (Struthers et 
al 1983). Angiotensin II may enhance sympathetic activity or may itself contribute to
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electrolyte disturbances (Horton & Biglieri 1962).
With regard to the ACE inhibitors, captopril and enalapril reduce the frequency 
and severity of ventricular arrhythmias compared to placebo (Cleland et al 1984, 1985, 
Webster et al 1985). A number of the large trials in heart failure have demonstrated a 
reduction in sudden cardiac death related to ACE inhibitor therapy (Cohn et al 1991). The 
mechanism of the improvement in mortality obtained from the ACE inhibitors in CHF 
remains unclear but may be attributable to any one, or more likely, a combination of the 
known effects of these drugs in CHF: direct antiarrhythmic effects, decreased ventricular 
volume, reduced ventricular dilatation (Konstam et al 1991), retention of potassium 
(Packer & Lee 1986), parasympathomimetic effects and reduction in myocardial interstitial 
fibrosis (Brilla et al 1991). To what extent the improvement in loading conditions or 
alternatively neuroendocrine blockade contribute to these effects of ACE inhibition is at 
present unclear.
There is conflicting evidence on the relationship of aetiology of CHF to prognosis. 
The Framingham Study suggested that CHF of ischaemic aetiology holds a better 
prognosis than "idiopathic" cardiomyopathy (Ho et al 1993a). However the VHeFT-I 
study (Cohn et al 1986) and others (Franciosa et al 1983) suggest higher mortality in 
ischaemic cardiomyopathy. Such differences may be explained by the use of different 
diagnostic criteria for the presence of coronary artery disease.
2.5 DETERMINANTS OF EXERCISE CAPACITY IN CHF
2.5.1 Systolic function
Given that exercise capacity and left ventricular ejection fraction are important 
prognotic indicators in CHF, it is perhaps surprising that indices of left ventricular function
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correlate poorly with exercise capacity (Baker 1984, Franciosa et al 1981, Meiler et al 
1987). Approximately 50% of the variance in exercise capacity in CHF can be accounted 
for by changes in maximal heart rate and cardiac output at peak exercise (Myers & 
Froelicher 1991), leaving 50% unaccounted for. In CHF, a downward shift occurs in the 
Frank-Starling curve relating stroke volume to left ventricular preload. Any increase in 
preload such as occurs in exercise is not met with a sufficient rise in stroke volume, a 
defect which leads eventually to left ventricular dilatation, increased afterload, increasing 
pulmonary venous pressure, and right ventricular dilatation and failure. Treatment of 
systolic dysfunction is therefore based on reducing preload with diuretics and venodilator 
agents, reducing afterload with arterial vasodilators and to a lesser extent improving 
myocardial contractility, for example with inotropic agents.
2.5.2 Diastolic function
A significant proportion of patients with symptoms of heart failure have normal 
resting left ventricular systolic function, accounting for up to one third of referrals to 
specialist centres in the U.S.A. (Dougherty et al 1984, Marantz et al 1988). This implies 
that diastolic filling abnormalities may be relevant to the disease state in many patients and 
agrees with the finding of a close association between indices of ventricular filling and 
exercise tolerance in heart failure (Higginbotham et al 1983, Szlachcic et al 1985). In 
patients with ischaemic heart disease and mild to moderate systolic dysfunction there is a 
strong association between exercise capacity and diastolic filling abnormalities during 
exercise (Lele et al 1996). The abnormal LV diastolic filling of CHF is characterised by 
heterogeneity of mitral valve inflow patterns (Lavine & Arends 1989). In patients with 
CHF, Doppler flow pattern across the mitral valve is a better predictor of symptomatic
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status than left ventricular ejection fraction (Xie et al 1996). Both the above studies 
confirmed a poor association between either resting or exercise indices o f systolic function 
and exercise tolerance.
In patients with ischaemic heart disease (Nonogi et al 1989) and dilated 
cardiomyopathy (Sato et al 1993) there is an abnormal upward shift in the diastolic 
component of the left ventricular pressure/volume relationship during exercise. Although 
the ventricle with isolated diastolic dysfunction can increase stroke volume, reduced 
ventricular compliance leads to limitation of cardiac output during periods of rapid 
ventricular filling as occurs during exercise. The level of diastolic dysfunction may be 
fixed, in the case of myocardial fibrosis or myocyte hypertrophy (Grossman 1990) or may 
be exacerbated by myocardial ischaemia (Carroll et al 1988). Myocardial ischaemia results 
in a marked reduction in the rate of isovolumic relaxation as a result of reduced intra­
cellular levels of cyclic AMP. In patients with exercise induced ischaemia, abnormalities of 
diastolic function occur earlier than those of systolic function (Feldman et al 1987). 
Changes in filling pressure on the right side of the heart relate to improvements in exercise 
tolerance (Wilson & Ferraro 1982) and high ventricular filling pressure has been related to 
the reduction in exercise capacity (Pouleur et al 1990). The improvement in exercise 
capacity seen with the beta-adrenoreceptor agonist xamoterol in the study of Pouleur was 
associated with an improvement in the diastolic pressure-volume curve.
All of the disease states commonly associated with CHF will, if inadequately 
treated, lead to reductions in ventricular compliance associated with diastolic dysfunction. 
As recently reviewed, the identification and interpretation of parameters of diastolic 
dysfunction is difficult and complex (Brecker & Gibson 1996). With particular regard to 
the ACE inhibitors, interest in the future will centre on whether these drugs can improve
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Table 2.3
Factors affecting exercise capacity in CHF.
Central mechanisms
Systolic function 
Diastolic function 
Pulmonary haemodynamics
Peripheral factors
Regional blood flow abnormalities 
Skeletal muscle abnormalities 
Vasodilatory limitation
Pulmonary factors
Ventilation-perfiision mismatch 
Physiological dead space 
Pulmonary artery pressure 
Respiratory control
exercise capacity and prognosis in patients with isolated diastolic dysfunction, given their 
proven efficacy in all degrees of symptomatic and asymptomatic systolic dysfunction.
2.5.3 Pulmonary function and haemodynamics
Abnormalities of respiratory function are found in a significant proportion of CHF 
patients. In a large series of patients being evaluated for heart transplantation, abnormal 
respiratory function tests were found in 67% (Wright et al 1990). Abnormalities of 
diffusion capacity, forced expiratory volume (FEV,), the ratio of FEV, to vital capacity 
(VC), minute ventilation and airway flow have been described. Respiratory function is 
often normal at rest with changes taking place during exercise. Indeed cardiopulmonary 
exercise testing allows accurate assessment of maximal exercise capacity in CHF (Weber 
& Janicki 1985). Maximal oxygen uptake during exercise (V 02 max) is a strong predictor 
of prognosis (Cohn et al 1987).
A number of variables, such as resting pulmonary capillary wedge pressure, resting 
mean pulmonary artery pressure and resting total pulmonary resistance have been reported 
to correlate better with V 02 max than any systemic haemodynamic parameter (Franciosa 
et al 1985). Other studies have failed to find any correlation between peak pulmonary 
wedge pressure during exercise and exercise tolerance (Fink et al 1986). Pulmonary 
hypertension is an adverse prognostic factor in CHF and exercise capacity is increased by 
improvements in pulmonary haemodynamics (Pellicia et al 1993). However there is no 
correlation between pulmonary haemodynamic measurements and the ventilatory response 
to exercise (Fink et al 1986). It has been proposed that a minimum level of cardiac output 
in response to exercise is necessary to perfuse all areas of the lungs to prevent 
ventilation/perfusion mismatch (Davies et al 1992).
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Compared to normal individuals, increased ventilation relative to workload 
(Sullivan et al 1988) is seen in patients with CHF and a high ratio of minute ventilation to 
C 02 production (VE/VC02) reflects the higher than normal ventilatory cost of C 02 
excretion during exercise (Buller & Poole-Wilson 1990, Lewis et al 1992). This increase 
in turn reflects a degree of ventilation/perfusion mismatch (Buller & Poole-Wilson 1990, 
Davies et al 1991). The VE/VC02 slope is inversely related to exercise tolerance and to 
V 02 max (Buller & Poole-Wilson 1990) but appears not to correlate with haemodynamic 
variables (Fink et al 1986, Sullivan et al 1988). A subgroup of patients with CHF appear to 
have a high VE/VC02 ratio at rest, implying improvement of the expected ventilation- 
perfusion mismatch (Wada et al 1993). However impairment of the ability to maintain 
ventilation-perfusion matching on exercise appears to exist (Uren et al 1993a), perhaps 
due to the enhanced state of matching at rest. Although V 02 max predicts prognosis in 
CHF, the clinical applicability of this measure is limited by the inability of a great many 
CHF patients to achieve V 02 max. Recently changes in the VE/VC02 ratio with early 
exercise have been shown to correlate with V 02 max and thus serve as a predictor of the 
severity of CHF (Milani et al 1996). Moreover, these investigators demonstrated that a 
reduction in the VE/VC02 ratio of < 10% during early exercise predicts severely impaired 
functional capacity.
The VE/VC02 slope in patients with CHF has been compared to that in patients 
with coronary artery disease and normal resting left ventricular function, pacemaker 
dependent patients, and normal controls (Banning et al 1995). Patients with normal left 
ventricular function at rest all had exercise induced myocardial ischaemia and dysfunction 
comparable to that of the CHF patients. While the expected high VE/VC02 slope during 
exercise was apparent in the CHF patients, the slope in the patients with ischaemic heart
disease was normal. This suggests that the ventilation/perfusion mismatch in CHF is not 
due to acute limitation of pulmonary blood flow during exercise. Moreover, in pacemaker 
dependent patients with left ventricular dysfunction, the abnormal VE/VC02 slope was 
increased further if the exercise induced increase in cardiac output was limited by fixed 
rate as opposed to rate responsive pacing. Such dependence on heart rate was not seen in 
pacemaker dependent patients with normal LV function. This latter finding is not 
consistent between studies, the VE/VC02 ratio being reported as abnormal in pacemaker 
dependent patients with apparently normal LV function (Tani et al 1992).
There is no doubt that acute broncho spasm occurs in patients with acute 
pulmonary oedema and resolves with resolution of the oedema. Inhaled broncho dilators 
appear to improve FEV, and V 02 max (Uren et al 1993b) although some investigators 
have been unable to show such a response (Moore et al 1993). However in treated CHF 
abnormalities of airway function persist. The reduction in FEV, and VC parallels the 
severity of the patients' symptoms (Puri et al 1994) and FEV, correlates well with V 02 
max. The bronchoconstrictor response to inhaled methacholine in patients with CHF is 
abolished by inhalation of the vasoconstrictor methoxamine (Cabanes et al 1989). It has 
thus been suggested that high left ventricular filling pressure causes transudation of plasma 
from bronchial wall vessels thereby causing bronchial hyper-responsiveness.
In summary,abnormalities of both pulmonary haemodynamics and airway function 
exist in CHF. These appear to represent the consequences of alterations in pulmonary 
ventilation-perfusion relationship at rest, chronic changes in bronchial blood vessel 
structure, altered airway function, and impaired ability of the cardiorespiratory unit to 
respond appropriately to the stimulus of exercise.
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2.5.4 Regional blood flow
Cardiac output is reduced in CHF both at rest and during exercise (Sullivan et 
al 1989, Weber & Janicki 1985). Marked abnormalities occur in regional blood flow, 
the degree of disturbance being directly related to the severity of CHF (Zelis & Flaim 
1982). Flow to the coronary and cerebral vasculature is preserved longest but during 
exercise there is an early reduction of flow to the skeletal muscle circulation (Zelis & Flaim 
1982). Blood flow to exercising tissue is disproportionately reduced in CHF 
(Sullivan et al 1989).
2.5.5 Skeletal muscle abnormalities
Although a number of skeletal muscle abnormalities occur CHF, such changes are 
also seen in muscles deconditioned for reasons other than heart failure (Kayanakis 1989). 
The finding that V 02 max and anaerobic threshold improve after cardiac transplantation 
has been taken by some authors to indicate that the skeletal muscle abnormalities in CHF 
are secondary to altered central haemodynamics (Davies 1993) and by others to indicate 
"localised deconditioning" unrelated to reduced cardiac output (Myers et al 1991). While 
some studies have demonstrated impaired vasodilatory reserve in CHF (Le Jemtel et al 
1986, Zelis et al 1968), others have suggested that the failure of skeletal muscle blood 
flow to increase during exercise is due to a reduction in the driving pressure rather than to 
limitation of vasodilatation (Wilson et al 1986, 1988).
Closely allied to the changes in regional blood flow seen in CHF are alterations in 
skeletal muscle biochemistry. Phosphorous-31 magnetic resonance imaging (31P-MRI) 
has been used to study the biochemistry of working muscle. In patients with CHF the rapid 
development of acidosis and depletion of skeletal muscle phosphocreatine levels have been
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observed in-vivo in comparison to controls (Massie et al 1987, Rajagopalan et al 1988). 
This and other metabolic abnormalities in CHF, such as greater glycolysis, appear not to 
be wholly explained on the basis of reduced muscle blood flow (Massie et al 1987). 
Histological studies of skeletal muscle from patients with CHF have revealed a variety of 
changes, none of which are consistent across studies. Many suggest a shift from aerobic to 
anaerobic metabolism. The changes include atrophy of type II fibres, an increased 
percentage of type II B fibres and an increased percentage of type I fibres (Drexler et al 
1992). Increased lipid content (Lipkin et al 1988) and decreased levels of mitochondrial 
enzymes (Sullivan et al 1990) are also found.
Lindsay and colleagues recently demonstrated the presence of a number of 
histological abnormalities in skeletal muscle and diaphragm biopsies from patients with 
heart failure of either ischaemic or idiopathic aetiology (Lindsay et al 1996). These authors 
used a number of monoclonal antibodies to neonatal myosin and to fast and slow myosin 
heavy chains to establish fibre type and to establish the presence of abnormal myosin. A 
number of the abnormal findings suggested fibre metaplasia and regeneration: neonatal 
myosin was present 7 of the 17 patients; a number of biopsies showed internal nuclei, 
tubular aggregates or subsarcolemmal deposits. Of particular note was the presence of 
central cores in type I fibres from 4 of 10 dilated cardiomyopathy patients and 1 of 7 with 
ischaemic cardiomyopathy. Although no consistent changes were found, it is of interest 
that abnormalities were more marked in subjects with dilated compared to those with 
ischaemic cardiomyopathy. In addition, myopathic changes were found in all muscles 
biopsied (vastus lateralis, pectoralis major and sternothyroid) but were most severe in the 
diaphragm. No such changes were seen in biopsies from patients with normal left 
ventricular function but restricted exercise capacity due to ischaemic heart disease,
suggesting that the myopathic features in the CHF patients were specific to CHF. The only 
other study to have compared the histology of skeletal muscle biopsies from patients with 
CHF of differing aetiologies failed to show any differences, although immuno-histological 
methods were not used (Mancini et al 1989).
The skeletal muscle of patients with CHF shows reduced activity of the oxidative 
enzymes citrate synthetase and 3-hydroxyacyl-CoA dehydrogenase compared to the 
muscle of normal individuals (Schaufelberger et al 1996). In the same study, muscle 
biopsies taken at maximal exercise showed increased levels of adenosine triphosphate, 
creatine phosphate and glycogen with reduced glucose and lactate concentrations. It is 
also of note that there was no correlation between haemodynamic variables and levels of 
oxidative enzymes. On the basis of their findings, the authors concluded that neither 
skeletal muscle substrate content nor lactate accumulation are limiting factors for exercise 
performance in CHF. The authors also concluded that the oxidative capacity o f skeletal 
muscle is reduced in CHF, leading to a reduction in effective muscle mass. Similar results 
were obtained in a recent study using31P magnetic resonance imaging during exercise in 
patients with CHF (Kemp et al 1996). Maximum oxidative capacity was improved by 
exercise training in this study.
Thus a plethora of abnormalities exist which may contribute to reduced exercise 
capacity in CHF. Reduced metabolic efficiency results from macroscopic and microscopic 
muscle fibre changes as well as altered mitochondrial numbers and function. Marked 
histological changes seen in the diaphragm (Lindsay et al 1996) may help to explain the 
correlation between the sensation of dyspnoea and the amount of diaphragmatic work 
performed (Mancini et al 1992). A recent study showing that the determinants of exercise 
capacity in CHF change, with the development of cardiac cachexia, from the age of the
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patient and muscle mass to peak skeletal muscle blood flow (Anker et al 1997). This 
finding may explain at least some of the disparate findings of previous studies.
2.5.6 Neurohormonal response to exercise in CHF
Relative vasoconstriction is known to exist in CHF, at least partly in response to 
the increased activity of the sympathetic nervous and renin-angiotensin systems. Elevated 
levels of noradrenaline, renin and a number of other neurohormones are associated with 
poor prognosis in CHF (Cohn et al 1984). Levels of plasma catecholamines are elevated in 
heart failure, particularly after initiation of diuretic therapy. Increases in total body (62%) 
and in cardiac (277%) noradrenaline spillover rates have been demonstrated in patients 
with severe heart failure (Kaye et al 1994). The role of elevated catecholamine levels in the 
pathophysiology of heart failure is however unclear. Little in the way of haemodynamic 
change is seen after inhibition of noradrenaline synthesis (Franciosa & Schwartz 1989). 
Sympathetic neural activity to skeletal muscle is markedly increased in CHF (Ferguson et 
al 1990) and could theoretically interfere with metabolically driven vasodilatation during 
exercise. A significant positive correlation exists between skeletal muscle sympathetic 
nervous activity and left ventricular filling pressure (Leimbach et al 1986), suggesting a 
possible role for cardiopulmonary baroreceptors in the regulation of overall sympathetic 
activity.
Down-regulation of beta-adrenergic receptors occurs in the human myocardium in 
CHF (Colucci et al 1989) and abnormal baroreceptor reflexes are apparent in animals with 
CHF (Higgens et al 1972). In contrast to the elevated levels of catecholamines at rest, the 
sympathetic response to exercise may be abnormal in CHF. For a given uptake of oxygen 
the blood pressure response in CHF is normal. However when expressed as a percentage
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of maximal oxygen uptake, the response is less than seen in normal subjects (Francis 
1987).
Activation of the renin-angiotensin system occurs in heart failure, again particularly 
after initiation of treatment with diuretics (Massie et al 1988). The importance of 
activation of this system in CHF is suggested by the efficacy of the ACE inhibitors in 
improving exercise tolerance. However the observation that vasodilators other than the 
ACE inhibitors improve exercise tolerance in CHF indicate that mechanisms other than 
inhibition of an activated renin-angiotensin system play a role. The proposed interaction 
between the sympathetic nervous system and the renin-angiotensin system may be of 
relevance and increased activity of both systems is likely to contribute to the decreased 
vasodilatory reserve in heart failure. Angiotensin II stimulates the release of noradrenaline 
from cardiac sympathetic nerves in animals (Blumberg et al 1975). However blockade of 
the renin-angiotensin system does not improve leg blood flow acutely (Wilson & Ferraro 
1985).
Data from the CONSENSUS study indicates that the degree of neuroendocrine 
activation correlates with the beneficial response to ACE inhibition in CHF. It would 
appear that exercise tolerance is limited in CHF at least partly as a result of a combination 
of abnormalities leading to skeletal muscle hypoperfusion. Exercise capacity and skeletal 
muscle oxygen utilisation do not improve immediately after an improvement in 
haemodynamics, suggesting that intrinsic abnormalities of skeletal muscle in CHF 
contribute to the limitation of exercise capacity in this condition. The observation that 
physical training improves skeletal muscle metabolism has been taken to indicate that 
muscle deconditioning is important in the reduction in exercise tolerance seen in CHF 
(Adamopoulos et al 1993).
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Activation of the sympathetic nervous system and renin-angiotensin system in CHF 
has the purpose of maintaining arterial blood pressure. As noted above, such activation is 
exacerbated by diuretic therapy. Studies of the neurohormonal response to exercise in 
CHF in the absence of diuretic therapy are rare. In a recent study, Ferrari et al studied the 
neurohormonal response to exercise and standing in response to mild exercise in patients 
with severe untreated CHF due to myocardial disease or chronic constrictive pericarditis 
(Ferrari et al 1996). These authors found that compared to normal control subjects, 
patients with CHF showed greater heart rate and plasma levels of noradrenaline, renin 
activity, aldosterone, cortisol and ANP. Levels were elevated in the patient groups both at 
rest and during gentle exercise. Similar neurohumoral responses were seen to exercise and 
to standing in both patient and control subjects. In response to exercise, patients with CHF 
due to constrictive pericarditis showed a greater rise in heart rate and those with CHF due 
to myocardial disease showed a greater rise in plasma renin activity. Thus the response to 
standing and to gentle exercise appeared to be largely normal although superimposed on 
abnormal resting conditions.
2.5.7 The effect of ACE inhibition on exercise tolerance
As reduction in exercise capacity is such a prominent symptom and exercise 
capacity an important prognostic indicator in CHF, exercise testing is often used to assess 
work capacity and the effect of intervention (medical or surgical) on this parameter. 
Changes in exercise capacity are often used as part of the assessment of the effect of 
therapy on quality of life. A number of different protocols have been used and doubts have 
been cast on the relevance of at least some of these to the impact of therapy on patients' 
incapacity during routine daily activities (Walsh et al 1995).
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There is no doubt that the ACE inhibitors improve mortality in CHF. However the 
benefit of these agents in terms of improved lifespan is modest. In many patients the main 
benefit of the use of these agents is in improved morbidity in terms of exercise capacity 
and relief of symptoms. This is particularly so for those patients with more severe CHF in 
whom the improvement in mortality from ACE inhibition can be measured on average in 
terms of a few months. It is for this reason that many clinical studies of pharmacological 
intervention in CHF have formally assessed exercise tolerance using specific exercise 
protocols. A number of studies have suggested that changes in exercise capacity following 
ACE inhibition correlate poorly with mortality and morbidity benefits, and also with 
patients’ perceptions of symptoms. In the V-HeFT II study exercise capacity was 
improved to a greater extent by the combination of isosorbide dinitrate and hydralazine 
than by ACE inhibition (Cohn et al 1991). Similarly no effect on exercise capacity was 
seen with ramipril although symptoms did improve (Gundersen et al 1994). However 
studies of the changes in exercise capacity following ACE inhibition in CHF have used a 
variety of protocols, were of a number of different designs, patient characteristics, study 
size and duration of follow up. Thus differences in the findings with regard to exercise 
capacity are perhaps unsurprising. A recent review of this area concluded that ACE 
inhibitors improve exercise capacity and symptoms in patients with CHF (Narang et al 
1996). In the vast majority of trials of ACE inhibition in CHF there was good agreement 
between the effect of therapy on both symptoms and exercise capacity. A number of 
factors including study size, duration of follow up and method of exercise testing were 
found to affect outcome. Interestingly, complex measurements of gas exchange and 
oxygen consumption appeared to add little to the simple assessment of exercise capacity 
using defined exercise protocols. From this review it appears that adequately powered
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studies with prolonged (> 4-6 months) follow up are required for the proper evaluation of 
changes in exercise capacity following intervention in CHF.
Recently the importance of the peripheral circulation and tissues to abnormalities 
of exercise capacity in CHF has become apparent. A number of central and peripheral 
abnormalities have been shown to affect exercise capacity in CHF (Table 2.3). However 
the relative importance of these factors remains largely unresolved. Moreover the relative 
importance of cardiac, pulmonary and peripheral circulation factors defining the patients 
perception of breathlessness are complex (Wasserman & Casaburi 1988).
2.6 THE TREATMENT OF HEART FAILURE
2.6.1 General
The results of clinical trials conducted over recent years have indicated that the 
progression of heart failure can be slowed by physical exercise (Coats et al 1990) resulting 
in measurable improvements in physiological abnormalities such as skeletal muscle 
metabolism (Adamopoulos et al 1993). All patients with heart failure require control of 
fluid balance. In the early stages of the disease this can be achieved by restriction of 
dietary fluid and sodium intake. Although drug treatment initially consists of the use of 
diuretics, there is now an established case for the addition of an ACE inhibitor at as early a 
stage as possible after diagnosis of CHF.
2.6.2 Pharmacological treatment of CHF
2.6.2.1 Diuretics
The use of diuretics reduces ventricular preload thereby reducing ventricular size
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and wall stress. All patients with systolic ventricular dysfunction and many with diastolic 
dysfunction will require a diuretic for management. This generally requires the use of loop 
diuretics; in more severe heart failure the combination of a loop diuretic with a thiazide 
and /or an aldosterone antagonist may be required. The efficacy of diuretics in heart failure 
depends upon adequate natriuresis, and the combination of thiazide with loop diuretic is 
especially potent in this regard.
2.6.2.2 Positive inotropic agents
All inotropic agents so far identified exert their effect by increasing the 
availability of intracellular free calcium. Two of the major classes of inotropic agent, the 
phosphodiesterase inhibitors (PDI) and the (3-adrenoceptor agonists, act to increase 
availability of the nucleotide cyclic AMP (cAMP), higher levels of which increase calcium 
influx at a given level of cell membrane depolarisation. Inotropic agents can be classified 
according to their dependence or otherwise on cAMP.
cAMP-independent inotropic agents 
Digitalis glycosides
The treatment of heart failure has long had as one of its cornerstones the use of 
the digitalis glycosides, in particular digoxin. The extent of the use of these compounds 
for the treatment of heart failure now varies widely depending on the standard practice of 
the individual physician or the accepted treatment of heart failure on a regional or national 
basis. Marked differences in patterns of its use in CHF are also seen within the same 
country. For example in the SOLVD treatment trial only 60% of CHF patients with 
ejection fraction less than 35% were receiving digoxin at entry to the study (The SOLVD
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investigators 1991). Digitalis glycosides are however relatively mild inotropic agents. 
Limited data exists in terms of the effects of digoxin on symptoms and exercise capacity in 
CHF. Published results on the effect of digoxin on exercise capacity in CHF are 
conflicting, with beneficial (DiBianco et al 1989) and neutral results (Fleg et al 1991) 
being reported. An increase in ventilatory oxygen intake following digoxin therapy has 
been reported (Sullivan et al 1989). Morisco et al have utilised ambulatory radionuclide 
monitoring to study the effect of digitalis as compared to placebo on left ventricular 
function in CHF (Morisco et al 1996). Treatment with digitalis for 3 weeks elicited 
normalisation of the heart rate response to exercise and improvements in both left 
ventricular end-systolic and end-diastolic volumes during exercise and in ejection fraction 
at rest and during exercise. Interestingly, the improvements in hamodynamic parameters 
were largely independent of changes in heart rate.
There is evidence of both short-term and sustained haemodynamic benefits of 
digoxin in CHF (Arnold et al 1980). While the drug is undoubtedly of benefit in atrial 
fibrillation, its efficacy in sinus rhythm has been questioned. A number of uncontrolled 
trials have shown that withdrawal of digoxin from patients with stable CHF does not lead 
to adverse clinical effects (Dali 1970, Fonrose et al 1974, Hull & Makintosh 1977). 
However a number of controlled trials have reached the opposite conclusion. A meta­
analysis of 7 such trials involving 617 patients with CHF in sinus rhythm found a 
significant benefit from continuation of digoxin compared to its withdrawal (Jaeschke et al
1990). These studies were limited by a number of factors, in particular by the fact that they 
studied the effects of the withdrawal of of digoxin rather than its commencement. In 
addition the applicability of the results to current practice in the treatment of CHF is 
unclear in that the patients were on the whole not receiving an ACE inhibitor. Two recent
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studies have addressed the issue of the effect of withdrawal of digoxin from the drug 
regimen of patients with stable CHF (Packer et al 1993, Uretsky et al 1993). The results of 
both trials were similar, with decreased exercise capacity and greater frequency of 
treatment failure in those patients randomised to withdrawal of digoxin. Both studies were 
however small, with 100 and 178 patients randomised. None of these trials was designed 
to study the effects of digoxin on mortality in CHF, about which concerns have been 
expressed (Yusuf et al 1992). Information on the effects of digoxin on mortality is awaited 
from the results of two ongoing clinical trials, the Digoxin Investigation Group, and V- 
HeFT III (Yusuf et al 1992).
In terms of the symptomatic improvement elicited by digoxin in CHF, positive 
inotropism may be of secondary importance to other properties of the drug. Digoxin has a 
number of effects on autonomic function, causing vagal enhancement and impairment of 
sympathetic outflow, and there is enhanced sensitivity of barorereflexes. Acute inhibition 
of the activity of the renin-angiotensin-aldosterone axis is also seen. The net result is 
vasodilatation, which is of course in itself likely to be of benefit in CHF.
Calcium-sensitising agents: vesnarinone and pimobendan
A number of agents have been identified which in addition to inhibiting 
phosphodiesterase have a variety of additional effects which may potentially explain 
their inotropic properties. Of these agents two have reached the stage of clinical trials 
in heart failure. Pimobendan (UDCG-115) increases the sensitivity of the contractile 
apparatus to calcium in vitro (Fujino et al 1988) and in heart failure decreases in 
systemic vascular resistance and MAP are seen with concomitant increases in stroke 
volume, cardiac index and heart rate (Hasenfuss et al 1989). The compound also has
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cAMP phosphodiesterase inhibiting activity. Vesnarinone has multiple effects on ion 
channels (Lathrop et al 1989, Yatani et al 1989), any of which may increase intracellular 
calcium concentration.
Although the overall experience with PDIs in CHF has been unfavourable (vide 
infra), a number of studies with each of these two compounds have produced encouraging 
results for their use in CHF. A number of small trials demonstrated a beneficial effect of 
pimobendan on exercise capacity (Katz et al 1992, Kubo et al 1992), haemodynamics 
(Hasenfuss et al 1989) and quality of life (Kubo et al 1992) in CHF. Although the larger 
Pimobendan in Congestive Heart Failure (PICO) trial confirmed the effects of this 
compound on exercise capacity, no benefits were evident in terms of quality of life and 
there was a trend towards increased mortality in the pimobendan group (The Pimobendan 
in Congestive Heart Failure (PICO) Investigators 1996). It has been suggested, on the 
basis of meta-analysis of a number of small trials, that vesnarinone may have a beneficial 
effect in CHF (Nony et al 1994). Of the 3 studies with vesnarinone, two involved a total o f 
138 patients with 1 vesnarinone and 8 placebo deaths and were insufficiently powered to 
detect a meaningful mortality difference (OPC-8212 Research Group 1990, Feldman et al
1991). In a third placebo-controlled study of vesnarinone 60mg or 120 mg daily, the 
higher dose was associated with increased mortality compared to placebo while the lower 
dose was associated with a 62% reduction in all-cause mortality (Feldman et al 1993). 
There was in addition a reduction in the rate of progression of heart failure and in quality 
of life. However the VEST trial, comparing the effect of addition of vesnarinone 30 mg or 
60 mg in CHF, was stopped early in 1996 due to increased mortality in both active 
treatment groups compared to placebo.
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cAMP-dependent inotropic agents
Phosphodiesterase inhibitors
Selective inhibitors of phosphodiesterase III (phosphodiesterase inhibitors, PDI's) 
combine positive inotropic with peripheral vasodilator properties. Many of these 
compounds produce short- and long-term haemodynamic improvement at rest and during 
exercise: this is the case for amrinone, milrinone, piroximone, and enoximone.
Unfortunately this effect has not translated into improved mortality; on the 
contrary, a number of the agents have been associated with increased mortality on long 
term treatment. Initial experience with PDI's in the treatment of CHF was in the setting of 
uncontrolled clinical trials. These on the whole demonstrated haemodynamic improvement 
but the incidence of side-efifects was often high. Reported 1-year mortality varied widely 
but was on average around 75%, comparing unfavourably with trials of standard 
vasodilator therapy in CHF (Packer & Leier 1987). In controlled trials milrinone was 
associated with a 34% increase in the risk of death from cardiovascular causes (Packer et 
al 1991). Similar results were obtained with enoximone (Uretsky et al 1990).
Flosequinan
Flosequinan, like vesnarinone, is a quinolone derivative and a weak PDI.
This drug was marketed for the treatment of CHF but withdrawn by the manufacturer 
following an increase in mortality associated with its use (Boots Company 1993). The 
inotropic effect produced by flosequinan in animal and in vitro studies is dose 
related and not apparent in the accepted therapeutic range (Yates 1991). The mechanism 
of the vasodilator effect of flosequinan is not fully understood. In isolated cardiomyocytes, 
flosequinan is chronotropic at therapeutic concentrations, positive inotropism and PDI
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activity being seen only at higher concentrations (Kelso et al 1995).
In spite of the apparent deleterious effects on mortality seen with a number of 
positive inotropic agents, significant beneficial effects on quality of life have been observed 
in a number of trials of these agents in CHF, e.g., enoximone (Cowley & Skene 1994). 
Given that the poor prognosis for heart failure, particularly in more severe cases, there 
may be a place for agents which can improve quality of life in spite of adverse effects on 
mortality.
Catecholamines
Both pi and p2 adrenoceptors are found in human myocardium, the pi subtype 
predominating in ventricular tissue. Stimulation of either subtype leads to increased cAMP 
levels via activation of adenylate cyclase. Catecholamines have a direct chronotropic as 
well as inotropic effect. Beta receptor agonists also have a lusitropic effect, i.e., they 
increase the rate of cell relaxation. While activation of the sympathetic nervous system is a 
compensatory mechanism in early heart failure, progressive sympathetic activity appears to 
have deleterious effects in the long-term. The prognosis in CHF is directly related to the 
plasma noradrenaline level at presentation (Cohn et al 1984, Francis et al 1993). Chronic 
adrenergic stimulation leads to a reduction in the number (down-regulation) of cell surface 
P-receptors. The extent of reduction is directly related to the severity of heart failure 
(Fowler et al 1986). In the myocardium, preferential down-regulation of p i receptors 
occurs.
Animal models of heart failure have demonstrated that intermittent 
sympathomimetic stimulation improves exercise capacity, reduces resting heart rate and 
improves heart rate during exercise. In addition, and perhaps significantly, plasma
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noradrenaline concentration and renin activity are reduced. Unfortunately to date it has not 
been possible to translate encouraging animal experiments into beneficial effects in human 
heart failure. Initial studies of the effects of intermittent infusion of dobutamine in CHF 
resulted in improved haemodynamic parameters, symptoms and exercise tolerance. 
However a multi-centre trial comparing intermittent inotropic therapy via weekly infusion 
of dobutamine (48 hours per week) to placebo was halted prematurely due to a dramatic 
increase in mortality with active therapy (Dies et al 1984). Infusion of dobutamine in 
animal studies was over 1-2 hours while periods of 4-72 hours have been used in man. 
Down-regulation of p-receptors occurs only with continuous receptor stimulation for 
periods of greater than 4 hours (Tohmeh et al 1980). A regime of dobutamine infusion 
(20-25 mg/kg/min) of 30 minutes duration on 4 days per week for three weeks has been 
employed inpatients with CHF (Adamopoulos et al 1995). This resulted in significant 
improvements in exercise capacity, reduction in peripheral vascular resistance and 
increases in lymphocyte p-receptor density, indicating receptor up-regulation. As in animal 
studies, plasma noradrenaline concentration fell. The observed changes mimic those seen 
in response to exercise.
Dopamine receptors (DAI) are present in the vasculature mediating arteriolar 
vasodilatation and inhibition of noradrenaline release from sympathetic nerves. The 
pharmacology of drugs acting at these receptors is complicated by alpha adrenergic 
agonism in some cases, e.g., ibopamine. Beneficial haemodynamic responses to these 
agents have been demonstrated (Dei Cas et al 1989) but haemodynamic tolerance has 
occurs after short-term intravenous administration of feldopam (Munger et al 1990) and 
down regulation of dopamine receptors with chronic usage has been postulated as a 
potential problem with these agents (Davies & Sheridan 1993). A recent placebo-
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controlled study (PRIME II) of the effect of long-term oral therapy with the dopaminergic 
agonist ibopamine, on symptoms and mortality in patients with NYHA class III or IV 
heart failure was halted prematurely due to significantly increased mortality in patients 
receiving active therapy (D. Barnett, personal communication).
2.6.2.3 Vasodilator drugs
The central problem in CHF, whatever the aetiology, is failure of the heart to 
sustain adequate organ perfusion pressure. Neurohormonal activation in response to 
heart failure, while initially acting to re-establish homeostasis, in the long term causes 
further salt and water retention, exacerbating the problem. Vasodilator therapy is used in 
an attempt to reduce cardiac pressures by reducing preload using venous vasodilators, 
afterload using arterial vasodilators, or both using drugs with mixed properties or 
combinations of agents. At the time of writing, vasodilator therapy represents a vital part 
of the effective treatment of CHF.
Arterial vasodilators
By their effect on peripheral vascular resistance, arterial vasodilators act to reduce 
left ventricular afterload. Alpha adrenoreceptor antagonists such as prazosin, while 
reducing systemic blood presure and left ventricular filling pressures acutely, do not 
sustain these beneficial haemodynamic effects with chronic use in CHF (Bayliss et al 
1985). Although a great many arterial vasodilators can be shown to have beneficial 
haemodynamic effects after acute administration to patients with CHF, the long-term 
efficacy of these drugs is related not simply to their acute haemodynamic effects. This has 
been demonstrated for the vasodilator combination of hydralazine plus isosorbide dinitrate
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compared to enalapril in the V-HeFT study. Treatment with the ACE inhibitor resulted in 
a greater improvement in mortality in spite of the vasodilator combination giving a greater 
haemodynamic response and improvement in exercise tolerance (Cohn et al 1991).
Venous dilators
Venodilatation improves cardiac function in CHF by reducing preload. The 
standard group of venodilator drugs are the organic nitrates. As in the chronic use of these 
drugs in angina pectoris, tolerance to their haemodynamic effects occurs unless a nitrate 
free period is present (Elkayam et al 1991). Notwithstanding this problem, there is no 
doubt that the nitrates are of symptomatic benefit if given in adequate dosage in CHF. It 
has been suggested that haemodynamic tolerance to nitrate preparations may be prevented 
by the concomitant administration of diuretics (Mohanty et al 1995).
Mixed vasodilators
On pathophysiological grounds an effect on both cardiac preload and afterload in 
CHF is desirable. The only vasodilator therapy shown to improve prognosis in CHF is the 
combination of the arterial vasodilator hydralazine and the venodilator isosorbide dinitrate. 
In the first Veterans Administration Heart Failure Trial, V-HeFT I, this combination was 
associated with a 28% reduction in mortality compared to placebo over a mean follow up 
period of 2.3 years (Cohn et al 1986).
One of the most recently studied drugs with both arteriolar and venous dilator 
properties is the quinolone flosequinan. This drug has been shown to have a variety of 
effects on symptoms and exercise tolerance (Pitt 1991), positive inotropism dependent 
upon dosage (Perreault et al 1991), and reduced sympathetic and enhanced 
parasympathetic tone (Binkley et al 1992). As discussed above the drug has shown an
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adverse effect on mortality in long term use and has recently been withdrawn, other 
than for use on a "named-patient" basis.
Calcium channel blockers
To date, studies of the use of calcium antagonists in CHF have been disappointing. 
The calcium antagonists are among the most effective vasodilator agents known. However 
well controlled studies with verapamil (Ferlinz & Gallo 1984), nifedipine (Elkayam et al
1990), diltiazem (Goldstein et al 1991) and minoxidil (Franciosa et al 1984) in CHF have 
shown treatment with these agents to be associated with an increased risk of death or 
worsening heart failure. The deleterious effects of the calcium antagonists may be due to 
their negative inotropic effects but activation of the sympathetic and renin-angiotensin 
systems may also play a part (Packer 1990). Newer drugs of this class may be less 
negatively inotropic (Kassis & Amtorp 1990) and in some studies have been shown to 
improve exercise capacity in patients with CHF (Dunselman et al 1989). The recently 
introduced agent lacidipine produces beneficial effects on cardiac output and peak oxygen 
consumption during exercise in comparison to placebo in patients with CHF (de Vries & 
Dunselman 1995). This was achieved without changes in heart rate or in neurohormonal 
parameters. A recent placebo-controlled study suggested that the calcium antagonist 
amlodipine may have beneficial effects on mortality and morbidity in severe CHF of non- 
ischaemic origin (Packer et al 1996). No benefit was seen in patients with ischaemic heart 
disease. Further developments are awaited but there is as yet little evidence to support the 
routine use of calcium antagonists as vasodilators in CHF.
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2.6.2A Beta adrenoceptor antagonists
As discussed above elevated levels of plasma catecholamines are associated with a 
poor prognosis in CHF and down regulation of cardiac beta receptors is known to 
occur (Bristow et al 1982). Blockade of adrenergic activity to the failing myocardium 
has theoretical benefits in terms of reduced oxygen consumption and restoration of 
receptor density towards normal. The pooled results of all clinical trials of the effect of 
beta adrenoceptor antagonists after acute myocardial infarction provide powerful evidence 
of a beneficial effect (Yusuf et al 1985). The magnitude of the effect is of the order of a 
20% reduction in mortality from long-term P-blockade after MI. There is also a similar 
reduction in nonfatal reinfarction among this group of patients. In-hospital, short-term 
p-blockade reduces early mortality by around 15% (ISIS-1, First International Study of 
Infarct Survival Collaborative Group, 1985). There appears to be little evidence of a 
greater effect of cardioselective p-blockers in this regard although it is of interest that 
those p-blockers with intrinsic sympathomimetic activity (ISA) appear relatively less 
efficacious in terms of outcome after acute MI (Yusuf et al 1985).
In spite of this evidence, the administration of a P-blocker in the setting of acute 
MI is by no means routine and the pattern of the use of these agents varies considerable 
both within and between countries. A multi-centre study studying variations in the 
treatment of acute MI in several thousand patients across 11 European countries revealed 
marked differences in the use of P-blockers in acute MI (Ketley & Woods 1995). The rate 
use of intravenous p-blockade ranged from < 1% in some countries to a maximum of 
50%, and that of oral P-blocker use at discharge from 25% to >75%. Such wide variation 
is not seen in the use of other secondary preventive measures such as aspirin.
At least some of this variation can be explained on the basis of physicians' concerns
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regarding the precipitation or exacerbation of heart failure in these patients (Braunwald et 
al 1983). The majority of trials of p-blockers following acute MI have excluded those with 
evidence of heart failure at entry. However two early studies which included such patients 
did not find any increase in mortality or in heart failure subsequent to inclusion (Balcon et 
al 1966, Clausen et al 1966). Indeed in terms of mortality the beneficial effects of 
p-blockade following MI have been shown to be greater in patients with CHF than in 
those without (Chadda et al 1986). The fear of acutely precipitating or exacerbating heart 
failure is often an overriding consideration to the physician attending the patient soon after 
acute MI, particularly where there is now unequivocal evidence of the long term benefits 
of ACE inhibition in this situation. This appears to have led to a relative decrease in the 
use of P-blockers after MI despite there being no evidence that these agents cause harm in 
the long term when there has been evidence of left ventricular dysfunction.
In addition to their efficacy in ischaemic heart disease, p-blockers have beneficial 
effects in dilated cardiomyopathy. Benefits are seen in terms of haemodynamic parameters 
(Anderson et al 1991), morbidity (Waagstein et al 1993) and mortality (Engemeier et al 
1985). Although the largest of these trials (Waagstein et al 1993) failed to show any effect 
on mortality of the p-blocker metoprolol in dilated cardiomyopathy, all other primary 
endpoints were improved by active treatment. The improvements in left ventricular 
ejection fraction, echocardiogarphic fractional shortening and ventricular volume of 12 
months of treatment with metoprolol are equivalent to those obtained with enalapril 
(Regitz-Zagrosek et al 1995).
Newer agents of the class have combined beta adrenoceptor antagonism with beta- 
2 agonist properties (celiprolol), or with alpha antagonism (carvedilol), the latter 
conferring peripheral vasodilatory properties in each case. Carvedilol in particular has
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undergone extensive investigation and early experience with its use in CHF has been 
encouraging. The drug possesses antioxidant and antiproliferative effects in smooth muscle 
which may confer beneficial cardiovascular effects (Feuerstein & Rufifolo 1995).
Carvedilol improves symptoms and both resting and exercise haemodynamics compared to 
placebo in patients with ischaemic or dilated cardiomyopathy (Das Gupta et al 1990, Krum 
et al 1995, Olsen et al 1995). A large, placebo-controlled trial of carvedilol as an adjunct 
to standard therapy in CHF has recently been terminated prematurely due to the finding of 
improved mortality with active therapy (Packer et al 1996). 1094 patients with CHF were 
randomised to receive placebo (n=398) or carvedilol (n= 696) in addition to standard 
therapy with digoxin, diuretic and ACE inhibitor. Over 6 months of follow up, mortality in 
the carvedilol group was 3.2% compared to 7.8% in the placebo group. A remarkable 
65% reduction in risk was reported as well as 27% reduction in the risk of hospitalisation 
for cardiovascular causes, and a 38% reduction in the risk of the combined end-points of 
hospitalisation or death.
The place of p-blocker therapy in the routine management of CHF is by no means 
established. As discussed above there are theoretical grounds for their use in this setting 
and the evidence from early intervention trials is very encouraging. Further studies are 
required to confirm the above findings and to explore the potential benefit of these 
compounds in patients after acute MI. At the time of writing, large clinical trials which will 
study the effects of carvedilol in patients with left ventricular dysfunction after myocardial 
infarction, carvedilol in patients with severe CHF and carvedilol or metoprolol in all grades 
of CHF, are planned.
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2.6.3 Angiotensin converting enzyme inhibitors
2.6.3.1 .The role of ACE inhibitors in the treatment of heart failure
It has been known for many years that vasodilating drugs can be used to treat the 
signs and symptoms of CHF. However it was only relatively recently that the such effects 
were parallelled by improvement in mortality compared to placebo in patients with heart 
failure. The first such trial (the Veterans Administration Cooperative Vasodilator-Heart 
Failure Trial (V-HeFT I), Cohn et al 1986) demonstrated the improved mortality from the 
combination of hydralazine and isosorbide dinitrate. Of equal interest from V-HeFT I was 
the observation that another vasodilator, prazosin, had no beneficial effect on mortality. 
The finding from a later study, V-HeFT II, that the ACE inhibitor enalapril was superior to 
the combination of hydralazine and isosorbide dinitrate in terms of the effect on mortality 
(Cohn et al 1991) has led to extensive investigation of the effects and mechanisms of 
action of the ACE inhibitors in CHF and also to a dramatic change in the practice of the 
treatment of heart failure of all grades of severity.
A consistent finding of the trials involving the ACE inhibitors in heart failure has 
been that these drugs improve mortality (Table 2.4). As discussed above, the importance 
of the ACE inhibitors in the treatment of CHF can be gauged from the fact that trials of a 
number of alternative vasodilators in CHF, while demonstrating efficacy in terms of 
symptomatic improvement, have shown increased mortality compared to placebo. This is 
true for xamoterol (The Xamoterol in Severe Heart Failure Study Group 1990), milrinone 
(Packer et al 1991), amrinone (Massie et al 1985) and flosequinan (Boots Company 1993).
Interest in the use of ACE inhibitors in CHF was kindled following the 
demonstration of the beneficial effect on mortality of the vasodilator regimen of 
hydralazine/isosorbide dinitrate (Cohn et al 1986) and a number of placebo controlled
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Figure 2.6.1:
Percentage of events in the SOLVD treatment (Top) and prevention (Bottom) trials. 
In the SOLVD events were defined as death or hospitalisation for CHF. In the 
prevention trial, events were defined as death or progress to CHF (from asymptomatic 
LV dysfunction).
trials which suggested a potential benefit from ACE inhibition (Furberg & Yusuf 1985). 
The effect of an ACE inhibitor on mortality in CHF was first studied in the CONSENSUS 
(Cooperative North Scandinavian Enalapril Survival Study) trial. Enalapril was shown to 
improve mortality in patients with severe CHF, New York Heart Association functional 
class IV (The Consensus Trial Study Group, 1987). A 31% improvement in 1-year 
mortality was observed, with additional improvements in functional class and symptoms. 
However at this time it remained common practice to restrict the use of ACE inhibitors to 
patients with severe heart failure. Uncertainty about the use of the ACE inhibitors in mild 
to moderate heart failure represented the origins of the SOLVD (Studies of Left 
Ventricular Dysfunction) trial. This study randomised patients with left ventricular 
ejection fraction of 35% or less to therapy with placebo or enalapril 2.5mg-10mg b.d. as 
tolerated. Symptomatic patients requiring standard therapy for CHF, i.e., digoxin, diuretics 
or vasodilator, were enrolled in the treatment trial, while asymptomatic patients were 
enrolled in a prevention trial run in parallel. The end points in the treatment trial were 
mortality, morbidity and hospital admissions due to heart failure, while in the prevention 
trial the end point was the prevention of or delay in development of symptomatic or overt 
CHF. Both arms of the trial demonstrated benefit from the ACE inhibitor (Figure 2.6.1). 
The treatment trial (The SOLVD investigators 1991) showed an overall reduction in all­
cause mortality of 16% and in cardiovascular mortality of 18%, both highly statistically 
significant. In the prevention trial 8% and 12% reductions in all-cause and cardiovascular 
mortalities were seen and heart failure was prevented in 37% of patients (The SOLVD 
investigators 1992).
A further trial, V-HeFT II, logically sought to compare the two vasodilator 
regimens previously shown to be superior to placebo, namely enalapril or the combination
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of hydralazine and isosorbide dinitrate (Cohn et al 1991). In spite of the fact that 
combination vasodilator therapy with hydralazine and isosorbide dinitrate resulted in a 
relatively greater improvment in left ventricular ejection fraction and exercise tolerance, 
enalapril treatment was associated with significantly greater reduction in mortality.
2.6.3.2 ACE inhibitors after myocardial infarction
The place of the ACE inhibitors in the treatment of all grades of chronic heart 
failure was established unequivocally from the results of the above studies. Studies in 
experimental animals (Pfeffer et al 1985) and also in humans (Pfeffer et al 1988,
Sharpe et al 1988) have shown that the ACE inhibitors limit the progressive dilatation of 
the left ventricle which occurs after myocardial infarction. In addition the animal studies 
demonstrated increased survival after ACE inhibition (Pfeffer et al 1985). Given that the 
degree of left ventricular dilatation after myocardial infarction is a powerful prognostic 
indicator, the logical next step was to investigate the effect of the administration of an 
ACE inhibitor shortly after myocardial infarction. A number of trials have now been 
completed in this area.
In the CONSENSUS II study (Swedberg et al 1992), 6090 patients with acute 
myocardial infarction and presenting within 24 hours of the onset of chest pain were 
randomised to receive placebo or intravenous enalaprilat lmg over 2 hours.
Maintenance ACE inhibitor therapy was with enalapril 2.5mg twice daily increasing to 
20mg once daily on day 5. No specific criteria pertaining to ejection fraction or severity of 
heart failure existed. The trial was terminated prematurely as determined by the study 
protocol when it became clear from interim analysis of the results that there was a high 
probability of no benefit from active therapy. Mortality was increased after 1 (7.2 % cf
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Figure 2.7.1:
Cumulative all-cause mortality in the ramipril and placebo groups in the 
Acute Infarction Ramipril Efficacy (AIRE) study.
6.3 %) and 6(11 % vs 10.2 %) months in the enalapril group compared to placebo and 
was higher in patients aged 70 years and over receiving enalapril. Development of 
hypotension after the first dose of ACE inhibitor was associated with increased mortality; 
17 % of those patients developing first dose hypotension after enalapril died during follow- 
up compared to 9.3 % of those not showing this phenomenon. The study did however 
demonstrate a significant reduction in the incidence of the onset of heart failure in enalapril 
treated patients (27%) compared to placebo (30%).
In the Survival and Ventricular Enlargement (SAVE) trial 2231 patients were 
recruited within 3 to 16 days of myocardial infarction (Pfeffer et al 1992). Only those 
patients with ejection fraction of 40% or less, but without overt cardiac failure were 
randomised to receive placebo or captopril, 6.25mg as a test dose followed by 12.5mg 
titrated to a maximum of 50mg three times daily. Survivors were followed for 42 months 
on average. All-cause mortality was reduced from 25% in the placebo group to 20% in the 
captopril group, a risk reduction of 19%. Risk reduction for death from cardiovascular 
causes was 21%, for the development of severe heart failure 37% and for recurrent 
myocardial infarction 25%. These effects of captopril were independent of other 
demographic or treatment variables. It is perhaps of note that no difference in mortality 
between groups became apparent until 10 months of treatment.
The third study of the effects of ACE inhibitors on mortality and morbidity 
after myocardial infarction was the AIRE (Acute Infarction Ramipril Efficacy) study . In 
this study 2006 patients were randomised to receive placebo or ramipril 2.5mg daily, 
titrated up to 5mg or down to 1.25mg as tolerated. Recruitment was within 3 to 10 days of 
myocardial infarction and mean time of follow up was 15 months. Clinical evidence of 
heart failure was necessary for recruitment, although those with severe CHF or in whom
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the open prescription of ACE inhibitor was felt clinically necessary were excluded. All­
cause mortality was reduced from 23% for those receiving placebo to 17% for ramipril, an 
observed risk reduction of 27% (Figure 2.7.1). A risk reduction of 19% for death, severe 
heart failure, recurrent MI or stroke was observed (The Acute Infarction Ramipril Efficacy 
Study Investigators, 1993).
Most recently the TRACE (The Trandolapril Cardiac Evaluation) study 
demonstrated the efficacy of the new ACE inhibitor trandolapril in patients with echo- 
cardiographic evidence of left ventricular dysfunction after acute MI (Kober et al 1995). 
Patients were randomised to trandolapril or placebo between 3 and 7 days after infarction 
and followed up for between 24 and 50 months. There was a signficant 22 % reduction in 
mortality associated with active therapy and a 39 % reduction in progression to severe 
heart failure. There was no reduction in the incidence of recurrent myocardial infarction.
The overall results of these trials are positive with regard to the benefits which may 
be accrued from the use of ACE inhibitors soon after MI. The lack of benefit from 
enalapril in CONSENSUS II is somewhat surprising given the beneficial effects of 
enalapril upon left ventricular dilatation in man and additionally on mortality in 
experimental animals after myocardial infarction. However this study differs from the other 
two discussed above in terms of the very early and intravenous administration of the ACE 
inhibitor. The duration of follow up in this study was also much shorter than in the others. 
It is also of note that the timing of ACE inhibitor commencement in both AIRE and 
TRACE, ie, not before 3 days post MI, stemmed directly from the results of the 
CONSENSUS II study.
Although the results to date of the studies of the effect of ACE inhibitors after MI
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indicate overall benefit, many questions remain unanswered. In particular it is unclear to 
which patients and at what stage in the development of heart disease physicians should be 
prescribing ACE inhibitors. Should their use be restricted to those with reduced ejection 
fraction ? Should an age limit be set ? What is the appropriate dose ? At least some of 
these questions may be answered by ongoing clinical trials.
2.6.3.3 The effect of ACE inhibition on mode of death in heart failure
As discussed above the role of the ACE inhibitors in the treatment of all grades of 
CHF and in heart failure following acute myocardial infarction has been demonstrated 
unequivocally. However the mechanism by which ACE inhibitors reduce the risk of death 
remains unclear. Some studies have ascribed the beneficial effect of ACE inhibition to a 
slowing of the progress of heart failure (Swedberg et al 1987, Yusuf 1991). A single study 
ascribed the benefit entirely to a reduction in the incidence of sudden death (Cohn et al 
1991). Others have reported a benefit in terms of both reduction in heart failure 
progression and in sudden death (Pfeffer et al 1992, Kober et al 1995).
Ascribing a mode of death in individual cases is problematic and recent studies 
have highlighted the marked inter-observer variation that occurs in this respect (Ziesche et 
al 1995). Moreover the definition of death due to heart failure is controversial, as is that 
of a sudden death. There has been little uniformity of definitions among the various 
intervention trials of heart failure treatments and few studies have attempted prospectively 
to define what constitutes a death due to heart failure (Narang et al 1996).
The AIRE study included as an end point mode of death as defined by a 
predetermined classification system (Cleland et al 1993). This study also recorded place 
and cause of death, and also events associated with death. The details of this analysis have
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recently been reported (Cleland et al 1997). Treatment with the active agent ramipril 
reduced both progression to severe resistant heart failure by 23% and the risk of sudden 
death by 30%. The incidence of death from circulatory failure was reduced by 18% 
althought his difference did not reach statistical significance. Of interest is the finding that 
over 80% of deaths classified as sudden were preceded by deterioration of the patient's 
heart failure. The analysis provided no evidence to support the hypothesis that ACE 
inhibition reduces the rate of reinfarction. The authors concluded that the main effect of 
ACE inhibition on mortality in the AIRE study was through a reduction of progression of 
heart failure. These findings are perhaps most important for highlighting the fact that most 
sudden deaths occurring in patients with heart failure after myocardial infarction occur in 
the context of worsening heart failure. There is no evidence to suggest that the same does 
not hold for sudden death in heart failure in situations other than following myocardial 
infarction.
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CHAPTER 3
THE RENIN ANGIOTENSIN SYSTEM AND ANGIOTENSIN CONVERTING
ENZYME INHIBITION
3.1 THE RENIN ANGIOTENSIN SYSTEM IN HEALTH AND DISEASE
The renin angiotensin system is ubiquitous in the vertebrate animal kingdom, and 
indeed may have a physiological role in some invertebrate species. To date it has been 
impossible to identify a unifying phylogenetic function for the system across all species. 
There is however no doubt as to its functional importance in man.
The importance of the renin-angiotensin system (RAS) in salt and water 
homeostasis was first noted by Tigerstedt and Bergman at the end of the last century.
The RAS plays a pivotal role in cardiovascular homeostasis in terms of blood pressure 
control and salt and water homeostasis. The octapeptide angiotensin II is one of the most 
powerful vasoconstrictor agents known and is formed from its precursor angiotensin I by 
the action of angiotensin converting enzyme (ACE). Angiotensin I is itself formed from its 
precursor angiotensinogen under the influence of the protease enzyme renin. The activity 
of renin is rate limiting for the formation of angiotensin I. Recently, alternative pathways 
for the generation of angiotensin II have been demonstrated (de Silva et al 1988, Okamura 
et al 1990) but their physiological importance is as yet unclear.
3.1.1. Renin
At the time of the discovery by Tigerstedt and Bergman of a pressor substance 
extracted from the renal cortex of rabbits, its significance was not clear . However the 
characteristics of the substance, which they called "renin" were well defined at this stage
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and were recognised to be those of a protein; intravenous administration elicited a pressor 
effect, the substance was destroyed by heating and did not pass through a semi-permeable 
membrane (Tigerstedt & Bergman 1898). Little research was published on the possible 
significance of these findings until the experiments over 30 years later of Goldblatt, who 
showed that clamping of the renal arteries produced sustained hypertension (Goldblatt et 
al 1934).
Renin was only purified in stable form in the 1970s. Its purification in large 
quantities from mouse submaxillary gland was described in 1982 (Misono et al 1982). 
Renin (EC 3.4.23.15) has a molecular weight of 38 kDa and belongs to the group of 
aspartyl proteases. Renin is initially produced from the gene as preprorenin, which 
undergoes post-translational processing to prorenin. The cleavage site of prorenin to renin 
is species specific; in man the activation of prorenin occurs at -Arg66-Leu67-. Renin has a 
number of characteristics which set it apart from other aspartyl protease enzymes. The 
enzyme is active at neutral pH, in contrast to the acid conditions favoured by other 
aspartyl proteases. The enzyme has marked substrate specifity, angiotensinogen being the 
only known substrate in vivo. However many body fluids contain acid pro teases at much 
higher concentrations than that of renin, and these other enzymes can contribute a 
significant proportion of the renin-like activity of tissue extracts in vitro (Naruse et al 
1981). Separation from other acid proteases is required for the accurate identification of 
renin in tissues. This may be achieved using fractionation on columns containing a-casein 
or haemoglobin or alternatively via the use of antibodies to renin. The use of renin 
antibodies has allowed the demonstration of the role of renin in blood pressure 
homeostasis in a variety of pathophysiological circumstances in a number of species, e.g., 
in spontaneously hypertensive rats (Inagami et al 1991), and salt-deplete dogs (Dzau et al
1980).
The renin-producing cells of the kidney are located in the juxtaglomerular 
apparatus (JGA). This consists of the distal afferent arteriole, the proximal efferent 
arteriole, the glomerulus, the macula densa (a specialised area of the distal tubule) and the 
Goormaghtigh cells, which lie in the area bordered by the macula densa and the two 
arteriolar portions. The function of the juxtaglomerular apparatus is thought to be the 
translation of renal tubular stimuli into changes in renin secretion and glomerular filtration 
rate. Renin producing cells are located in the media of the afferent arteriole where they 
replace the smooth muscle cells. The renin producing cells are contiguous with adjacent 
vascular smooth muscle cells, which are themselves capable of metaplastic transformation 
to renin-producing cells under conditions of chronic stimulation. Such conditions also 
stimulate the transformation of previously non-secretory JGA cells into ones containing 
renin granules. Such transformation occurs in response to stimuli which increase the 
release of renin and include: reduced renal blood flow; salt depletion; converting enzyme 
inhibition; beta-adrenergic stimulation; renal nerve activity. Acute activation of the 
system results in sodium retention secondary to increased aldosterone levels and to 
vasoconstriction secondary to increased angiotensin II concentrations. As might be 
expected, renin release is inhibited by angiotensin II.
3.1.2. Angiotensinogen
Angiotensinogen, or "renin substrate" is a 55-60 kDa glycoprotein present in 
plasma in micromolar concentrations. The human gene has been sequenced and located to 
chromosome lq4. The genetic apparatus for the production of angiotensinogen is 
possessed by a variety of tissues and, while the angiotensinogen gene is expressed in a
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number of tissues, expression within a particular organ is restricted to specific areas or cell 
types. Renal tubular cells in vitro are able to produce angiotensinogen (Yanagana et al
1991) and astrocytes appear to be the site of production in the CNS (Stometta et al 1988). 
The presence is established in cardiac tissue of DNA, mRNA for angiotensinogen and 
angiotensinogen itself (Lindpainter et al 1990).
Changes in levels of angiotensinogen take place slowly in response to a number of 
stimuli. Glucocorticoids, oestrogens, angiotensin II and thyroid hormones stimulate the 
synthesis and release of angiotensinogen (Menard et al 1983). A low salt diet increases 
angiotensinogen mRNA in aortic smooth muscle cells (Naftalin et al 1991) and in renal 
proximal tubular cells while expression in the liver is unaffected (Ingelfinger et al 1990). 
Angiotensinogen may have a role in the inflammatory process. Elevated angiotensinogen 
levels are seen in patients suffering from a number of acute conditions such as pneumonia 
and acute pyelonephritis (Nielsen & Knudsen 1987). It has been postulated that 
angiotensinogen, or its metabolite des-Ang I-angiotensinogen, may act as an inhibitor of 
proteases, and that activation of local RAS in the presence of the vasodilation associated 
with fever may act to maintain blood pressure at a local level. Currently much interest is 
focused on the possible link between the angiotensinogen gene and hypertension.
3.1.3. Angiotensin peptides
3.1.3.1 Angiotensin I
Angiotensin I is an inactive decapeptide prohormone formed from the enzymatic 
activity of renin on angiotensinogen. In man angiotensin I is formed from the N-terminal 
portion of angiotensinogen by cleavage at Leu10-Val],. Angiotensin I is degraded to 
angiotensin II by cleavage of the N terminal dipeptide His-Leu, the reaction catalysed by
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ACE.
3.1.3.2 Angiotensin II
Under physiological conditions, the conversion of angiotensin I to the active 
octapeptide angiotensin II occurs in significant amounts in the lung via the action of 
angiotensin converting enzyme located on the surface of pulmonary vascular endothelial 
cells. Due to the ubiquitous nature of ACE, formation of significant amounts of 
angiotensin II occurs across other vascular beds including those of the heart, kidney and 
spleen (Coghlan et al 1982, Campbell 1987, Oliver & Sciacca 1984).
Angiotensin II has a short half-life in vivo and is broken down by a variety of 
widely distributed angiotensinase enzymes. Catabolism occurs primarily in peripheral 
vascular beds. Angiotensin II is broken down into a number of fragments including the 
biologically active angiotensin III. Angiotensin III (des Aspr Ang II) retains approximately 
30% of the pressor activity of angiotensin II. While in man concentrations are much lower 
than those of angiotensin II (Semple et al 1976) levels of angiotensin III in other species 
are relatively much higher. In man it is generally accepted that the physiological role of 
angiotensin III is minor. The peptide may have a role as a neurotransmitter in the CNS. A 
number of other peptide fragments of angiotensin II may be formed, particularly from the 
N-terminal of angiotensin II. Whereas in some animal species these appear to biologically 
active, their physiological relevance in man is unclear.
It is now apparent that a number of non-renin angiotensinogenases exist which are 
capable of generating angiotensin I and in some cases angiotensin II directly from 
angiotensinogen (Rosenthal et al 1990). In addition, a number of enzymes exist, in 
addition to ACE, capable of converting angiotensin I to angiotensin II (Okamura et al
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1990). There is increasing evidence suggest that these pathways may be of physiological 
relevance. Firstly, such enzymatic activity can lead to generation of angiotensin II in 
sufficient quantities to elicit physiological responses. This is the case for isolated arteries 
(Bund et al 1989), isolated heart preparations (Hirakata et al 1990), and isolated perfiised 
limb vascular beds (Ideishi et al 1990). The physiological relevance of these pathways is 
further suggested by the high substrate specificity for angiotensin I of some of these 
enzymes: the major angiotensin II forming enzyme in human heart extracts is a neutral 
serine protease with a high specificity for angiotensin I (Urata et al 1990). Finally, a 
number of these enzymes are located specifically in potentially important physiological 
sites (Okamura et al 1990).
The response of vascular smooth muscle cells to angiotensin II varies from 
transient contraction to hyperplasia and hypertrophy. The nature of the response is 
governed by the intracellular pathway activated by receptor activation, and the phenotypic 
state of the cell. Transient smooth muscle cell contraction results from increased 
intracellular Ca2+, via phospholipase C mediated inositol triphosphate (IP3) generation. 
The result is activation of myosin light chain kinase via calmodulin, with resultant 
phosphorylation of myosin, and actin-myosin cross-bridge formation. Angiotensin II also 
plays a role in sustaining smooth muscle cell contraction and stimulates the receptor 
operated calcium channels which are important in maintaining increased tone.
Angiotensin II stimulates hypertrophy of vascular smooth muscle cells in vitro 
(Geisterfer et al 1988). This response appears to be dependent upon gene transcription 
(Berk et al 1989). Hypertrophy occurs in response to prolonged stimulation with 
angiotensin II. While a generalised increase in protein synthesis is seen, a preferential 
increase in the synthesis of a number of specific proteins occurs, namely actin,
tropomyosin and vimentin. In some pathological conditions, angiotensin II causes vascular 
smooth muscle cell hyperplasia. This is the case in some forms of hypertension (Paquet et 
al 1990) and after balloon angioplasty (Daemen et al 1991). In this context the increase in 
tyrosine phosphorylation (Tsuda et al 1991) and increase in proto-oncogene expression 
(Naftilan 1992) which results from angiotensin II stimulation are likely to be relevant. The 
increase in expression of platelet derived growth factor A-chain (PDGF-A), transforming 
growth factor beta (TGF-P) and basic fibroblast growth factor (FGF) are all of relevance 
to smooth muscle cell proliferation and in the context of chronic congestive heart failure 
may be relevant to the remodelling process which is of such prognostic importance in this 
condition. The relevance of the renin angiotensin system to vascular wall remodelling in 
hypertension and myocardial remodelling in CHF is implied by the effect of the ACE 
inhibitors in each condition (see Chapter 1). In hypertension, vascular smooth muscle cells 
from hypertensive animals appear to be hyper-responsive to angiotensin II. Further to this, 
angiotensin II elicits a relatively greater increase in the amount of extracellular matrix in 
smooth muscle cells from the spontaneously hypertensive rat (SHR) compared to 
normotensive animals (Scott-Burden et al 1991). In SHR, ACE inhibition with captopril is 
more effective in inhibiting vascular hypertrophy than are other antihypertensive agents, in 
spite of similar falls in blood pressure (Owens 1987).
3.1.3.3 Angiotensin II receptors
Specific angiotensin II receptors have been identified. The two major receptor 
subtypes are designated ATI and AT2. The former has been cloned and is selectively 
blocked by biphenylimidazoles such as losartan (Dup 753). The AT2 receptor is blocked 
by tetrahydro-imidazopyridines such as PD 123177.
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The ATI receptor is a 7 domain transmembrane G-protein which mediates smooth 
muscle cell contraction and aldosterone secretion as well as blood pressure and heart rate 
responses. The receptor is down-regulated in response to prolonged exposure to 
angiotensin II. The receptor appears to be coupled intracellularly to four enzymes, namely 
adenylate cyclase, phospholipase A2, phospholipase C and phospholipase D. Stimulation 
of ATI receptors in hepatocytes, adrenal zona glomerulosa cells or pituitary cells results in 
a reduction in the activity of adenylate cyclase. The coupling of the ATI receptor to 
phospholipase C (PLC) is likely to be of greater physiological significance. Receptor 
stimulation under these circumstances leads to the generation of the second messengers 
IP3 and diacyl glycerol. This in turn activates cell contraction in the short term and cell 
hypertrophy and hyperplasia in the long term. In those cell types in which the ATI 
receptor is coupled to PLC, there is also coupling to phospholipase D (PLD). This 
interaction may be important in cell growth.
While the physiological role of the AT2 receptor is unclear, evidence is 
accumulating for the existence of a physiological antagonism between the ATI and AT2 
receptors. Rogg and colleagues studied the relative numbers of angiotensin receptor 
subtypes in the atria o f patients undergoing coronary artery or heart valve surgery, and the 
relationship between receptor subtype and a number of measures of cardiac function 
(Rogg et al 1996). Angiotensin II receptors were present in high density in membranes 
from human right atrium; ATI receptors made up 33% of the population, AT2 receptors 
67%. While there was no correlation between any measure of cardiac function and total 
receptor number or affinity, the proportion of ATI receptors was higher in the atria of 
patients with normal right atrial pressure. Left ventricular ejection fraction was directly 
correlated with the proportion of ATI receptors, while right atrial pressure was inversely
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correlated with this parameter. The authors concluded that the ratio of ATI to AT2 
receptors correlates with left ventricular function and that the AT2 receptor is up- 
regulated in cardiac disease states. While ATI receptor stimulation elicits cell proliferation 
and hypertrophy, an "anti-growth" effect of cardiac myocyte AT2 receptor stimulation has 
been demonstrated (Booz et al 1995). Thus, increased expression of the AT2 subtype in 
conditions of increased cardiac filling pressure and reduced ventricular function may be 
involved in the process of myocardial remodelling. On the basis of this and other evidence 
the suggestion has been made that there exists a functional antagonism between the ATI 
and AT2 receptors (Dzau & Horiuchi 1996). This may have important implications for the 
physiological effects and therapeutic use of angiotensin II receptor antagonists: selective 
ATI receptor antagonism may, by channeling angiotensin II to AT2 receptors, have 
important but as yet ill-defined effects on the remodelling process.
3.1.3.4 Assay of angiotensin peptides
The assay of angiotensin II and the other angiotensin peptides is based upon 
sensitive radioimmunoassay techniques (Nussberger et al 1988). The low picomolar 
concentrations of angiotensin II found in the plasma of man require a sensitive assay, 
particularly where levels are suppressed, eg by ACE inhibition. There is in addition a 
significant amount of cross-reactivity of the antibody with other angiotensin peptides such 
as angiotensin I. The very short plasma half-life of angiotensin II adds a further stumbling 
block to the accurate assay of angiotensin II levels. Thus sample collection into pre-chilled 
tubes containing a mixture of proteinase inhibitors is required, with rapid freezing of 
plasma. The in-vitro generation of angiotensin I, and the conversion of angiotensin I to 
angiotensin II must be prevented. Such a situation is particularly likely to pertain during
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treatment with ACE inhibitors as a consequence of stimulation to renin secretion and high 
angiotensin I levels. At the time of writing, the separation of angiotensin by reversed- 
phase HPLC with subsequent radioimmunoassay is considered as state-of the art by 
authorities in this field. Further to this, the estimation of the ratio o f angiotensin II to 
angiotensin I can be regarded as an estimate of in-vivo ACE activity during ACE inhibition 
and may have advantages over in-vitro methods (Gorski et al 1991). The application of 
this technique to the assessment of in-vivo activity of ACE is assessed as part of this 
thesis.
3.1.4. Angiotensin converting enzyme
Angiotensin converting enzyme (ACE = kininase II = EC 3.4.15.1) was first 
characterised in horse plasma (Skeggs et al 1956). ACE is known to be a very widely 
distributed enzyme, present in plasma and in many tissues. The activity of the enzyme 
varies markedly between species and also among tissues within a single species.
The bulk of angiotensin converting enzyme is membrane bound in vivo and activity 
is found in the vascular endothelium of a number of tissues. ACE activity is higher in 
arterial compared to venous endothelial cells. Epithelial cells tend to have greater ACE 
activity than do endothelial cells: for example, the human kidney has 5-6 times more ACE 
per unit weight than does the lung (Erdos 1990). High ACE activity is also found in other 
heavily vascularised tissues such as brain and retina. ACE is also present in soluble form in 
human plasma and is also found in other body fluids such as urine, semen, CSF and 
amniotic fluid. Under physiological conditions in human plasma, angiotensin converting 
enzyme is found in concentrations of approximately 400ng/ml although concentrations 
vary according to genetic polymorphism for the ACE gene. With angiotensin I as
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substrate, the enzyme has an absolute requirement for anions, in particular chloride. ACE 
contains zinc, which has an important role in substrate binding. A relative shortage of zinc 
may result in a reduction in activity of the enzyme.
ACE is a glycoprotein of molecular weight of approximately 147 000 Da. 
Membrane bound ACE is anchored by 17 amino acid region near the C-terminus. A single 
human gene encodes for the two types of membrane bound ACE, the endothelial form (~ 
150 000 Da) and the testicular form (~ 90 Da). The shorter testicular form is produced via 
a tissue specific promoter. Its production is under the control of androgens, whereas 
production of the endothelial form appears more influenced by glucocorticoids. The 
process by which ACE appears in the plasma is poorly understood.
The endothelial enzyme is heavily glycosylated in vivo; human renal ACE contains 
approximately 25% by weight of a mixture of carbohydrates. The ratio of carbohydrate 
moieties varies in ACE from different tissues; while human lung ACE contains a majority 
of sialic acid residues, ACE from human kidney contains minimal amounts of sialic acid. 
The high proportion of sialic acid residues in lung ACE is in keeping with the putative 
origin of plasma ACE from this site, and appears to protect circulating ACE from uptake 
by hepatic lectins.
ACE contains two identical binding sites although it seems that only one active site 
is involved in enzyme activity under physiological conditions. Indeed the sites have 
different catalytic constants and patterns of chloride activation suggesting that they may 
each subserve different functions (Wei et al 1991). The enzymatic activity of the C- 
terminal domain is 3-10 times higher than that of the N-terminal domain. The activity of 
ACE is highly dependent upon chloride, although this requirement varies among 
substrates. While the conversion of angiotensin I to angiotensin II depends upon the
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presence of chloride ions, the breakdown of bradykinin proceeds at approximately 30% of 
the maximal rate in the absence of chloride. Activation of ACE by chloride probably 
results from interaction of chloride with a lysine residue at or near the active site, resulting 
in a conformational change.
There appear to be at least four functional amino acid residues at or near the active 
site of ACE. Two histidine residues and one of glutamic acid coordinate the zinc atom at 
the active site while arginine binds the C-terminal carboxyl group of the substrate; a 
tyrosine molecule donates a proton to the amine moiety of the leaving group. The binding 
site for angiotensin I also binds ACE inhibitors. The zinc ion at the active site interacts 
with negatively charged elements of ACE inhibitor drugs. ACE is capable of catalysing 
the metabolism of a variety of peptide substrates, at least in vitro: angiotensin I, 
bradykinin, opioid peptides, substance P, neurotensin, luteinising hormone releasing 
hormone and gastrin. The relevance of this capability to the situation in vivo is not always 
clear.
Assay of angiotensin converting enzyme
A variety of laboratory methods exist for the assay of ACE. These largely involve 
either the use of a radiolabelled ACE inhibitor, or enzyme kinetic methods utilising one of 
a variety of natural or, more commonly, synthetic substrates for the enzyme.
Radiolabelled ACE inhibitors have been utilised in attempts to characterise tissue 
ACE, in particular with regard to putative differences in enzyme activity and drug 
penetration to the enzyme in different tissue sites. Marked differences in enzyme activity 
and affinity have been demonstrated; in the rat relatively low ACE activity is apparent in 
the kidney compared to the enzyme from lung (Jackson et al 1986). Autoradiographic
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studies using tissue incubated with radiolabelled ACE inhibitor have localised high levels 
of ACE activity to the caudate nucleus, lung, renal cortex and adrenal medulla 
(Mendelsohn 1984).
Differences appear to exist among ACE inhibitors in terms of drug penetration to 
tissue ACE. For example perindopril inhibits renal and plasma ACE to a similar extent and 
with a similar time course, whereas inhibition of the enzyme from aorta and lung is more 
protracted but of a lesser degree (Jackson et al 1988). The relevance of such differences in 
man under physiological or pathophysiological conditions remains speculative.
The activity of ACE is routinely assessed using enzyme kinetic methods: these 
utilise as substrate either angiotensin I or, more commonly, any one of a number of 
synthetic polypeptides. The in vitro activity of ACE using angiotensin I as substrate is low. 
In addition, the presence of naturally occurring peptidases and the low sensitivity and 
specificity of the assay make the use of angiotensin I unsuitable for the routine assay of 
ACE activity. The spectrophotometric assay of hippuric acid or the spectrofluorometric 
assay of His-Leu generated from the tripeptide substrate Hip-His-Leu is one of the more 
commonly used assay methods (Cushman & Cheung 1971). Although this amino blocked 
tripeptide is resistant to the actions of aminopeptidases, the actions of His-Leu peptidases 
may lead to underestimation of ACE activity. Assay of ACE using this substrate is more 
sensitive than that using angiotensin I due to the greater activity of the enzyme with the 
synthetic substrate. A number of other amino-blocked synthetic tripeptide substrates are 
available for the assay of ACE activity. An additional number of intramolecularly quenched 
substrates have been synthesised . Assay of ACE activity using these substrates relies upon 
a change in the intensity of their fluorescence following cleavage by ACE. Finally, ACE 
activity can be assayed using hydrolysis of the carboxy terminal dipeptide of furanacrolyl-
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Table 3.1 Synthetic substrates of angiotensin converting enzyme
N-acylated tripeptides:
Hip-His-Leu
Hip-Gly-Gly
Bz-Phe-His-Leu
Furanacrolyl-blocked tripeptides:
furanacrolyl-Phe-Phe-Arg
fiiranacrolyl-Phe-Gly-Gly
Intramolecularly quenched tripeptides:
ABz-Gly-Phe^O^-Pro
BzCNO^-Gly-Trp-Gly
blocked tripeptides (Table 3.1).
3.1.5 Tissue based renin angiotensin systems
3.1.5. 1 Introduction
Until relatively recently the RAS was regarded as a purely circulating endocrine 
system, the various components of which were secreted by a number of organs. As early 
as 1964, the presence of renin in blood vessel walls was demonstrated (Gould et al 1964) 
and it is now known that the genes for components of the RAS are found in a wide variety 
of tissues (Dzau 1987). The organisation and physiological function of tissue based renin- 
angiotensin systems remains unclear.
The most direct evidence that a significant amount of angiotensin I is generated 
outside the intravascular compartment has come from studies of the metabolism of 
angiotensin peptides across various vascular beds. A number of such studies have 
demonstrated that within vascular beds, angiotensin I taken up and metabolised is replaced 
by amounts of peptide generated within the tissue. Admiraal and colleagues demonstrated 
extraction rates for angiotensin I of 47-96% in various vascular beds (Admiraal et al 1990, 
Danser et al 1992, Danser et al 1992). In spite of these high extraction rates, similar levels 
of angiotensin I were found in venous and arterial blood. These authors calculated that 20- 
30% of angiotensin I activity from limb and kidney, and 60% of that from the gastro­
intestinal circulation is generated from circulating renin. The bulk of extravascular 
angiotensin I generation appears to be due to renally derived renin. Indeed, angiotensin I is 
almost undetectable in the plasma after nephrectomy.
The evidence for local synthesis of components of the renin angiotensin system is 
overwhelming. Large amounts of renin are found in a variety of tissues, including areas of
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the CNS outside the blood-brain barrier (Bunnemann et al 1993) and in other areas, such 
as testis (Inagami 1993). The high levels seen in these sites are most unlikely to have come 
from circulating renin. In a number of tissues renin is located at an intracellular site, 
favouring local synthesis. Renin synthesis has been observed in a number of cell culture 
lines including vascular smooth muscle (Re et al 1982) and endothelial cells (Tang et al
1990). Renin mRNA has been located in a variety of tissues other than the kidney 
including heart, brain and liver. A number of studies have demonstrated the presence of 
angiotensinogen in a similar variety of tissue sites.
The role of tissue-based renin angiotensin systems is unclear although a number of 
possibilities have been suggested. To date it has proved impossible to ascribe any single 
function to tissue based systems from different organs. As many components of tissue 
RAS are expressed in the foetus, a role in development is likely (Ingelfinger et al 1988). A 
role for tissue RASs in hypertension has been postulated. In a number of strains of 
genetically hypertensive rats the renin gene locus appears to be involved in hypertension in 
spite of normal circulating renin levels (Rapp et al 1989). In a hypertensive strain of 
transgenic rat incorporating a mouse renin gene, low levels of plasma renin and 
angiotensin II are seen in the presence of high renin gene expression in particular tissues, 
namely adrenal gland and vascular tissues (Mullins et al 1990). Of note in this model is 
that, compared to control rats without the mouse gene, there is increased tissue formation 
of angiotensin peptides (Hilgers et al 1992).
The blood pressure lowering effect of ACE inhibitors in normal and low renin 
conditions has been taken as evidence for a role of tissue RASs in blood pressure control, 
as has the dissociation between the effect of renin inhibitors on blood pressure and their 
effect on the circulating RAS. The ACE inhibitors were initially thought to exert their
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physiological effects via inhibition of the enzyme in plasma. However there is a poor 
temporal correlation between the level of inhibition of plasma ACE and the haemodynamic 
effects of ACE inhibitors. This has been shown for a number of agents, for example 
captopril (Cohen & Kurz 1982), enalapril and lisinopril (Unger et al 1984). Although acute 
ACE inhibition results in a fall in plasma angiotensin II, during chronic ACE inhibition 
there occurs a reactive increase in renin with reemergence of angiotensin II generation 
(Mooser et al 1990). In addition, ACE inhibitors are effective in low renin states 
(Chatteijee & Opie 1987). Taken together this information suggests that the haemo­
dynamic effect of ACE inhibitors may be due to inhibition of enzyme at a site other than in 
plasma, or alternatively to an effect other than inhibition of ACE. Of note is that in a 
number of animal models, such as the spontaneously hypertensive rat, the magnitude of the 
effect of ACE inhibition correlates better with inhibition of tissue ACE rather than the 
circulating enzyme (Unger et al 1984, Weishaar et al 1991).
3.1.5.2 Vascular tissues
Angiotensin converting enzyme is found on the luminal surface of the endothelial 
cells o f all vascular beds. The physiological significance of ACE at this site in man is 
unclear. The enzyme has also been localised to the adventitia of the blood vessels of a 
number of species (Rogerson et al 1992) although in this context the enzyme is probably 
associated with the endothelial surface of the vasa vasorum.
Although all of the elements of the RAS have been demonstrated in the human 
vasculature, no definitive evidence of functional interaction of these elements yet exists. 
However the circumstantial evidence is strong. Campbell calculated that approximately 
80% of the total venous angiotensin I and 70% of angiotensin II is from local production
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(Campbell 1985). Similar figures have been calculated for the generation of angiotensin 
peptides in various vascular beds in man (Reams et al 1989, Schalekamp 1989). It has 
been suggested that locally produced angiotensin II may contribute to chronic 
hypertension and that circulating angiotensin II is of secondary importance to the 
autocrine and paracrine effects of that produced locally in terms of the regulation of 
vascular tone (Dzau 1988, Schalekamp et al 1989) and in blood pressure regulation (Dzau 
& Safar 1988).
As noted above the transgenic rat TGpos shows normal plasma renin activity in 
the presence of elevated vascular renin and angiotensin synthesis (Mullins et al 1990, 
Hilgers et al 1992). Although vascular renin activity in arterial tissue from rats with 
renovascular hypertension is elevated, this appears to be renally derived (Ubeda et al 
1988). Elevated angiotensinogen mRNA synthesis has been reported in experimental 
hypertension (Shioto et al 1992). Vascular ACE activity is increased in a number of animal 
models of hypertension and is associated with increased mRNA for ACE (Shioto et al
1992). Although this evidence suggests that RAS components may have roles at a local 
tissue level, functional interaction of the components of the system as a whole has not 
been demonstrated. Alternative mechanisms have been suggested by which locally derived 
angiotensin II may influence vascular tone. A number of these involve interaction with the 
sympathetic nervous system at a local level. Indeed, there is little doubt that locally derived 
angiotensin II influences autonomic nervous control of vascular tone (for review see 
Squire & Reid 1993). The location of RAS components in the adventitial layers of the 
vasculature (Rogerson et al 1992) would of course be compatible with such a role.
There is also a possible role for local RAS in influencing the structure of both 
resistance and conduit arteries. Chronic administration of a low dose of angiotensin II
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alters the structure of resistance arteries without affecting blood pressure (Griffin et al
1991). ACE inhibitors have in some studies been reported to better reverse vascular 
changes than other agents in the face of similar effects on blood pressure (Sano & Tarazi
1987). Further to this, ACE inhibition in the young spontaneously hypertensive rat results 
in a permanent reduction in blood pressure, an effect not seen in older animals (Harrap et 
al 1990). All of this evidence suggests a role for the RAS in the structural development of 
the small blood vessel. The RAS of larger blood vessels may also be important to the 
changes seen in pathological states such as hypertension. ACE inhibition improves large 
artery compliance in hypertensive subjects, an effect not seen in normotensive individuals 
(Simon et al 1985). No such improvement is seen with other antihypertensive treatments.
3.1.5.3 Cardiac tissues
While the evidence for the existence of a cardiac RAS is clear, its patho­
physiological significance is unclear. Myocardial angiotensin II receptors have been 
identified in human ventricle (Urata et al 1989). These receptors have high affinity for the 
peptide, the Kd being around InM (Baker et al 1984). The second messenger system 
appears to be the inositol triphosphate/protein kinase C system. The result of receptor 
stimulation is mobilisation of intracellular free calcium, an effect which is augmented by 
stimulation by angiotensin II of L-type calcium channels (Dosemeci et al 1988). In 
cultured myocytes, angiotensin II increases the rate of spontaneous beating (Allen et al
1988). Angiotensin II also has a positive inotropic effect (Moravec et al 1990) and acts as 
a growth factor for myocytes (Schelling et al 1991). The isolated rat heart is capable of 
converting angiotensin I to angiotensin II, a reaction which can be prevented by ACE 
inhibition (Linz et al 1986). An alternative pathway to ACE for the production of
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angiotensin II from angiotensin I exists in the human heart (Kinoshita et al 1991).
Thus activation of the RAS, for example in CHF, may theoretically result in a 
number of local effects of angiotensin II in cardiac tissues. As already noted, relative 
changes occur in the numbers of myocardial ATI and AT2 receptors in cardiac failure 
(Rogg et al 1996). While activation is adaptive in the short term, long term activation of 
the RAS appears to be deleterious. Angiotensin II causes increased contractility of cardiac 
myocytes in vitro and has a constrictor effect on coronary arteries. Angiotensin II also 
elicits cardiac myocyte hypertrophy and interstitial collagen deposition in animal models of 
hypertension (Brilla et al 1990). In animal models, intravenous infusion of angiotensin II 
produces patchy myocardial necrosis (primarily in the left ventricle) in a concentration 
related manner (Kremer et al 1981). Modulation of the RAS in such circumstances may 
therefore have important therapeutic implications for the heart (Table 3.2). As discussed 
previously, a physiological antagonism may exist between the cardiac ATI and AT2 
angiotensin II receptors (Dzau & Horiuchi 1996).
Although the above evidence suggests a possible role for the RAS in terms of 
structural and functional changes occuring in the myocardium in disease processes it is not 
clear to what extent the cardiac, as opposed to the circulating RAS, is specifically 
involved. The right side of the heart, in particular the right atrium, is the main cardiac 
site for angiotensin II production and ACE activity (Johnson et al 1989, Rosenthal et al
1987). High concentrations of ACE activity are found on the surface of the valves and 
especially in association with the coronary vasculature (Fabris et al 1989). Specific 
induction of cardiac ACE activity has been demonstrated in animal models of experimental 
heart failure (Hirsch et al 1991); ACE activity was not induced in other tissues or in 
plasma. It may be of significance that in these studies, there was a positive correlation
Table 3.2 Possible therapeutic implications of cardiac ACE inhibition
1. Myocardial hypertrophy:
- reduced left ventricular hypertrophy in hypertension
- normalised isomyosin profile
2. Congestive heart failure:
- improved mortality/morbidity compred to alternative vasodulator regimes
- activation of cardiac mRNA and angiotensin II in experimental heart failure
3. Ischaemic heart disease
- reduction of post ischaemia arrhythmias by ACE inhibitors
- benefit antagonised by angiotensin II and by bradykinin
4. Post infarct remodelling
- Improved experimental remodelling by ACE inhibitors
between the level of right ventricular ACE activity and the size of experimentally induced 
myocardial infarction. The size of myocardial infarction correlates well with the degree of 
impairment of left ventricular function (Pfeffer et al 1979). By implication the magnitude 
of activation of the cardiac RAS is related to the degree of left ventricular dysfunction. 
Such findings may be relevant to the beneficial effects of ACE inhibitors in heart failure. 
Treatment with ACE inhibitors does reduce infarct size (Ertl et al 1982) and ventricular 
remodelling (Pfeffer et al 1988, 1992; SOLVD 1992) in both experimental and clinical 
heart failure. Similarly, ACE inhibition reduces the pathological structural changes which 
occur secondary to ventricular hypertrophy (Michel et al 1988, Yoshimura et al 1989). In 
vitro studies have confirmed that cardiac ACE shows differing binding affinities for 
various inhibitors (Fabris et al 1989, vide infra). Thus the potential exists for differential 
effects among ACE inhibitors in terms of inhibition of cardiac ACE.
3.1.5.4 Pulmonary tissues
The pulmonary vasculature has long been regarded as the major site of conversion 
of angiotensin I to angiotensin II (Ng & Vane 1968, Said 1982). As in other tissues, ACE 
activity in the lung is located largely on the endothelial surface of the blood vessels. The 
enzyme is inducible, as occurs with chronic ACE inhibitor therapy (Fyhrquist et al 1982) 
and an increase in plasma ACE activity has been regarded as a marker of lung injury in a 
number of settings (Foresti et al 1989, Kelley et al 1988, Oliver et al 1989). Apparent 
inhibition of pulmonary ACE has been demonstrated after administration of ACE inhibitor. 
In such studies the time course of the hypotensive response to the ACE inhibitor 
correlated better with pulmonary as opposed to plasma ACE inhibition (Chen et al 1984). 
More prolonged inhibition of pulmonary ACE has been demonstrated following ramipril
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compared to enalapril (Unger et al 1985). In the only study to date of the trans-pulmonary 
kinetics of an ACE inhibitor, MacFadyen and colleagues attempted to define the trans- 
pulmonary uptake of perindoprilat given by intravenous infusion in patients undergoing 
cardiac catheterisation (MacFadyen et al 1991). Uptake into tissue sites would be 
expected to alter the plasma concentration time profile. In spite of the high concentration 
of ACE in lung tissue this study failed to demonstrate any significant transpulmonary 
uptake of drug. The significance of this finding is unclear.
3.1.5.5 Brain tissues
The presence of components of the RAS in the CNS has long been recognised 
although their precise functional significance is not clear. A facilitatory interaction exists 
between the RAS and the sympathetic nervous system: angiotensin II appears to enhance 
the effect of adrenergic neurotransmission at a number of sites (for review see Squire & 
Reid 1993). Most areas of the CNS are within the blood-brain barrier and as such are not 
readily accessible to either angiotensin II or to ACE inhibitors. A number of areas of the 
CNS outside the blood-brain barrier, in particular the circumventricular organs, do possess 
ACE activity and their proximity to structures such as the dorsal motor nucleus of the 
vagus nerve make these areas well placed to modulate autonomic function. Angiotensin II 
has a central pressor action, as shown in the landmark experiments of Bickerton and 
Buckley (Bickerton and Buckley 1961). This effect is mediated via increased central 
sympathetic outflow. Direct intra-cerebroventricular injection of angiotensin II elicits a 
pressor response and drinking via actions at distinct sites. Circulating angiotensin appears 
to play a role in the release of a number of pituitary hormones, in particular vasopressin 
and prolactin. All components of the RAS, including angiotensin II receptors, have been
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demonstrated in distinct areas of the CNS. The presence of mRNA for angiotensinogen 
(Dzau et al 1986) and the localisation of its expression to the astrocytes (Stometta et al
1988) has confirmed the presence of an endogenous brain RAS. A particularly high degree 
of correlation between the various components of the RAS is seen in the hypothalamus. 
Thus the possible roles for brain renin angiotensin systems include blood pressure and 
body-fluid homeostasis, regulation o f pituitary hormone release, and perhaps also as a 
local neurotransmitter.
ACE inhibitors given locally into the cerebral ventricles cause a hypotensive 
response in experimental hypertension (Sakaguchi et al 1988). The penetration of ACE 
inhibitors to areas outside the blood-brain barrier is concentration related and in 
comparative studies, some agents do not penetrate in the administered doses (Sakaguchi et 
al 1988). The relative pharmacokinetic properties of different agents may be relevant in 
this respect. However there is no conclusive evidence for a central action of ACE 
inhibitors in any pathophysiological condition.
3.1.5.6 Renal tissues
Given the importance of the kidney in salt and water homeostasis it is not 
surprising that the renal RAS has a vital role in the normal functioning of this organ. In 
phylogenetic terms the renal RAS appears to predate the appearance of species with lung 
tissue. Although the physiological role of this system is unclear it has been suggested that 
the intrarenal RAS represents a primitive volume-control apparatus. In addition to the 
endocrine function of the kidney in releasing renin in response to stimuli such as salt 
depletion, the autocrine functions of renal based elements o f the RAS are now 
increasingly seen of importance. All the elements of the RAS are known to be present in
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renal tissue. The renal content of mRNA for angiotensinogen is increased by low-salt diet, 
providing a mechanism for activation of the local RAS in response to this stimulus 
(Ingelfinger et al 1986). ACE activity is found not only in association with the renal 
vasculature but also with the tubular and interstitial tissues (Marchetti et al 1987). 
Although angiotensin I is converted to angiotensin II in the kidney, local production means 
that there is little arteriovenous gradient in angiotensin I (Admiraal et al 1990). The cells 
of the brush border of the proximal tubule contain high levels of ACE, and the fluid of the 
proximal tubules contains concentrations of angiotensin II many times higher than seen in 
plasma (Siekely et al 1990). A possible role in the control of proximal tubule sodium 
reabsorption has been suggested for the RAS in this location (Ingelfinger et al 1990).
Renin secretion from the juxtaglomerular cells is under the influence of a number of local 
factors including renal baroreceptor input, salt delivery to the macula densa, angiotensin II, 
and atrial natriuretic factor (Davis & Freeman 1976). The final response is dependent 
upon integration of the neural and hormonal input.
Angiotensin II has multiple roles in the kidney, all of which lead to salt and water 
conservation. As noted above, all the elements of the RAS have been localised to renal 
tissue, and it is generally accepted that angiotensin II is generated within renal tissue. 
Angiotensin II acts on both afferent and efferent arterioles to modulate pre- and post- 
glomerular resistance with preferential activity at the efferent side of the glomerular 
microcirculation. Angiotensin II also elicits directly contraction of the mesangial cells, 
resulting in reduction of the available filtration area and thereby of the glomerular 
ultrafiltration coefficient. Subpressor doses of angiotensin II elicit marked reduction in 
urine flow and sodium excretion, independent of changes in systemic and renal 
haemodynamics (Levens et al 1981), suggesting an action on the renal tubule. Auto­
radiographic studies have localised angiotensin II receptors primarily to renal cortical 
glomeruli and secondarily to the outer cortex. The former are down-regulated by salt 
depletion and by angiotensin II, and up-regulated by ACE inhibition. The latter receptors, 
located in the area of the proximal convoluted tubule, are up-regulated by sodium 
depletion and down-regulated by salt loading and by guanine nucleotides. Such 
distribution and properties suggest multiple intrarenal actions of angiotensin II.
The renal RAS may have a role in the development of hypertension in 
genetically hypertensive rats. In young WKY rats before the development of hypertension, 
high renal mRNA for renin, renin levels, angiotensinogen levels and angiotensin II 
concentrations have been reported. However plasma renin levels are not elevated (Samani 
et al 1989). All these parameters are normal in older WKY rats and it has been suggested 
that the overactivity of the renal RAS in the young animals is the trigger to the 
development of hypertension (Harrap 1991).
Renal artery stenosis leads to hypertension via an increase in peripheral vascular 
resistance. While in man renin is likely to be the major pathogenetic factor, plasma renin 
levels are elevated in only 50% of patients with renovascular hypertension (Grim et al 
1977). However there is a positive correlation between blood pressure and plasma 
angiotensin II levels (Brown et al 1979) and increased sensitivity to angiotensin II exists in 
the chronic phase of renovascular hypertension.
3.1.6 ACE inhibition and renal artery stenosis
Glomerular filtration depends upon differential tone between the afferent and 
efferent glomerular arterioles (Edwards 1983). The tone of these vessels is under the 
control of angiotensin II, the effect of receptor stimulation being relatively greater on the
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efferent vessel. Efferent arteriolar tone is exquisitely dependent upon angiotensin II in 
situations of low perfusion pressure (Blythe 1983). The classical example of this is in 
renal artery stenosis, although such conditions may often exist in situations of sodium 
depletion and in CHF. In early case reports of reversible renal failure in patients with reno­
vascular hypertension treated with ACE inhibitors (Farrow & Wilkinson 1979), it was 
unclear as to whether the treatment itself or the fall in blood pressure was to blame.
While the anatomical effects of stenosis of the renal artery, via clipping in 
experimental animals, are clear, the relevance of these changes to the situation in man are 
less so. This largely arises from our uncertainty about the natural history of the condition 
in man. However there is little doubt that ACE inhibition in such patients results in 
impairment of the function in the affected kidney or kidneys. In patients with unilateral 
renal artery stenosis ACE inhibition results in a fall in glomerular filtration rate (GFR) 
(Miyamori et al 1986) and creatinine clearance (Ribstein et al 1988). Compensatory 
increases occur in GFR and effective renal plasma flow in the contralateral kidney 
(Miyamori et al 1988). These changes are to some extent independent of the degree of 
blood pressure fall (Miyamori et al 1988). However any treatment which elicits a fall in 
systemic blood pressure may cause a fall in GFR in the presence of renal artery stenosis 
(Textor et al 1985).
The propensity for ACE inhibitors to elicit this effect in the presence of renal artery 
stenosis, even in the absence o f a fall in blood pressure, is a result of intrarenal effects, 
and is the basis of the diagnostic use of the captopril renogram (Geyskes et al 1987). In 
such patients the fall in blood pressure after ACE inhibition predicts the blood pressure 
response to surgical correction of the lesion (Staessen et al 1988). The reduction in renal
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function which accompanies brief ACE inhibition is reversible; a similar approach is used 
in commencing therapeutic ACE inhibition, in which renal function is routinely monitored 
during the few days after initiation of therapy.
Untreated renal artery stenosis is associated with renal artery occlusion from a 
variety of causes. The use of ACE inhibitors has been associated with an increased 
incidence of this phenomenon (Hollenberg 1983). The evidence for such an association is 
however limited. The presence of sodium depletion adds to the risk of deteriorating renal 
function with ACE inhibition, and significantly to the occurrence o f renal artery occlusion 
(Postma et al 1989). A study of the efficacy of enalapril plus hydrochloro- thiazide therapy 
compared to a regimen of timolol, hydralazine and hydrochloro- thiazide in the treatment 
of renovascular hypertension showed a relatively greater fall in systolic blood pressure 
with the regime containing the ACE inhibitor (Franklin & Smith 1985). This was at the 
expense of deterioration in renal function in 10 of 49 patients treated with enalapril 
compared to 1 of 39 treated with the alternative regime. Similarly, reduction in renal 
function in patients with renovascular disease is more likely to occur in those treated with 
a combination of ACE inhibitor plus diuretic (Hollenberg 1983).
Thus the routine treatment of renovascular hypertension with a regime containing 
an ACE inhibitor cannot be recommended. Similarly, the use of ACE inhibition in patients 
with CHF must be cautious where renovascular disease is suspected. At-risk patients will
0
include those with a history of severe hypertension, and widespread arterial disease 
including peripheral vascular disease (Salmon & Brown 1990). However some authorities 
suggest that a trial of ACE inhibition may be prudent in patients with severe hypertension 
(Hollenberg 1993), particularly in the elderly in whom the risk from uncontrolled
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hypertension is substantial.
3.1.7 Diabetic nephropathy
A number of disturbances of the RAS occur in diabetes mellitus, both type I, 
insulin dependent (IDDM), and type II, non-insulin dependent diabetes (NIDDM). No 
abnormalities are seen during the first few uncomplicated years of insulin-dependent 
diabetes. Thereafter the conversion of prorenin to renin appears to be impaired, the 
abnormality worsening as diabetic nephropathy progresses in severity (Wilson & Leutscher
1990). In patients with diabetic nephropathy plasma prorenin levels progressively increase 
through the stages of intermittent proteinuria, persistent proteinuria and overt nephropathy 
(Leutscher & Kraemer 1988) and correlate with the urinary albumin/ creatinine ratio.
While prorenin levels are often elevated, plasma renin levels are normal or low.
In diabetes the pressor response to angiotensin II is increased and the renal 
response to angiotensin II, in terms of the usual reduction in GFR and renal plasma flow, is 
blunted (Reineck & Kreisbergl983). Angiotensin II however enhances filtration fraction in 
diabetes (Bank et al 1988). Thus the loss of normal renal haemodynamic control by 
angiotensin II may play a part in the development of the hyperfiltration which is a feature 
of diabetic nephropathy. Similar changes in the components and behaviour of the RAS are 
seen in diabetes complicated by retinopathy or neuropathy, and are also seen in patients 
with non-insulin dependent diabetes. In both experimental and human diabetes, diabetic 
microangioapathy affects glomeruli and arterioles including the juxtaglomerular apparatus, 
with separation of the renin secreting cells from the macula densa. In end-stage diabetic 
renal disease, there are significantly fewer renin secreting cells, as would be expected in a
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situation of hyperfiltration of the renal microcirculation. It is not clear if the renal 
histological changes are linked to the observed abnormalities of circulating renin and 
prorenin.
The importance of proteinuria in diabetes is in its relationship to prognosis. In 
prospective studies in IDDM patients the presence of persistent microalbuminuria is a 
sensitive but non-specific marker of patients at risk of developing diabetic nephropathy. In 
the individual patient the specificity for predicting nephropathy can be improved by 
considering other factors, namely blood pressure and the degree of metabolic control. In 
patients with NIDDM the presence of microalbuminuria is a strong predictor o f mortality. 
The majority of the excess mortality seen is from cardiovascular disease (Mogensen 1984); 
indeed microalbuminuria is more strongly associated with cardiovascular death in NIDDM 
than with end-stage renal disease (Schmitz et al 1990).
A number of therapeutic strategies slow the rate of progression of diabetic 
nephropathy. These are protein restriction (Zeller et al 1991), optimal glycaemic control 
(KROC collaborative study group 1984) and the control of hypertension (Mogensen
1982). To date only the control of hypertension has been associated with improved 
mortality in addition to a reduction in the rate of deterioration of renal function (Parving et 
al 1987).
ACE inhibition in diabetic nephropathy: data from animal models
Data from experimental models of diabetes suggest that increased glomerular 
capillary pressure is important in the development of renal injury in diabetes (Hostetter et 
al 1982). Crucially, increased glomerular capillary pressure occurs in the absence of 
systemic hypertension, and renal renin appears to be involved in mediating the increase
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(Anderson et al 1990).
Studies in animals suggest ACE inhibition may provide benefits to diabetic patients 
over and above simple blood pressure control. In the normotensive, hyperglycaemic rat, 
enalapril reduces glomerular capillary pressure with no effect on glomerular filtration (Zatz 
et al 1986) and with concomitant reduction in albuminuria (Zatz et al 1987). Further to 
this, while the combination of hydralazine, reserpine and hydrochlorothiazide slows the 
development of proteinuria in diabetic rats, captopril treatment results in a similar blood 
pressure and the prevention of nephropathy (Anderson et al 1989). In this study the early 
fall in glomerular pressure seen with combination therapy was not sustained, and in spite 
of a sustained effect on blood pressure, glomerular hypertension developed late. In the 
obese Zucker rat, metabolic disturbances akin to those seen in NIDDM are seen. These 
animals show moderate hyperglycaemia, insulin resistance, hyperlipidaemia, obesity and 
hypertension from around 10 weeks of age. Elevation of blood presure is accompanied by 
progressive glomerular injury. In this model of NIDDM, enalapril reduced blood pressure, 
albuminuria and renal glomerular injury compared to control rats (O'Donnell et al 1989). 
The lack of effect of enalapril on glomerular pressure in this model may suggest that ACE 
inhibition may be renoprotective by mechanisms other than via reduced glomerular 
pressure.
ACE inhibition in diabetic nephropathy: data from human studies
Data regarding the effects of ACE inhibition on proteinuria in the early stages of 
diabetic nephropathy in man are conflicting. In one study ACE inhibition resulted in a 
reduction in urinary albumin excretion (Pedersen et al 1988). Other studies have failed to 
confirm this (Pasa et al 1987, Brichard et al 1989). In IDDM patients with incipient
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proteinuria, a number of studies have demonstrated that urinary protein excretion is 
reduced by ACE inhibition. The beneficial effect is seen irrespective of the presence of 
systemic hypertension. In normotensive patients, progression of microalbuminuria to overt 
nephropathy was prevented by enalapril, which reduced fractional excretion of albumin 
and prevented the fall in GFR which was seen in patients receiving placebo over a one year 
period (Marre et al 1988). Data from longer term studies suggests that the effect is 
sustained. In normotensive IDDM patients, captopril prevents the progression of 
microalbuminuria to overt nephropathy, i.e. albuminuria > 300mg/24 hr (Mathiesen et al
1991). A similar effect is seen in hypertensive IDDM patients and in those with type II 
diabetes (NIDDM) (Melbourne Diabetic Nephropathy Study Group 1991). In patients 
with advanced diabetic nephropathy (renal impairment, marked proteinuria and 
hypertension), ACE inhibition reduces urinary protein excretion to a similar extent to that 
seen in less severe disease (Parving et al 1988).
A number of studies comparing ACE inhibition with alternative anti- hypertensive 
therapy, primarily calcium channel blockers, have been conducted. In the Melbourne 
study, nifedipine had no effect on albuminuria in normotensive diabetic patients in contrast 
to the reduction seen with the ACE inhibitor perindopril, although this was not statistically 
significant. In hypertensive patients in this study, both drugs were associated with similar 
reductions in albuminuria, as was the case in a comparison of enalapril and nicardipine in 
hypertensive NIDDM patients (Baba et al 1989). Other studies suggest a comparatively 
better effect of ACE inhibitor compared to calcium anatagonist in normotensive IDDM 
patients with incipient nephropathy (Insua et al 1988). In advanced diabetic nephropathy 
ACE inhibition with enalapril produced a greater reduction in albuminuria than p-blockade 
with metoprolol in spite of similar blood pressure falls (Bjorck et al 1990). However
similar effects on albumin excretion have been seen in comparisons of lisinopril and 
diltiazem (Bakris 1990), captopril and nicardipine (Stomello et al 1989) and enalapril and 
atenolol (Stomello et al 1991). Angiotensin converting enzyme inhibition slows the 
progression of advanced diabetic nephropathy (Bjorck et al 1986), although the rate of 
loss may be similar with P- blockade (Bjorck et al 1990).
Thus ACE inhibition reduces urinary protein excretion in all stages o f diabetic 
nephropathy. The extent of the reduction in proteinuria correlates with the fall in blood 
pressure. In a multivariate analysis of 24 trials of ACE inhibitor treatment in diabetic 
nephropathy, Kalil et al (Kalil et al 1993) calculated that the fall in blood pressure could 
explain only 12.4% of the reduction in protein excretion. These authors postulated that 
intrarenal mechanisms, among others, may play a role in the response.
3.1.8 The renin angiotensin system in CHF
Activation of the RAS in the condition of congestive heart failure was first 
described in 1946 (Merrill et al 1946), but largely forgotten or ignored for 20 years 
thereafter. The significance of the RAS in CHF was confirmed by the effects of inhibitors 
of angiotensin II (Johnson & Davis 1973), ACE inhibitors (Freeman et al 1979), and renin 
inhibitors (Fitzpatrick et al 1990) on haemodynamic and neuro- hormonial parameters in 
the condition. At the onset of left ventricular dysfunction, plasma renin activity and 
aldosterone levels rise. As a new steady state is reached, plasma renin activity returns 
towards baseline values. The rise in plasma renin activity may be in part inhibited by 
elevated atrial natriuretic factor levels (Lee et al 1989). Thus renin levels are often normal 
in stable CHF (Francis et al 1990). Acute heart failure is associated with activation of the 
RAS and concomitantly high plasma renin levels (Dzau et al 1981). The aetiology of CHF
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does not appear to influence the magnitude of the response, although the degree of 
activation of the RAS has been suggested to be lower in high-output cardiac failure due to 
beri-beri than in low output conditions (Ikram et al 1981).
Strong inverse relationships between plasma renin levels and arterial blood 
pressure on the one hand and fractional excretion of sodium on the other suggest that the 
afferent arteriolar baroreceptor and macula densa are important in regulating renin 
secretion in CHF. Renal sympathetic nerve activity is increased in CHF in man and there is 
good correlation between plasma renin and catecholamine levels well. This suggests that 
increased renal sympathetic activity contributes to elevated plasma renin activity, and is in 
keeping with information from animal studies. Cardiac and arterial baroreceptor 
dysfunction may contribute to increased sympathetic activity. Elevated angiotensin II and 
concomitantly elevated aldosterone levels contribute to elevated total body sodium and 
reduced total body potassium in CHF. In addition there appears to be increased renal 
responsiveness to aldosterone (Barger et al 1959).
While diuretics remain the mainstay of the treatment of CHF, such therapy alone 
does not improve prognosis. Indeed, by reducing circulating fluid volume, diuretics can 
reduce ventricular filling pressure and contribute to both the activation of the RAS and the 
electrolyte disturbances seen in CHF. In the patient with mild CHF in whom there is little 
or no salt and water overload, diuretic treatment stimulates a rise in plasma renin activity. 
This contrasts with the lack of such effect with acute treatment in oedematous patients, in 
whom plasma renin may initially fall in response to natriuresis before rising as natriuresis 
diminishes (Brown et al 1970). Chronic diuretic therapy results in elevated plasma renin 
activity. In the long-term there is a correlation between maintenance diuretic dose and 
plasma renin and angiotensin II levels (Fitzpatrick et al 1985). The addition of a potassium
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sparing diuretic to chronic loop diuretic treatment elicits a brisk activation of the RAS 
(Nicholls et al 1976).
The reported effect of vasodilators on plasma renin activity in CHF is variable. 
Short-term infusion of nitroglycerin has been reported to have no effect (Packer et al 
1987b) or to elicit a moderate rise in plasma renin activity (Dupuis et al 1990). The 
available data for calcium channel blockers is likewise inconclusive. Plasma renin levels are 
stimulated by intravenous administration of digoxin (Covit et al 1983) while there is no 
effect of chronic oral therapy (Alicandri et al 1987). While dobutamine elicits a rise in 
plasma renin activity (Uretsky et al 1986), no effect is seen with dopamine (Maskin et al
1985).
There is little doubt that the RAS is of fundamental importance in the patho­
physiology of human CHF. Indeed plasma renin activity and activation of the RAS as a 
whole is one indicator of prognosis in CHF (Packer et al 1987a). The evidence for a 
central role for the RAS in the pathophysiology of CHF is compelling. In addition to a role 
in altered central and peripheral haemodynamics, the RAS has profound influence on salt 
and water homeostasis. Direct vasoconstrictor effects of angiotensin II play a central role 
in the haemodynamic changes of CHF. Correlations have been reported between a variety 
of haemodynamic variables, such as cardiac output, systemic vascular resistance and 
ventricular filling pressures, and plasma renin activity. The haemodynamic response to 
ACE inhibition and to angiotensin II receptor antagonism (Cody et al 1982) has been 
related to pre-existing activity of the RAS. The relatively weak relationship between pre­
treatment RAS activity and the haemodynamic response to ACE inhibition is one factor 
which has led to the suggestion that the RAS at one or more tissue sites may be more 
important than the circulating system in mediating the acute blood pressure response
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(Dzau 1988).
The correlation between plasma renin activity and ventricular ectopic activity, and 
the reduction in such activity seen with ACE inhibitor treatment in CHF suggest a 
potential pro-arrhythmic effect of an activated RAS. Finally it is important to note that the 
degree of activation of the circulating RAS correlates inversely with prognosis in CHF 
(Rockman et al 1989). In this respect the relative role of RAS in renal and other tissues is 
as yet unclear.
3.1.9 ACE inhibition in CHF
3.1.9.1 Haemodynamic effects
The haemodynamic effects resulting from the administration of ACE inhibitor 
therapy in patients with CHF are well described and consistent. Arterial blood pressure 
and peripheral vascular resistance fall rapidly by around 20-35%. Cardiac output rises by 
10-20%, largely due to an increase in stroke volume. Left ventricular filling pressure and 
pulmonary capillary wedge pressure, usually elevated in CHF, fall by about 40%. Regional 
circulatory changes vary among vascular beds: renal vascular resistance shows the largest 
falls, with lesser changes in the coronary, cerebral and skeletal muscle vascular beds 
(Creager et al 1981, Crozier et al 1989). It is important to note that for patients with stable 
CHF, the haemodynamic response to ACE inhibition is maintained with long-term therapy 
(Packer et al 1983). Systemic venous dilatation may be of particular benefit to patients 
with CHF. The characteristic lack of reflex tachycardia following vasodilatation with ACE 
inhibition may be accounted for by the so-called "parasympathomimetic" effects of these 
drugs (Campbell et al 1985), although inhibition of the synergy between the RAS and 
sympathetic nervous systems may be relevant (Squire & Reid 1993).
97
3.1.9.2 First-dose hypotension
In spite of the unequivocal evidence of the beneficial effect of ACE inhibition in 
CHF, a significant proportion of patients who may benefit from treatment are not 
prescribed an ACE inhibitor (Clarke et al 1994). Failure to prescribe this most appropriate 
of therapies stems at least in part from physicians’ perceptions of two potential adverse 
effects of initiation of ACE inhibitor treatment, renal impairment and first-dose 
hypotension.
The relative magnitude of the initial blood pressure response to ACE inhibition is 
greater in CHF than in patients with hypertension (Wenting et al 1982). The incidence of 
first-dose hypotension varies according to patient populations and reporting procedures, 
some studies suggesting 10-15% (Hodsman et al 1983), others 30-40% (Packer et al
1986). In patients with heart failure the incidence of symptomatic hypotension is 
approximately 5-10% (The AIRE Study Investigators 1993, The CONSENSUS Trial 
Study Group 1987); 2-5% of patients withdraw from treatment as a result. In one of the 
early intervention trials of ACE inhibitors in heart failure, the occurrence of first dose 
hypotension was considered a sufficient problem to warrant a reduction in the starting 
dose of enalapril (The CONSENSUS Trial Study Group 1987). In CONSENSUS II, 
mortality was higher among those patients who developed first-dose hypotension after 
initiation of therapy with enalapril compared to those who did not (Swedberg et al 1992). 
The incidence of significant first-dose hypotension appears to have fallen as ACE 
inhibition has been introduced much earlier in the course of CHF.
Concerns regarding first-dose hypotension relate to the risk of renal, myocardial 
or cerebral hypoperfusion which may result (Cleland et al 1985) and have led to the 
development of a number of anecdotal protocols for the introduction of ACE inhibitor
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therapy in CHF in an attempt to minimise the likelihood or duration of hypotension 
(McMurray et al 1989). Such protocols have often involved admission of patients to 
hospital for a number of days, entailing inconvenience to the patient and having resource 
implications for the physician and institution. A number of case reports have highlighted 
the potential problem (Mujais et al 1984, Cleland et al 1985).
A number of physiological and biochemical parameters have been suggested to 
identify patients at high risk of significant first-dose hypotension. Elderly patients (O’Neill 
et al 1988) and those with pre-treatment activation of the RAS (Cleland & Oakley 1991) 
are thought to be at relatively high risk. However the magnitude of the relationship 
between haemodynamic response and plasma renin activity at baseline is weak (Packer et 
al 1985) and in some well-conducted, prospective studies not apparent (Motwani et al 
1994). The long-term blood pressure response to ACE inhibition is even less well related 
to pre-treatment plasma renin activity (Packer et al 1985). It has been suggested that the 
determinants of the response to chronic ACE inhibition may differ from those determining 
the acute response (Cleland & Dargie 1987). However although the phenomenon of 
symptomatic hypotension after ACE inhibition is best recognised as occurring at initiation 
of therapy, the available evidence indicates that the blood pressure response to the first 
dose of ACE inhibitor is the same as that seen after many months of treatment in patients 
with CHF (McLay et al 1992, Packer et al 1986b).
A number of factors, which have in common their ability to increase angiotensin II 
levels, have been suggested to increase the risk of first-dose hypo- tension. These are low 
pre-treatment blood pressure, high diuretic dose, hypo- natraemia and renal artery stenosis 
(Cleland & Oakley 1991). In patients with more severe grades of CHF, hyponatraemia and 
hypovolaemia associated with high doses of loop diuretic have been recognised as risk
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factors (Cleland et al 1985a, Hodsman et al 1983, Packer et al 1986). Of patients identified 
at being at high risk in the SOLVD study on the basis of the presence of severe CHF, pre­
treatment serum sodium of <130 mmol/L, or already prescribed a vasodilator, only 15% 
developed symptomatic hypotension (Hood et al 1991). In those with pre-treatment 
systolic blood pressure of less than 100mm Hg, symptomatic hypotension occurred in 
42%, but syncope in only 17%.
These relatively easily identifiable, high risk individuals are now in the minority of 
those being commenced on ACE inhibitor therapy. Hyponatraemia and hypovolaemia are 
seldom found in those with mild to moderate CHF, for whom there are no reliable 
indicators of the likelihood of a significant fall in blood pressure. In a study of the acute 
effects of captopril in 36 patients with mild to moderate CHF, no pre-treatment clinical or 
laboratory parameter other than mean arterial blood pressure could be identified to predict 
the blood pressure response (Motwani et al 1994).
The possible role of the Bezhold-Jarisch reflex in the occurrence of first-dose 
hypotension has been suggested (Semple et al 1988). Activation of the reflex in man is 
associated with marked cardiovascular depression. As the authors point out, activation of 
the reflex can occur in response to a number of hormones and cardiovascular drugs. The 
risk of activation is increased by the upright posture and by high doses of diuretic. In 
addition it may be of relevance as far as ACE inhibitors are concerned that the reflex is 
activated by bradykinin (Kaufman et al 1980).
In spite of the increasing prevalence of CHF and the established role of ACE 
inhibitors in the treatment of the condition, direct comparisons of the haemodynamic 
response to various ACE inhibitor agents are rare. In addition, no large analysis of the 
pathophysiological determinants of the blood pressure response to initiation of therapy has
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previously been carried out. This issue is addressed in the studies detailed in this thesis.
3.1.9.3 Renal effects of ACE inhibition in CHF
The RAS has an important role in regulating renal function in CHF. The effects of 
activation of the RAS upon salt and water balance in CHF are central to the 
pathophysiology of the condition. There is a strong correlation between angiotensin II and 
aldosterone concentrations in CHF. Increased RAS activity and aldosterone levels result 
in reduction of total body potassium and retention of sodium and water (Cleland et al
1987). The result is an increase in whole body sodium of 10-40% in untreated CHF. 
However angiotensin II stimulated thirst and secretion of vasopressin (Goldsmith et al
1983) exacerbates water retention with total body water being 5-30% greater than normal. 
The overall result is hyponatraemia. However hypokalaemia and hypomagnesemia also 
result, changes which may be of relevance in the pathogenesis of arrhythmias.
The renal response to ACE inhibition is dependent upon a number of factors, in 
particular the maintenance dose of diuretic, the degree of elevation of total body sodium 
and water, the magnitude of the blood pressure fall and the severity of cardiac failure. In 
patients with mild to moderate CHF, in whom pre-treatment GFR is only moderately 
impaired, ACE inhibition commonly results in unchanged or even improved GFR. In 
patients with more severe CHF, in whom GFR and effective renal plasma flow are 
markedly impaired at baseline, in those in whom blood pressure is low, and in those on 
high maintenance doses of diuretic, ACE inhibition often results in further deterioration in 
GFR (Robertson & Richards 1987, Motwani et al 1994). A number of studies have 
suggested that angiotensin II has a particularly important role in maintaining glomerular 
filtration pressure when systemic blood pressure is low (Packer et al 1986a, Motwani et al
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1994).
ACE inhibition corrects both hyponatraemia (Packer et al 1984) and total body 
potassium deficit (Cleland et al 1985b). Although angiotensin II helps to maintain 
glomerular filtration rate in CHF, there is a correlation between the degree of RAS 
activation on the one hand and hyponatraemia and blood urea concentration on the other 
(Brown et al 1970). Thus it appears that in CHF angiotensin II is essential to the 
maintenance of efferent arteriolar tone and thus glomerular filtration while at the same 
time responsible for the sodium retention of CHF. Motwani et al have suggested that there 
is, for each individual patient, an optimal level of inhibition of ACE which preserves 
sufficient efferent arteriolar tone to maintain glomerular filtration while reducing 
angiotensin II to a degree sufficient to allow natriuresis. In keeping with this suggestion is 
the observed attenuation of frusemide-induced natriuresis and reduction in GFR by high 
doses of captopril, while a low dose of captopril augment both GFR and frusemide 
induced natriuresis (Motwani et al 1992).
Differences exist in the renal responses to ACE inhibition and angiotensin II 
receptor blockade in rats after experimental MI (Deck et al 1996). While captopril and 
losartan elicited similar changes in arterial pressure, increases in renal blood flow and 
GFR, and decreases in urine flow rate and fractional excretion of sodium were less marked 
with losartan. Blockade of prostaglandin synthesis by indomethacin had no effect on renal 
haemodynamics in response to either ACE inhibition or angiotensin II receptor blockade. 
However, inhibition of bradykinin attenuated the effects of ACE inhibition on renal 
haemodynamics but was without effect on these parameters after angiotensin II receptor 
blockade. Blockade of bradykinin and of prostaglandin synthesis improved sodium 
excretion in both groups. These authors concluded that both the kinin and prostaglandin
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systems are of importance in the regulation of renal function during suppression of the 
RAS.
3.1.9.4 Cardiac effects
ACE inhibition elicits characteristic changes in cardiac function in CHF. As 
peripheral vascular resistance falls, stroke volume increases with a net reduction in cardiac 
work (Halperin et al 1982). Cardiac oxygen consumption is unchanged or falls. Heart rate 
falls as a result of increased cardiac vagal (Osterziel et al 1990) and reduced cardiac 
sympathetic (Mulligan et al 1989) activity. Myocardial oxygen consumption at rest is 
reduced and lactic acid production reduced or unchanged (Chatteijee et al 1982). Any loss 
of the inotropic effect of angiotensin II appears to be small and left ventricular function is 
almost always improved after systemic administration of ACE inhibitor. Infusion of ACE 
inhibitor into the coronary circulation of patients with CHF results in impairment of 
contractility (Foult et al 1988). The beneficial effect of ACE inhibitors on sudden death in 
CHF may be partly explained by a reduction in the frequency and severity of ventricular 
arrhythmias (Webster et al 1985) as a result of reduced sympathetic nerve activity, 
improved electrolyte balance or reduction of angiotensin II levels.
3.2 CHEMICAL STRUCTURE OF ACE INHIBITORS
The first orally active ACE inhibitor, captopril, was based on peptide elements 
from the venom of the South American pit viper. Orally active inhibitors of the enzyme 
were first synthesized in the late 1970's and were derived from the intravenous peptide 
ACE inhibitors. At that time the perceived possible clinical use of these agents was in the 
treatment of renovascular hypertension in which circulating levels of angiotensin II are 
elevated. At the time of writing, the ACE inhibitors are extensively used in hypertension
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but are for reasons outlined above relatively contraindicated in hypertension of 
renovascular origin. Latterly a central role in the treatment of CHF has been established 
for ACE inhibitors to the extent that these agents are now one of the mainstays of the 
treatment of the condition. The development of this class of drug has been based on the 
scientific evidence already discussed of the probable role of the renin-angiotensin system in 
these two common pathological conditions. A large number of ACE inhibitors have been 
synthesized over the last 25 or so years. At the present time in the UK., captopril, 
cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril and trandolapril 
are licensed for use.
The basic structure of the agents is based on a biochemical model of the active site 
of the enzyme. This is in turn based on the X-ray crystal structure of the enzyme 
carboxypeptidase A, closely related to angiotensin converting enzyme. A number of 
specific drug-enzyme interactions are thought to be important to binding affinity and 
specificity. These include occupation by part of the drug of a hydrophobic pocket formed 
by the tertiary structure of the enzyme; chelation of a zinc ion; and binding to a cationic 
resdue within the protein. Early ACE inhibitors possessed a sulphydryl group for the 
purpose of biding to zinc. This moiety has been associated with some of the unwanted side 
effects of ACE inhibitors, and second and third generation agents do not contain a 
sulphydryl group.
The affinity of ACE inhibitors for the enzyme is related to chemical class. The 
sulphydryl group of which captopril is an example binds strongly to the enzyme but rapid 
oxidation results in a short duration of action. Enalapril, cilazapril, lisinopril, quinapril, 
ramipril and perindopril bind to the enzyme via various carboxylic acid functions while 
fosinopril binds via its phosphinic acid group. The rigid N-terminal ring structure of the
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first ACE inihibitor captopril, an important element determining binding affinity, has been 
retained although the proline structure of the early agents has been modified in a number 
of cases.
The majority of ACE inhibitors are synthesized as prodrug esters of the active 
diacid moiety, improving solubility and oral bioavailability. De-esterification of the 
prodrug occurs predominantly in the liver and in the gut wall. The duration of action of 
prodrug ACE inhibitors is delayed and prolonged compared to the diacid moiety. Of the 
two isomers of a given ACE inhibitor, only the trans isomer is pharmacologically active. 
Modified forms of agents incapable of undergoing isomerisation have been produced.
3.3 PHARMACOLOGY OF ACE INHIBITORS
3.3.1 Pharmacokinetics
3.3.1.1 General
Differences in pharmacokinetic properties among ACE inhibitor agents should 
logically influence their tissue distribution. As elements of the renin angiotensin system can 
be found in numerous tissues, the implications are that differences among ACE inhibitors 
in terms of their availability at tissue sites may result in differential effects.
The pharmacokinetics of ACE inhibitors are determined by a number of factors 
(Table 3.3). Most available ACE inhibitors are prodrug ester agents which undergo de- 
esterification to the active diacid metabolite. Administration as the ester increases oral 
bioavailability. Of the currently available agents, captopril and lisinopril do not require de- 
esterification. For the other agents, de-esterification takes place in the wall of the gastro­
intestinal tract and liver. However relative lipophilicity of the parent ester may allow 
access to tissue sites from which the diacid metabolite is excluded.
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The pharmacokinetic profile of ACE inhibitors is usually described by a distribution 
phase followed by an initial elimination phase of 2-8 hours and a prolonged terminal 
elimination phase often lasting over 24 hours. This latter elimination phase is thought to be 
due to dissociation of drug from binding sites, including tissue ACE. At high 
concentrations the amount of drug bound to ACE is relatively small and elimination is 
determined by drug clearance. At low drug concentrations, drug binding and dissociation 
is more relevent to the elimination rate. Drug half life is represented by separate values for 
the initial and terminal elimination phase. Due to saturation of binding sites ACE inhibitors 
do not accumulate with repeated dosing .
3.3.1.2 Tissue distribution
Binding of ACE inhibitor drug to the enzyme can be demonstrated in a variety of 
tissues. Differences in protein-binding characteristics should influence tissue distribution of 
ACE inhibitors. Johnston et al assayed displacement of the lisinopril derivative [125 
I]351-A by different ACE inhibitors (Johnston et al 1989). The IC50 values of quinaprilat in 
plasma, lung, kidney and the heart were lower than those for benazeprilat, lisinopril, 
fosinoprilat or perindopril. The displacement of [125]351-A from membrane homogenates 
o f rat heart by various ACE inhibitors revealed similar results (Fabris et al 1989). The 
overall rank order of potency was quinaprilat = benazeprilat > perindopril > lisinopril > 
fosinoprilat. The results of these two studies suggest that quinaprilat has a high affinity for 
cardiac ACE in comparison to other agents. The clinical relevance of such differences is 
unclear.
3.3.1.3 Metabolism
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Table 3.3 Factors influencing pharmacokinetics o f ACE inhibitors
Absorption/bioavailability 
Transformation of prodrug 
Lipophilicity
ACE inhibitor/ ACE kinetics
protein binding
Availability at tissue sites
Metabolism 4  Active metabolites 
■^Inactive metabolites
Elimination ^  renal 
^  hepatic
Table 3.4 Haemodynamic effects o f ACE inhibitors
Arterial blood pressure 
Total peripheral resistance 4/
Cardiac output T7- 
Heart rate =/4/
Renal blood flow 4s 
Cerebral/coronary blood flow ^
Cardiac/vascular hypertrophy 4'
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Of the available ACE inhibitors lisinopril is excreted intact, the others being 
variably metabolised to inactive compounds. All of the available agents are eliminated via 
the kidney and will accumulate in renal impairment. Although a number of ACE inhibitors 
undergo hepatic metabolism, this is never sufficient to prevent any particular agent being 
accumulated in renal failure. Tailoring of the dose of ACE inhibitor to the GFR is therefore 
recommended. The more lipophilic agents (cilazapril, enalapril, quinapril, ramipril) 
undergo relatively greater hepatic metabolism. Captopril is metabolised to disulphide 
moieties which may regenerate captopril and prolong its duration of action.
3.3.1.4. ACE inhibitor/ACE interaction
There are two known binding sites for an ACE inhibitor drug on the enzyme 
(Perich et al 1991). Enzyme inhibition is competitive and complete inhibition of 
circulating ACE occurs at low circulating concentrations of ACE inhibitor. Following 
inhibition of ACE, circulating levels of angiotensin II fall, while angiotensin I and plasma 
renin concentrations rise.
During chronic ACE inhibition, some increase in plasma ACE levels occurs via 
enzyme induction. Sensitive assays of angiotensin peptide levels during chronic ACE 
inhibition have shown that the initial very low levels of angiotensin II are not maintained. 
This does not appear to be reflected in ACE inhibition as estimated using the traditional in 
vitro assay of plasma ACE activity. Thus traditional methods may overestimate the true 
extent of ACE inhibition. While this phenomenon was previously thought not to be 
relevant to the clinical use of ACE inhibitors, it has been suggested recently that escape of 
only a small percentage of ACE from inhibition may allow production of a patho- 
physiologically significant amount of angiotensin II, given the abundance of the enzyme
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(Nussberger et al 1994).
3.3.2 Pharmacodynamics
Although it is generally accepted that the pharmacological effects of inhibition of 
ACE are mediated via a reduction in the amount of circulating angiotensin II produced 
from angiotensin I, the enzyme has as potential substrates a number of other peptides of 
which bradykinin may be the most clinically relevant. The haemodynamic effects of ACE 
inhibitors in patients with CHF have been described in section 3.1.7 and are summarised in 
Table 3.4. Broadly similar effects are seen in hypertension and to a lesser extent in normal 
man.
While it is accepted that the acute hypotensive response to ACE inhibition is due to 
reduction in circulating angiotensin II levels, the long-term blood pressure response does 
not correlate well with this parameter. There are a number of alternative modes of action 
of ACE inhibitors by which they may influence blood pressure and inhibition of ACE 
located at a site or sites other than in plasma is likely to be of relevance. As stated above, 
interaction between the RAS and sympathetic nervous systems appears to occur at a 
number of sites and may be of relevance to the haemodynamic effect of ACE inhibition. 
With chronic treatment, the negative sodium balance which results from suppression of 
aldosterone production may contribute.
Potentiation of the vasodilator effects of kinins and resultant effects on 
prostaglandins may be of relevance to the haemodynamic response to ACE inhibition 
(Carbonell et al 1988). The recent development of specific bradykinin B2 receptor 
antagonists has allowed detailed exploration of the contribution of bradykinin potentiation 
to the effects of ACE inhibition. Data from animal studies support a role for bradykinin
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potentiation in this regard. In the aortic banded hypertensive rat, the prevention of left 
ventricular hypertrophy obtained with ramipril is prevented by the specific bradykinin B2 
receptor antagonist Hoe 140 (icatibant) (Linz & Scholkens 1992). Further to this, Hoe 140 
reduces the antihypertensive effects of perindoprilat in spontaneously hypertensive rats, 
the effect being more pronounced when the animals are exposed to a high salt diet 
(Bouaziz et al 1994). To date no information is available on the relevance of these findings 
to man.
3.3.3 Unwanted effects of ACE inhibition
The two best recognised unwanted effects of ACE inhibitor therapy are 
hypotension, usually cited as occurring after the first dose, and renal impairment, the onset 
of which appears to be rather more variable. The phenomenon of first-dose hypotension 
has been discussed in section 3.1.9.2. The reported incidence of the phenomenon in the 
major trials of ACE inhibition in CHF and after acute MI are shown in Table 3.5 and 3.6 
respectively.
3.3.3.1 Renal impairment
As discussed above, the potential role of ACE inhibitors in the treatment of 
diabetic nephropathy is currently of great interest. On the other hand, renal impairment is 
widely perceived as a potential adverse event associated with ACE inhibitor therapy. The 
risk in patients with uncomplicated hypertension appears to be very low, with no deaths 
from renal failure being reported in over 11,000 such patients taking enalapril (Cooper et 
al 1987). The overall incidence of ACE inhibitor induced renal impairment has been 
reported as less than 1% (Inman et al 1988). A number of potential contributory factors 
were identified in this study: hypovolaemia as a consequence of high doses of loop
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diuretics, diarrhoea or vomiting; hyperkalaemia as a consequence of concomitant 
administration of potassium sparing agents or potassium supplementation; and 
concomitant administration of non-steroidal agents.
Proteinuria has been reported as a result of ACE inhibition, largely associated with 
the use of high doses of captopril in the early days of ACE inhibitor therapy (Frohlich et al 
1984). Reports of proteinuria attributable to ACE inhibitor therapy are now rare. It 
appears likely that at least so renal damage previously attributed to ACE inhibitorme of the 
therapy was in fact due to the disease state for which the drug was prescribed (Captopril 
Collaborative Study Group 1982). The incidence of renal impairment secondary to the use 
of ACE inhibitors in CHF is unknown. As with the use of ACE inhibitors in hypertension, 
a number of confounding factors are relevant, not least of which the association between 
progression of chronic CHF and resultant deterioration in renal function.
3.3.3.2 Cough
The incidence of cough induced by ACE inhibitor therapy has been variously 
reported at between 5% and 25% of patients (Yeo & Ramsay 1990). As with hypotension, 
rather fewer patients withdraw from treatment as a result (Yeo et al 1991). The cough is 
typically dry, unproductive and worse at night. In controlled trials some improvement is 
obtained with non-steroidal compounds (Gilchrist et al 1989), suggesting potentiation of 
kinins and/or prostaglandins to be responsible. Cough as a side effect of ACE inhibition is 
more common among women and may be dose related. There is little evidence to suggest 
that the incidence of cough varies among ACE inhibitors.
3.3.3.3 Angioneurotic oedema
Angioneurotic oedema represents a rare unwanted effect of ACE inhibition. The
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mechanism is unknown; patients present with swelling of the face and tongue or 
occasionally of the perineum and peripheries. The majority of episodes occur within 3 
months of commencing treatment Hedner et al 1992).
3.3.3.4 Neutropenia
Neutropenia was initially described with high dose captopril therapy but has been 
reported with non-sulfhydryl containing agents. The incidence is related to the presence of 
renal impairment and more closely to the presence of collagen vascular disease (Cooper 
1983). The majority of cases of neutropenia occur within 2-3 months of starting therapy. 
The effect is reversible with discontinuation of therapy.
3.3.4 Potential interactions of ACE inhibitors
3.3.4.1 Interaction between the RAS and the sympathetic nervous system.
There is a considerable body of evidence indicating a functional interaction 
between the RAS and the autonomic nervous sustem (ANS) (for review see Squire & Reid 
1993). The earliest evidence of an interaction was the demonstration that angiotensin II 
can increase the release of catecholamines from the adrenal medulla (Braun-Menendez et 
al 1946). In the 1960s, facilitation of central (Bickerton & Buckley 1961) and peripheral 
(Zimmerman 1962) adrenergic neurotransmission was shown. Since then, interaction of 
the RAS and ANS at a number of sites has been demonstrated in a variety of species. 
Angiotensin II stimulates the superior cervical ganglion of a number of experimental 
animals and enhances noradrenergic transmission in a variety of isolated tissue and whole- 
animal preparations. A number of mechanisms have been proposed by which the 
interaction occurs, including presynaptic stimulation of noradrenaline release, increased
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noradrenaline synthesis, reduced uptake, enhanced target cell responsiveness, and 
enhancement of transmitter release via stimulation of prejunctional angiotensin II 
receptors.
A striking feature of the use o f ACE inhibitors in clinical practice is the lack of 
reflex tachycardia seen with these agents, in distinction to the effect of other vasodilators. 
This effect has been described as "parasympathomimetic” and has been demonstrated in 
hypertensive man (West et al 1989) and in CHF (Binkley et al 1993). Further to this, ACE 
inhibition improves the disturbed baroreceptor-cardiac reflex sensitivity seen after acute 
myocardial infarction (Marakas et al 1995), with relatively greater augmentation of 
parasympathetic activity than suppression of sympathetic activity. Thus evidence is 
accumulating that the interaction between the RAS and the ANS may be of patho­
physiological significance. The site or sites of interaction remains unknown.
3.3.4.2 Effects mediated via bradykinin/prostaglandins
The possible role of bradykinin in mediating the effects of ACE inhibition continues 
to be the subject of much debate. It has been suggested that both the hypotensive effect of 
ACE inhibitors and the well recognised side effect of cough may be mediated via 
potentiation of bradykinin. As ACE catalyses the breakdown of bradykinin, ACE inhibition 
potentiates this hormone, which in turn leads to increased production of nitric oxide (NO), 
via stimulation of B2-kinin receptors, and arachidonic acid metabolites such as prostacyclin 
and PGE2. All of these act as vasodilators although in man the principle mediator appears 
to be NO (Bonner et al 1990). Plasma levels of bradykinin are not increased to any 
significant degree during ACE inhibition (Mombouli et al 1991). It is likely that the 
contribution of bradykinin to vascular tone is determined by local concentration of the
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compound and the endothelial relaxing factors which it releases. In vitro studies show that 
vascular smooth muscle relaxation mediated via NO is augmented by ACE inhibition 
(Mombouli et al 1991).
Human studies regarding the relative contribution of bradykinin to the effects of 
ACE inhibition have been limited by the lack of orally active bradykinin antagonists. 
Studies in animals suggest that potentiation of bradykinin is of relevance to at least some 
of the effects of ACE inhibition. In spontaneously hypertensive rats, blockade of 
bradykinin receptors with Hoe 140 prior to administration of perindoprilat completely 
abolishes the hypotensive effect of the ACE inhibitor (Bouaziz et al 1994). Similarly, Hoe 
140 abolishes the antihypertrophic effect of ramipril in aortic banded rats (Linz & 
Scholkens 1992).
3.3.4.3 Effects mediated via ANF
Atrial natriuretic factor (ANF) is a potent vasodilator substance which interacts 
with the RAS at a number of sites. In general terms ANF antagonises the secretion of 
renin and aldosterone, inhibition of angiotensin Il-mediated sodium reabsorption from the 
proximal tubule, and attenuation of angiotensin II mediated vasoconstriction. Atrial 
natriuretic factor and the RAS show reciprocal responses to manipulations of sodium 
status (Tuchelt et al 1990).
Angiotensin converting enzyme may be involved in the degradation of ANF. In 
health, plasma levels of renin and aldosterone levels are inversely related to those of ANF. 
However in CHF both plasma renin levels and concentrations of ANF rise progressively as 
the condition progresses (Richards et al 1986). Infusion of ANF in animal models o f heart 
failure suggest that the peptide can reverse the sodium retention and overall RAS
113
activation characteristic of the condition (Lee et al 1989). The antagonistic effect is lost in 
severe heart failure (Riegger et al 1988). Inhibition of ACE, if sufficient to lower renal 
perfusion pressure, reduces ANF-induced natriuresis (Gaillard et al 1989). The clinical 
importance of these findings are doubtful in view of the findings of studies from infusion of 
ANF in patients with CHF, showing little or no change in RAS parameters (Munzell et al 
1991).
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CHAPTER 4 
GENERAL METHODS
4.1 LABORATORY METHODS
4.1.1. Drug concentrations
Concentrations of both ester and diacid ACE inhibitor were analysed using a 
standardised inhibition assay as described by Tocco et al (1982) and modified by Francis 
(Francis et al 1987). Endogenous ACE activity is inactivated by heating. A constant amount 
of exogenous angiotensin converting enzyme is incubated with the exogenous substrate Hip- 
His-Leu and the hippurate generated detected by high performance liquid chromatography 
(HPLC) to quantify the amount of inhibitor present. Rabbit plasma is used as the source of 
high activity ACE. Drug concentrations are determined against standard curves. 
Concentrations of ester prodrug ACE inhibitors are determined by alkaline degradation of an 
aliquot in addition to the determination of diacid ACE inhibitor. Subtraction of diacid from 
total substrate inhibition allows quantification of ester and diacid concentrations in a sample of 
plasma where both are present.
Solutions 
Drug standards
Three 10 mg lots of drug were each dissolved in 100 ml distilled water to give
solutions of 100 pg/ml. These solutions were then designated to the standard curve, and 
quality control 1 (QC 1) and quality control 2 (QC 2) respectively. Each was then diluted
with distilled water to:
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Standard curve 500 ng/ml 
QC 1 100 ng/ml 
QC2 50 ng/ml.
20 |l l 1 of each of these working standards were each added to 480 pi blank plasma
(patient's own) giving solutions of the following concentrations:
Standard curve 20 ng/ml 
QC 1 4 ng/ml 
QC 2 2 ng/ml
For the construction of the standard curve, 20 ng/ml standard solution was diluted 
down to 0.3 ng/ml, all dilutions being prepared in duplicate. An aqueous blank, control blank 
(0.9% Na Cl) and plasma blank (100 pi plasma as used for standard curve) were then run in 
addition to standard solutions as prepared above. Standard curves were fitted using non-linear 
regression, 2 exponentials, to the equation:
Y = A. exp(alpha.X) + B. exp(beta.X)
Sample peak areas were read from the fitted line using an in-house programme, 
Newton 2.
5 mM Hip-His-Leu (Exogenous substrate)
21.48 mg Hip-His-Leu was dissolved in 10 ml assay buffer. The substrate shows
gradual degradation to produce hippuric acid and the substrate solution was freshly made 
for each assay.
100 mM potassium phosphate buffer pH 8.3
4.375g ofNaCl and 5.705g of K2HP04 were dissolved in 250ml distilled water. 1.361
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of KH2P 0 4 was dissolved in 100ml distilled water. The monopotassium salt was added to the 
dipotassium salt until the pH reached 8.3.
Hippuric acid standards
179.2 mg of hippuric acid was added to 100ml distilled water. Two ml of this solution 
was then taken and added to 18 ml of drug-free plasma. A standard calibration curve over the 
concentration range 0.05 to 1.0 mmol/L hippurate was prepared.
Internal standard
20.4 mg phthalic acid was dissolved in 20 ml methanol and 80 ml o f distilled water 
added. The solution was then diluted 1:2.5 with distilled water to give the standard solution of
0.41.mmol/L.
Mobile phase
5.44 g KH2P 0 4 was dissolved in 1.5 litres of distilled water and the pH adjusted to 4.0 
with orthophosphoric acid. The solution was made up to a total of 2 litres with distilled water 
and 140 ml of the solution replaced with 140 ml of methanol. The mobile phase was filtered 
through a 0.8 micron aqueous filter and degassed by bubbling through with helium.
Analytical procedures 
Procedure for diacid metabolites
1. A sample of standard or patient plasma, 100 pi in duplicate, was inactivated by heating at 
60°C for 1 hour.
2. Add 400 pi of substrate in buffer.
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3. Add 50 pi diluted rabbit serum.
4. Incubate at 37°C for 45 minutes.
5. Add 100 50% (v/v) HC1. Vortex briefly.
6. Add 100 pi (IS).
7. Add 50 mg NaCl. Vortex briefly.
8. Add 1 ml ethyl acetate. Vortex briefly.
9. Centrifuge at 2000 rpm for 5 minutes.
10. Remove 500 pi of the organic layer into a clean tube.
11. Concentrate under air at 37°C. Redissolve in 150 pi of mobile phase.
12. Inject 50 pi aliquot.
Procedure for total drug concentration
This measures total drug concentration (i.e. parent ester + diacid metabolite). 
Concentration of parent ester is obtained by subtraction of diacid concentration from total 
drug concentration.
1. Take 100 pi samples (prepared as above) of standard or patient plasma in duplicate.
2. Add 100 pi rat serum.
3. Incubate at 37°C for 1 hour
4. Inactivate by heating at 60°C for 1 hour.
5. Continue as for steps 2-12 above.
HPLC conditions
Column: Spherisorb 5pm ODS 1 cartridge 10 cm x 4mm
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Mobile Phase: 20 mmol KH2P 0 4/L, pH 4.3, in methanol 93:7
Flow: 2.5 ml/min giving approximate column pressure of 1000 p.s.i.
Detector: Ultraviolet, 228 nm, Range 0.16 AUFS.
Injection volume: 50 pi.
Approximate retention times:
IS 1.5 minutes 
Hippuric Acid 2.5 minutes
The assay is not drug specific and was applied to the quantification of perindopril,
perindoprilat, enalapril, enalaprilat, quinapril and quinaprilat in the studies reported here.
Intra- and inter-assay variability was approximately 3-5 and 5-8% respectively for both
metabolite and total drug. The lower limit of drug detection was 0.1 ng/ml for both metabolite
and total drug.
4.1.2. Angiotensin converting enzyme activity
Angiotensin converting enzyme activity (ACE) was determined by the method of
Chiknas (1979). Plasma ACE activity is estimated using the measuremnt of hippuric acid
generated from the exogenous synthetic substrate Hippuryl-Histidyl-Leucine (Hip-His-Leu).
The hippuric acid produced by the action of ACE on this substrate is quantified against an
internal standard by HPLC. This gives an indirect index of ACE activity. One
unit of ACE activity (1 EU/L) is that amount of ACE producing 1 mole of hippuric acid
per minute at 37°C under controlled reaction conditions in vitro.
Analytical procedure 
Procedure for standards
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Into 4 ml polypropylene tubes were placed (in duplicate)
1. 200 pi substrate
2. 50 pi 50% HCL (v/v)
3. 20 pi standard plasma
4. 50 pi internal standard solution. Vortex briefly.
5. 50 mg NaCl. Vortex briefly.
6. 1 ml ethyl acetate. Vortex for 15 seconds.
7. Centrifuge at 2000 rpm for 5 minutes.
8. Remove 500 pi of the organic layer to a clean polypropylene tube and 
concentrate under air/N2 at 37°C.
9. When dry add 100 ul of mobile phase and vortex briefly.
10. Inject 20 pi onto HPLC system.
Procedure for unknown samples
Into 4 ml polypropylene tubes were placed (in duplicate)
1. 200 pi 5 mmol Hip-His-Leu in substrate buffer.
2. 20 pi unknown plasma sample. Vortex briefly.
3. Incubate in water bath at 37°C for 30minutes.
4. Stop the reaction by adding 50 pi 50% HC1 and vortexing.
5. Steps 4-10 as for procedure for internal standard solution.
The minimum limit of detection was 0.2 EU/L. The accuracy of the method as 
determined using a quality control sample provided by Sigma Chemicals was 104%. Analysis 
of 10 replicates of this 18 EU/L standard gave figures of 2.0 and 3.3% for intra- and inter­
assay variability respectively.
4.1.3 Plasma renin activity
Plasma renin activity was determined by radioimmunoassay of angiotensin I formed
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from exogenous angiotensinogen (Derkx et al 1979). The detection limit of this sensitive and 
specific assay (renin activity) was 0.1 ng Al/ml/hr. Inter assay coefficient of variation was 7%.
4.1.4 Plasma aldosterone
Plasma aldosterone was measured using an established radioimmunoassay based
on a commercial kit (Aldosterone MAI A, Biodata, SPA, Italy). Intra-assay coefficient of
variation was 2.5%, inter-assay coefficient of variation 6%.
4.2 CLINICAL STUDIES
4.2.1 Blood pressure and heart rate measurement
In the clinical studies described, procedures for the measurement o f blood pressure 
and heart rate and for blood sampling were identical. Blood pressure and heart rate were 
recorded using a validated (Johnson and Kerr 1985) semi-automatic device (Sentron, Bard, 
Sunderland, U.K.). This device was calibrated and maintained by the Clinical Physics 
Department of the Western Infirmary. The device utilises an oscillometric technique for 
indirect measurement of blood pressure.
All subjects had baseline blood pressure recordings made after 30-45 minutes supine 
rest. Recordings were made at 2 minute intervals to establish baseline values and in triplicate 
at pre-determined time points (5,10, 15, 20, 30, 40, 50 minutes and at 1,2, 3, 4, 5, 6, 8, 10 
and 24 hours) after administration o f a single dose of study medication during each study for 
comparison of drug effects.
4.2.2 Blood sampling
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Blood sampling for the assessment of neurohumoral parameters was carried out at 
pre-determined time points in each study (5,10, 15, 20, 30, 40, 50 minutes and at 1, 2, 3,
4, 5, 6, 8, 10 and 24 hours after administration of a single dose of study medication).
Blood was sampled into chilled tubes as appropriate and immediately centrifuged at -4° C 
for 15 minutes at 3000 rpm. Plasma was then separated and stored at -70° until assay.
4.2.3 Study protocols
All studies described here were approved by the local regional Research and Ethical 
Committee after submission of detailed protocols. All studies were reviewed and granted 
approval by this committee prior to their commencement. All subjects were screened for 
suitability for inclusion in the relevant study. Suitability in terms of the meeting of specific 
inclusion and exclusion criteria, physical examination and clinical history was determined by 
myself. Each subject was given a full verbal explanation of the purpose of the study and the 
procedure involved and was also provided with a written information sheet detailing the aims 
and procedures of the study prior to written informed consent being obtained.
4.3 Statistical Analysis
Blood pressure and heart rate were measured in triplicate at pre-determined time
points in each study. Mean arterial pressure was calculated using the standard formula
MAP = DBP + (SBP+DBP)/3.
The mean of the three recordings of systolic, diastolic and mean blood pressure was taken as
the value used for statistical analysis. All blood pressure data are expressed as mm Hg and all
heart rate data as beats per minute. Heart rate, mean arterial pressure, systolic blood pressure
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and diastolic blood pressure were compared both as absolute values and after correction for 
baseline values. The values obtained were analysed using repeated measures analysis of 
variance using a statistical package (RUMMAGE) on an ICL 3988 mainframe computer. The 
model used contained two fixed factors (time with variable levels, and treatment with variable 
levels) and one random factor (patients, with 12 levels for each of the heart failure studies). 
Treatment-time interactions were estimated using Bonferroni correction for repeated 
comparisons, comparing only treatments at each set time point. No within treatment 
comparisons at different time points were carried out.
All heart rate and blood pressure data were subjected to baseline correction by 
subtraction of pre-treatment values from the value at each time point before statistical 
analysis. Statistical significance was assumed if p<0.05 in all cases. Angiotensin converting 
enzyme activity was calculated from the formula:
% inhibition = 100 x (1-ACE activity/pre-treatment ACE activity).
Graphical representation in all cases represents the mean value for each treatment 
group at each time point. Error bars represent one standard deviation of the mean. For all 
graphs, time after dosing is shown on a linear scale on the x-axis. Twenty four and forty eight 
hour values are shown separately on the right of the x-axis where appropriate.
Baseline laboratory indices and subject demographic data were compared amongst 
treatment groups by Freidman one way analysis of variance. Comparison of the New York 
Heart Association classification of heart failure severity was achieved using Kruskal-Wallis 
analysis of variance by ranks.
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CHAPTER 5
COMPARISON OF THE HAEMODYNAMIC RESPONSE TO INITIATION OF 
ACE INHIBITION WITH ORAL PERINDOPRIL , ORAL ENALAPRIL OR 
INTRAVENOUS PERINDOPRILAT IN CONGESTIVE 
HEART FAILURE
5.1 INTRODUCTION
This section describes the comparative haemodynamic effects of initiation of ACE 
inhibitor therapy with a number of agents in patients with stable, chronic CHF. A 
randomised, double-blind, parallel group, placebo controlled comparison of the effects of 
the established ACE inhibitor enalapril with the new, long-acting agent perindopril and its 
active diacid metabolite perindoprilat was carried out in 48 patients with congestive heart 
failure.
Previous work from this Department has demonstrated qualitative and quantitative 
differences in the first dose haemodynamic response to ACE inhibitors in CHF. Whereas 
enalapril 2.5mg p.o. produced a significant fall in supine mean arterial pressure, the blood 
pressure profile seen following perindopril 2mg p.o. did not differ from that seen after 
placebo. These differences were seen despite similar profiles of plasma ACE inhibition 
(MacFadyen et al 1991b). In a separate study, no such differential blood pressure 
responses were seen to the intravenous administration of the diacid compounds enalaprilat 
and perindoprilat in patients with heart failure (MacFadyen et al 1993). With regard to the 
haemodynamic response to the initiation of ACE inhibition, the aims of the study were:
1. To confirm a difference in haemodynamic response between perindopril 2mg
p.o. and enalapril 2.5mg p.o.in elderly patients with stable, chronic CHF.
2. To establish whether oral perindopril treatment is associated with a fall in blood 
pressure between 10 and 48 hours after initiation of treatment and to compare this
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response with that after enalapril. A fall in blood pressure occuring after a dose other than 
the first dose of ACE inhibitor would have important implications for the clinical use of 
such a compound.
3. To establish the haemodynamic response to a low dose of perindoprilat, 
0.167mg, administered by constant rate intravenous infusion over 1 hour.
Additional aims were:
4. To investigate the neurohormonal response to each therapy.
5. To establish the pharmacokinetic profiles of the three active therapies in this 
population.
A consistent finding in a previous study was an initial rise in blood presure over the 
first hour of a constant rate intravenous infusion of both enalaprilat and perindoprilat 
(MacFadyen et al 1993). It was postulated that displacement of angiotensin peptides from 
binding sites on ACE may be responsible for this phenomenon. Thus, the present study 
was designed to investigate further this phenomenon. In the previous study, infusion of 
diacid ACE inhibitor had to be terminated prematurely in a number of patients due to 
excessive blood pressure falls. In the present study the ACE inhibitor agent was infused at 
the same rate as previously but over 1 hour only, ie 1/6 of the maximum dose in the 
previous study. The aims were to avoid the need to interrupt infusion and thus ensure all 
patients received the same dose whilst not altering any parameters which might contribute 
to an early rise in blood pressure.
5.2 PATIENTS AND METHODS
An observational study was carried out in patients with chronic, stable congestive 
heart failure (n=48, 51-85 years; 34:14, M:F), New York Heart Association (NYHA)
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functional class II-IV. All patients were symptomatic and receiving stable doses of diuretic 
therapy (>80 mg frusemide or equivalent daily) prior to the study. Patients were recruited 
from the medical wards and from the general medical and cardiology clinics of the 
Western Infirmary. Each patient was admitted to hospital for elective commencement of 
ACE inhibitor therapy. All had erect systolic blood pressure > 100mm Hg and none had 
significant disturbance of renal (plasma creatinine > 250umol/L) or hepatic ( yGT > 3x 
upper limit of normal, transaminase > 2x upper limit of normal) function. The study was 
approved by the local ethical committee and written informed consent to participate in the 
study was obtained in all cases. The diagnosis of CHF was confirmed by full clinical 
history and by physical examination in all cases. All subjects had echocardiography 
performed to confirm impaired left ventricular function. A number had also undergone 
cardiac catheterisation and/or radionuclide scanning. Patient characteristics, by treatment 
group, are shown in Tables 5.1-5.4.
The haemodynamic status of each patient was assessed using the scoring system 
shown in Table 5.5. This allowed an estimate of the comparative status of fluid balance to 
be made among groups. All diuretic therapy was withdrawn for 48 hours prior to, and for 
the duration of, the study. All concomitant vasodilator therapy (oral nitrate, calcium 
channel blocker) and P-receptor antagonist therapy was witheld on the two days of the 
study. Digoxin, where prescribed, was continued. On the first study day each patient rose, 
washed and had breakfast as normal. A heparinised peripheral venous cannula was 
inserted in an antecubital vein for the purpose of blood sampling and in a vein of the 
contralateral forearm for infusion of intravenous study treatment (perindoprilat 0.167mg 
or placebo). The patients then returned to bed where they rested supine. Blood pressure 
was recorded at 2 minute intervals using a semi-automatic sphygmomanometer (Sentron,
Demographic details 
Placebo
Study No. Age Sex Aetiology NYHA Class Cardiac Rhythm
of CHF
4 85 F IHD II SR
5 72 F IHD III SR
9 76 M IHD IH AF
16 80 F IHD III - AF
20 74 F IHD II AF
21 76 M IHD III AF
28 65 M HT II SR
29 77 M VALVE II SR
36 80 F IHD III SR
39 76 M IHD II AF
44 64 M HT II AF
48 72 M IHD III AF
NYHA = New York Heart Association
IHD = Ischaemic heart disease
HT = Hypertension
VALVE = Valvular heart disease
AC = Alcohol related cardiomyopathy
Patient 29: Valve lesion = severe mitral regurgitation
Table 5.2
Demographic details
Perindopril 2mg po
Study No. Age Sex Aetiology 
of CHF
NYHA
3 71 M IHD III
8 66 M IHD H I
12 79 F IHD/HT II
15 75 M IHD II
17 78 M IHD III
24 69 M AC III
27 73 F IHD III
30 52 M IHD/AC HI
34 69 M IHD III
40 71 F IHD II
41 64 M IHD II
45 81 F IHD III
NYHA = New York Heart Association
IHD = Ischaemic heart disease
HT = Hypertension
VALVE = Valvular heart disease
AC = Alcohol related cardiomyopathy
SR
AF
AF
SR
AF
AF
SR
SR
SR
SR
SR
SR
Table 5.3
Demographic details
Enalapril 2.5mg po
Study No. Age Sex Aetiology 
of CHF
NYHA Class Cardiac
2 75 F IHD/VALVE III AF
7 75 M IHD II SR
11 70 M IHD/VALVE II - AF
13 55 M IHD III SR
18 71 M AC IV AF
22 76 M IHD II SR
26 66 M IHD IV SR
32 72 M IHD II SR
35 66 M IHD II SR
38 69 F IHD II SR
43 75 M IHD III SR
47 77 M IHD II AF
NYHA = New York Heart Association
IHD = Ischaemic heart disease
HT = Hypertension
VALVE = Valvular heart disease
AC = Alcohol related cardiomyopathy
Patient 2: Valve lesion = severe mitral and tricuspid regurgitation 
Patient 11: Valve lesion = severe mitral regurgitation
Table 5.4
Demographic details
Perindoprilat 0.167mg iv
Study No. Age Sex Aetiology 
of CHF
NYHA Class Cardiac
1 67 F VALVE/HT II AF
6 54 F IHD II SR
10 62 M IHD III SR
14 61 F IHD III SR
19 76 M IHD III AF
23 53 M AC III AF
25 77 M IHD III AF
31 69 M IHD II SR
33 71 M IHD III AF
37 69 M IHD III SR
42 71 M IHD III SR
46 60 M IHD II SR
NYHA = New York Heart Association
IHD = Ischaemic heart disease
HT = Hypertension
VALVE = Valvular heart disease
AC = Alcohol related cardiomyopathy
Patient 1: Valve lesion = mitral + aortic regurgitation
Bard, Sunderland, UK) to establish baseline values.
After at least 45 minutes supine rest, blood was drawn for estimation of baseline 
drug concentration, plasma ACE activity, plasma renin activity, aldosterone and 
angiotensin peptide levels. Study medication was then administered double-blind: 
intravenous therapy was administered as a constant rate intravenous infusion over 1 hour 
and oral therapy, in the form of the standard formulation of each drug within an opaque 
gelatin capsule, was administered at the same time as the intravenous infusion was 
commenced. Study drugs were administered in accordance with the randomisation 
schedule held by the department of pharmacy. Each patient received one of:
Perindopril 2mg p.o. + placebo i.v.
Enalapril 2.5mg p.o. + placebo i.v.
Placebo p.o. + perindoprilat 0.167mg i.v.
Placebo p.o. + placebo i.v.
After administration of study drug, supine blood pressure was measured at 2 
minute intervals with additional triplicate determinations at pre-determined time-points. 
Blood samples were withdrawn at frequent intervals for determination of pharmacokinetic
profile, angiotensin I and II levels, plasma renin activity and plasma ACE activity. Patients
remained supine until 10 hours after dosing during which time they received meals as
normal. At the end of this period they were allowed to rise and resume normal activity.
Prior to further blood sampling and blood pressure recording 24 hours after dosing,
the patients returned to bed where they rested supine for at least 45 minutes. At this point
a second oral dose of the study drug was administered. This was identical to that given on
day 1 in all cases except those patients who had received perindoprilat i.v. on day 1 (and
in whom oral therapy was placebo) who instead received perindopril 2mg p.o. on day 2.
Patients were fitted with a pre-programmed ambulatory blood pressure device (Spacelabs
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90207) and allowed to resume normal activities.
Twenty four hours after administration of dose 2, the ABP device was removed 
and after a further period of supine rest blood was drawn for determination of ACE 
activity, drug levels, plasma renin activity and angiotensin peptides. At this point the 
randomisation code was broken by the department of pharmacy to reveal only if the 
patient had received active or placebo therapy. Those patients who had received active 
therapy were continued on open ACE inhibitor therapy (the majority receiving enalapril 
5mg b.d.). Patients who had received placebo were given a standard test-dose of captopril 
6.25mg p.o., followed by open ACE inhibitor therapy thereafter. No patients were 
included in any other study. Blood sampling for routine haematology and biochemistry 
was carried out prior to commencement of the study and at the end of the 48 hour study 
period.
5.3 RESULTS
5.3.1 General
The study groups were well matched in terms of haemodynamic status (Table 5.5) 
baseline MAP, pre-treatment diuretic dosage, biochemical and haematological indices and 
NYHA class (Table 5.6). The patients in the placebo group were older (Mean age 
74.6±6.1 years) compared to those in the active treatment groups (oral perindopril 
69.1±9.1; i.v. perindoprilat 65.8±8.0; oral enalapril 70.1±6.1 years). The ages of patients 
among the active treatment groups were similar (p=0.204).
No significant changes occurred in any biochemical indices over the study period 
(Table 5.6). As in previous studies employing similar protocols in the Department, a 
modest fall in haemoglobin concentration of approximately lg/dl was seen and is 
attributable to blood sampling. None of the patients reported any symptoms during
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Table 5.5
Placebo Perindopril Enalapril Perindoprilat 
SCORE 6.8±5.4 5.2±2.1 5.7±3.4 6.2±2.6
Scoring system for assessment of haemodynamic status 
SCORE: 0 1 2 3
Heart rate <100
Lung None
crepitations
JVP(cm above 0 
sternal angle)
Oedema None
Hepatomegaly None
100-115 116-130
Basal Mid zones
0-2 >2 - angle jaw
Trace Pretibial
< 2 fb > 2 fb
>130
Above MZ
> angle jaw
Above knes/Ascites
> 2 fb
p value 
(ANOVA)
0.738
Ta
bl
e 
5.
6
Su
m
m
ar
y 
st
at
is
tic
s:
 B
as
el
in
e 
la
bo
ra
to
ry
 
va
lu
es
 
an
d 
ch
an
ge
 
ov
er
 
stu
dy
 
pe
rio
d 
, d
iu
re
tic
 
do
se
, 
NY
HA
 
cl
as
s.
 
M
ea
n 
(1 
SD
)
<
>
oz
<
TO
(N O O e'­ m ® inm CN en m OO r-iq CN in ■p rr rr oo
o ’ ® ® ® o ’ O o ’
®  V© CNso — Q
(N  O  OO
O O O
to3
u .
®
<n
o
a .o-ac
in m vO —
vq
®
rr
®
Os
CN
Os
® mCN
TT
CN o  c-^  o  oo
O (N 
CN
^  Ov 
8  w O
w  so 
2  d  j CN
oa .
a .o
T3C
<U
cl
so’ „_Os m
rr
o ’
rr
®‘ N"
Osm
S_4- '—^
Ov O CN m OSO — O N* o Os
m
<n m
Os m 
®
P  f-
OO W O
w  ^  CN  , -'f
coccu
P Co
w  cn
~  r- ® m 
—
CN N"
O
CNTf CN®
SO o '
CN m^^ m O
VO m o os CN
®i CN VO1
CN
i CN
o-O<uocO
CL
SO
so
so
rn O 
sq ^  
® N"’
®
• rJ 04O) CN —
P  oo
- 3 ®
P  ONm o
E
E
CD
3 ~o ■5■Q zz o00 o zz 10< GO o CO OCL
o
s 2. e Q-
<d c3 cC -3 <
-j-3cd CTJ "o <u -O
ZZ <ui— E wa -O >-
cO O cO I cO Z
c
CO
L—>
1»
OO
CO
MM(U
>
< Di
ur
el
ic
 
do
se
 
97 
(3
5)
 
10
6 
(6
8)
 
85 
(2
3)
 
90 
(4
1)
 
0.
69
6 
(m
g 
fr
us
em
id
e 
/d
ay
)
supervised diuretic withdrawal or over the study period. Similarly the period of diuretic 
withdrawal was in no case associated with clinical evidence o f decompensation of CHF. 
All left hospital after initiation of open ACE inhibitor therapy and reinstitution of diuretic 
and other medication.
5.3.2 Haemodynamic response
5.3.2.1 Baseline
Baseline mean blood pressures were similar in each treatment group. Mean arterial 
pressures for the 4 treatment groups were: placebo/placebo 89.5±11 mmHg; perindopril/ 
placebo 89.6±10 mm Hg; placebo/perindoprilat 90.7±12 mm Hg; enalapril/ placebo 
87.9±13 mmHg (p=0.947). The baseline heart rates did not differ between groups: 
placebo/placebo 71 bpm; perindopril/placebo 76 bpm; placebo/perindoprilat 79 bpm; 
enalapril/ placebo 73 bpm (p=0.332).
5.3.2.2 1st Dose response 
Blood pressure response
In three of the treatment groups, a transient rise in blood pressure was observed
over the early part of the study period immediately following administration of study
medication. The group receiving intravenous perindoprilat + oral placebo did not show
this response. This phenomenon was evident for mean arterial pressure (Figure 5.1), for
systolic pressure (Figure 5.2) and for diastolic pressure (Figure 5.3). This change did not
reach statistical significance in any treatment group. Values shown are mean (1 SD)
A. Placebo p.o.+ Placebo i.v.
Following the administration of placebo therapy, and as in previous studies, a 
diurnal variation in mean arterial pressure was observed. Mean arterial pressure fell by 7.2
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Figure 5.1:
Mean arterial p re ssu re  (C hange from baseline, mm Hg) following a  
single d o se  of p lacebo  p.o. (□ ), enalapril 2.5m g p.o. (A), perindopril 
2m g p.o. (■ ) or perindoprilat 0.167m g i.v. (O) in patients with congestive 
heart failure.
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Figure 5.2:
Systolic blood p ressu re  (C h an g e  from baseline, mm Hg) following 
placebo p.o. (□ ), enalapril 2 .5m g p.o.(A ), perindopril 2mg p.o. (■ ) or 
perindoprilat 0.167m g i.v. (O ) in patien ts with congestive heart failure.
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Figure 5.3:
Diastolic blood p re ssu re  (ch an g e  from baseline , mm Hg) following 
placebo p.o. (□ ), enalapril 2 .5m g p.o. (* ) ,  perindopril 2mg p.o. (■) 
or perindoprilat 0 .167m g i.v. (O) in patien ts with congestive heart failure.
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Figure 5.4:
Heart rate (C hange from  base line , bpm) following a  single d o se  of 
placebo p.o. (□ ), enalapril 2 .5m g p.o. (A), perindopril 2mg p.o. (■ ), 
or perindoprilat 0 .167m g i.v. in patien ts with congestive heart failure.
(9.6) mm Hg over the first 4.5 hours and returned towards baseline thereafter. Mean 
arterial pressure at 24 hours was similar to baseline (Figure 5.1).
B. Enalapril p.o. + placebo i.v.
Enalapril 2.5mg p.o produced a sustained fall in mean arterial pressure which was 
significantly different from placebo between 6 and 9 hours post dose (Figure 5.1). The 
maximum mean fall in MAP was 15.1 (12.2) mm Hg, occurring at 6 hours post dose. A 
similar profile of blood pressure response was observed for systolic blood pressure. 
Systolic blood pressure fell significantly compared to placebo between 4 and 9 hours post­
dose (Figure 5.2). The fall in diastolic blood pressure was lower in absolute terms than the 
systolic fall and was significantly different from placebo at 6.5 hours post dose (Figure
5.3). At 24 hours post-dose, MAP was approximately 9 mm Hg lower than at baseline. 
The difference was not significant.
C. Perindopril p.o. + placebo i.v.
In contrast to the marked blood pressure fall seen following enalapril, the MAP 
profile seen after perindopril 2mg p.o. did not differ from that seen with placebo (Figure 
5.1). The maximum mean fall in MAP was 6.8 (7.9) mm Hg at 4.5 hours post dose.
Similar patterns were observed for systolic and diastolic blood pressure. At 24 hours post­
dose, MAP was approximately 9 mm Hg lower than baseline. The difference was not 
significant.
D. Placebo p.o. + perindoprilat i.v.
An early fall in MAP was observed over the 1 hour period of the infusion of 
perindoprilat 0.167mg. The fall did not reach statistical significance. At the end of the
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infusion period an immediate though small "rebound” of MAP toward baseline was 
observed (Figure 5.1). Thereafter the BP profile was similar to that for placebo. The 
maximum mean BP fall was 7.8 mm Hg at 1 hour. Similar patterns were observed for 
systolic and diastolic blood pressure. Mean arterial pressure at 24 hours was similar to 
baseline.
Mean maximum BP fall
The mean maximum fall in MAP, irrespective of its time course was calculated for 
each treatment group. Values were: placebo 15 mm Hg (range 5-30); enalapril 21 mm Hg 
(range 4-30); perindopril 16 mm Hg (range 4-30); perindoprilat 14 mm Hg (range 6-25). 
There were no statistically significant differences among the treatment groups (ANOVA,
p=0.126).
Heart rate response
Mean supine heart rate remained unchanged throughout the first 24 hours after the 
first dose of placebo and after the first dose of enalapril 2.5mg p.o. Heart rate fell 
following perindopril 2mg p.o, the change being significantly different from placebo at 2, 
4.5 and 6.5 hours post dose. Heart rate fell following perindoprilat 0.167mg, the change 
being significantly different from placebo at 5.5 hours post dose (Figure 5.4).
5.3.2.3 Response to the 2nd dose 
Blood pressure response
There were no significant differences in MAP among groups either at baseline or at
24 hours after dose 1. The change in blood pressure over day 2 of the study was compared
to baseline (i.e. blood pressure prior to administration of the first dose of study
medication). The fall in MAP over day 2 of the study was not significant, compared to
placebo, for any treatment group (Figure 5.5). Similar results were obtained for systolic
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Figure 5.5:
M ean arterial p ressu re  (change  from base line , mm Hg) following treatm ent 
with p lacebo  p.o.+ placebo p.o (□ ), enalapril 2 .5m g p.o. + enalapril 2.5m g 
p.o. (A), perindopril 2mg p.o. + perindopril 2m g p.o. (■ ), or perindoprilat 
0.167m g i.v. + perindopril 2m g p.o. (O ) in patien ts  with congestive heart failure.
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Figure 5.6:
Mean arterial p ressu re  (change from  24-hour MAP, mm Hg) following 
placebo p.o. + placebo p.o. (□ ) , enalapril 2.5m g p.o + enalapril 2.5mg p.o. (A), 
perindopril 2mg p.o. + perindopril 2m g p.o., or perindoprilat 0.167m g i.v + 
perindopril 2mg p.o. (O) in patien ts  with congestive heart failure.
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Figure 5.7:
Ambulatory m ean arterial p re ssu re  (mm Hg) following placebo p.o.+ 
placebo p.o. (□ ), enalapril 2 .5m g + enalapril 2.5m g p.o. (A), perindopril 
2mg p.o.+ perindopril 2mg p .o .(B ) or perindoprilat 0.167m g i.v. + 
perindopril 2m g p.o.in patien ts  with congestive  heart 
failure.
* p< 0.05 com pared to p lacebo  
** p< 0.05 com pared to perindopril.
and diastolic blood pressures.
The change in blood pressure compared to blood pressure at 24 hours (i.e., prior 
to dose 2 of study medication) was also calculated for each treatment group. No 
significant change in MAP was found for any treatment group compared to placebo 
(Figure 5.6).
Comparison was made of the absolute values for MAP over day 2 of the study 
(Figure 5.7). Absolute MAP for the enalapril treatment group was consistently lower than 
for the other treatment groups and was statistically lower than for the perindopril group 
between 36 and 40 hours (21:00 - 02:00 on day 2) and from the placebo group at 42 
hours (03:00 on day 2). Mean hourly ambulatory blood pressure was lower for enalapril 
(79.6mm Hg) than for other treatments (Perindopril 88.6, perindoprilat 84.2, placebo 
88.0). Over day 2 of the study, mean hourly BP was lower for the group receiving 
perindoprilat as dose 1 plus perindopril as dose 2 than for those receiving perindopril or 
placebo as dose 1 (p<0.01), and greater than those receiving enalapril (p<0.01).
Comparison of the profiles of mean hourly systolic and diastolic blood pressures 
for perindopril and enalapril is shown in Figure 5.8. The mean hourly blood pressure 
profile for both systolic and diastolic blood pressure was consistently lower for the 
perindopril group than for enalapril. The difference was significant for diastolic blood 
pressure between 38 and 41 hours.
Heart rate response
Ambulatory heart rate showed marked fluctuation over the 24 hour period of the 
second study day (Figure 5.9). No differences were found among the treatment groups 
either in terms of the change in heart rate from the value at 24 hours or from baseline.
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Figure 5.8:
Ambulatory m ean  systolic an d  diastolic blood p ressu re  following two 
d o se s  of enalapril 2 .5m g p.o. (A) or perindopril 2mg p.o. (■ ) in patients 
with congestive heart failure.
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Figure 5.9:
H eart rate (bpm) following d o se  2 of study  trea tm en t in patients with 
congestive heart failure.
P atien ts received placebo p.o. + p laceb o  p.o.(D ), enalapril 2.5mg p.o. + enalapril 
2.5m g p.o., perindopril 2mg p.o. + perindopril 2m g p.o. (■ ) or perindoprilat 
0 .167m g i.v.+ perindopril 2m g p .o .(O )
5.3.3 Drug concentrations
A. Enalapril 2.5mg p.o.
The pharmacokinetic profiles of enalapril and its metabolite enalaprilat were similar 
to those seen in previous studies in congestive heart failure, with an early peak 
concentration of the parent ester enalapril followed by a protracted plateau concentration 
of the diacid metabolite enalaprilat (Figure 5.10). The mean maximum concentration 
(CmJ  of enalapril was 45.2 (20.5) ng/ml, (range 14.9-80.5). Cmax of enalaprilat was 11.2
(5.7) ng/ml, (range 1.7-22.8). The mean time to peak concentration (Tmax) of enalapril was 
1.9 (0.8) hours; Tmax of enalaprilat was 7.4 (2.0) hours.
Both enalapril and enalaprilat were detectable in the serum of all patients at 24 and 
at 48 hours after dose 1. At 24 hours after the first dose of enalapril 2.5mg p.o., mean 
enalapril concentration was 5.05 (5.69) ng/ml. At 48 hours after dose 1, i.e., after 2 doses 
of enalapril 2.5 mg p.o., enalapril concentration was 5.34 (6.98) ng/ml. Enalaprilat 
concentration at 24 hours was 3.86 (4.03) ng/ml. At 48 hours ,i.e., after 2 doses, 
enalaprilat concentration was 3.92 (3.94) ng/ml.
B. Perindopril 2mg p.o.
The pharmacokinetic profiles of perindopril and its active metabolite perindoprilat 
were similar to those seen in previous studies in congestive heart failure. Profiles were 
qualitatively similar to those for enalapril and enalaprilat with an early peak of parent ester 
followed by a prolonged plateau of diacid metabolite (Figure 5.11). The mean maximum 
concentration (Cmax) of perindopril was 32.2 (16.0) ng/ml (range 9.8-67.1). Cmax for 
perindoprilat was 4.10 (1.65) ng/ml (range 2.1-7.7). The mean time to peak perindopril
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concentration (Tmax) was 2.0 (0.9) hours (range 1.25-4.0); Tmax for perindoprilat was 5.1 
(3.0) hours (range 0.83-10). The diacid metabolite perindoprilat was detectable at 24 
hours in all 12 subjects receiving perindopril 2mg p.o on day 1. Mean plasma perindoprilat 
concentration was 1.9(1.6) ng/ml at 24 hours. Low levels of parent ester remained 
detectable in 10 of 12 subjects at 24 hours (mean concentration 1.9 ng/ml, range 0-1.8).
At 48 hours after dose 1, perindopril was detectable in the plasma of 9 of the 10 subjects 
for whom a drug concentration was obtained at this time. The mean area under the 
perindoprilat concentration-time curve (AUC) from 0-24 hours was 60.14 (29.46) 
ng/ml.hr., significantly higher than seen with the intravenous infusion (p=0.001).
C. Perindoprilat 0.167mg i.v.
The pharmacokinetic profile following constant rate i.v. infusion of 0.167mg 
perindoprilat is shown in Figure 5.12. Perindoprilat concentration reached a peak at the 
end of the 1 hour infusion period. Following termination of the i.v. infusion, perindoprilat 
concentration declined slowly over the 24 hour period. Mean maximum (Cmax) 
perindoprilat concentration was 4.4 (2.9) ng/ml (range 1.5-9.9).
Tmax was 0.96 (0.14) hours (range 0.67-1.25). Perindoprilat was detectable in all 
12 subjects at 24 hours, mean concentration at this time being 0.63 (0.38) ng/ml (range 
0.1-1.5). Mean perindoprilat concentration at 48 hours was 1.64 (0.89) ng/ml (range 0- 
2.8). Drug was detectable in the serum 9 of the 10 patients for whom a serum sample was 
obtained at this time. The mean AUC (0-24 hrs) for perindoprilat was 23.59 (12.64) 
ng/ml.hr, significantly lower than seen with perindopril 2mg p.o.(p=0.001).
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Figure 5.10:
P lasm a concentration (M ean±1 SD) of enalapril (A) and enalaprilat (A) 
after oral adm inistration of enalapril 2.5m g p.o. in patients 
with congestive heart failure.
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Figure 5.11:
P lasm a concentration (M ean ± 1SD) of perindopril (■ ) and perindoprilat (□ ) 
after oral adm inistration of perindopril 2mg in patients with heart failure.
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Figure 5.12:
P lasm a concentration of perindoprilat (0 )(M ean  ± 1SD) following infusion of 
perindoprilat 0.167 mg i.v. over 1 hour in patien ts with congestive heart failure.
5.4 DISCUSSION
5.4.1 1st dose haemodynamic responses 
Blood pressure response
The present study confirms disparate blood pressure responses to the first dose of 
the pro-drug ester ACE inhibitors perindopril 2mg p.o and enalapril 2.5mg p.o. in elderly 
patients with congestive heart failure. As in the previous study (MacFadyen et al 1991b), 
similar profiles of plasma ACE inhibition were seen with these doses. Quantitatively, 
enalapril showed slightly greater maximal inhibition of plasma ACE than perindopril, the 
reverse of the pattern seen in the previous study. The transient pressor response observed 
after intravenous dosing with perindoprilat in the previous study was not observed. A 
small, transient rise in MAP was observed after oral dosing with perindopril and with 
placebo but did not attain statistical significance. This trend was paralleled by a rise in 
heart rate over the first hour of the study with all oral therapies including placebo. In 
contrast to a previous study (MacFadyen et al 1993) these effects were not seen with 
intravenous perindoprilat. Although it is possible that the pressor response and increase in 
heart rate are due to displacement of bound angiotensin II, it is perhaps more likely that 
they simply reflect the stress associated with the start of the study, a period of intensive 
blood pressure monitoring and blood sampling. The tendency for these phenomena to be 
seen after dosing with placebo would tend to support this explanation.
Demographic differences among patient groups do not apear to explain the 
observed differences in haemodynamic profile. Groups were well matched in terms of 
NYHA class, diuretic dose and laboratory parameters. Similarly, the aetilogy of CHF does 
not explain the differences (see Chapter 8). In particular, in all 4 patients in whom valvular 
disease was felt to be contributory to CHF the lesions were regurgitant in nature and
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differences in this regard among treatment groups are most unlikely to explain the 
observed haemodynamic differences.
Heart rate response
Significant reductions in mean supine heart rate were seen following perindopril 
2mg p.o. and perindoprilat 0.167mg i.v. In contrast to previous observations (MacFadyen 
et al 1991) no fall in heart rate was seen following enalapril 2.5mg p.o. There is no 
obvious explanation for the diversity of findings in this respect between the two studies. 
The results confirm the lack of reflex tachycardia associated with the commencement of 
ACE inhibitor therapy in CHF. One possible explanation for the reduction in heart rate 
following commencement of ACE inhibitor therapy would be an effect on the autonomic 
nervous system. There is abundant evidence of a synergystic interaction between the renin- 
angiotensin system and the sympathetic nervous system (Squire and Reid 1993). Inhibition 
of ACE may theoretically reduce sympathetic activity and thus reduce heart rate. 
Alternatively, a parasympathomimetic effect of ACE inhibitors has been postulated (Ajayi 
et al 1985). There is no direct evidence for either effect from this study.
5.4.2 Blood pressure response 10-48 hours after initiation of therapy.
The haemodynamic response over the first 10 hours following initiation o f therapy 
differed between perindopril and enalapril. At 24 hours, MAP had fallen by a mean of 
approximately 9mm Hg in each group compared to baseline. Neither the change in MAP 
nor the absolute MAP at this time differed between the groups. At this point, 24 hours 
after the first dose of oral therapy, MAP appears to be falling in the perindopril group but 
rising in the enalapril group. The question as to whether perindopril is associated with a 
blood pressure fall between 10 and 48 hours after initiation of therapy has only been
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partially answered by the present study. Measured ambulatory blood pressure responses 
following the second dose of oral therapy were very variable and no difference between 
perindopril and enalapril groups could be identified in terms of the fall in ambulatory 
MAP. The results demonstrate that the mean hourly ambulatory blood pressure after the 
second dose of oral therapy was lower in those patients receiving enalapril compared to 
those receiving perindopril.
The present study has confirmed that the mean fall in MAP after perindopril 2mg 
p.o. is not different to that seen after placebo. Although the administration o f perindoprilat 
0.167mg i.v. over 1 hour also showed no effect on blood pressure compared to placebo, 
the trend in MAP over the period of infusion is unequivocally down as compared to the 
placebo response over the same period. If we postulate that the BP response is a 
phenomenon related to plasma drug concentration, intravenous infusion of 0.4mg 
perindoprilat (an amount of perindoprilat equivalent to 2mg perindopril p.o. assuming 
20% oral bioavailability of perindopril as perindoprilat) would have been more likely to 
elicit a fall in MAP. The greater mean area under the concentration-time curves (0-24 hrs) 
indicate that the oral dose provided a greater total amount of drug than intravenous 
perindoprilat. Intravenous doses of perindoprilat of lmg lower blood pressure in patients 
with CHF (MacFadyen et al 1993).
5.4.3 Pharmacokinetic profiles
It is of interest to compare the relative haemodynamic and pharmacokinetic 
profiles following perindopril 2mg p.o. and perindoprilat 0.167mg i.v. The Cmax for 
perindoprilat was the same after perindopril 2mg p.o. (4.1 ng/ml) as after perindoprilat 
0.167mg i.v. The maximum mean fall in MAP after perindoprilat i.v. (7.8mm Hg) was seen 
at the end of the 1 hour infusion period. Mean plasma perindoprilat concentration at this
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time was 3.68 ng/ml. This compares with a maximum mean fall of 6.8mm Hg seen at 4.5 
hours following perindopril p.o. The concentration of perindoprilat at this time was 
approximately 3 ng/ml. It is of note however that in the group receiving perindoprilat i.v., 
mean BP fall at this time, i.e., 4.5 hours post dose, was 6.7mm Hg and circulating 
perindoprilat concentration approximately 1.3 ng/ml. There appears therefore to be some 
discrepancy between the two treatments in terms of the relationship of haemodynamic 
response to plasma drug concentration. Overall the pharmacokinetic profiles o f all active 
treatments were broadly comparable to those seen with the same doses in previous studies.
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CHAPTER 6
THE HAEMODYNAMIC AND NEUROHORMONAL RESPONSE TO THE 
FIRST DOSE OF QUINAPRIL IN CHF
6.1 INTRODUCTION
In recent years a number of ACE inhibitor agents have been introduced for the 
treatment of CHF. A variety of claims have been made for the relative merits of each of 
these, such as preferential binding to tissue or cardiac ACE.The relative efficacy of the 
agents available in terms of improvement in mortality and morbidity in CHF has not been 
addressed and is unlikely to be so in the near future.
Quinapril is a recently introduced, non-sulphydryl ACE inhibitor. Previous reports 
associated quinapril with a lower incidence of first-dose hypotension than either enalapril 
or captopril (Wadworth & Brogden 1991). Moreover, this agent has been suggested to 
have a relatively higher affinity for tissue ACE (Nakajima et al 1992). A recent study 
showed that relatively greater inhibition of tissue ACE is produced bt a single 20mg dose 
of quinapril compared to the same dose of enalapril at a time when inhibition of plasma 
ACE is equivalent (Lyons et al 1997). Given that the relationship of the fall in BP to the 
level of plasma ACE inhibition is unclear, and that this response may be dependent upon 
inhibition of tissue ACE, this study set out to compare the first-dose haemodynamic 
response to the first dose of the prodrug ACE inhibitor quinapril in elderly patients with 
CHF. The currently recommended starting dose of the agent in heart failure was chosen 
for comparison with placebo on a background of supervised diuretic withdrawal. The main 
points of interest were to be the haemodynamic and neurohormonal responses and the 
pharmacokinetic profile following a single oral dose of quinapril 2.5 mg.
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6.2 PATIENTS AND METHODS
This study was carried out in patients with chronic stable congestive cardiac failure 
(n=24, 54-88 years; 11:13, M:F), New York Heart Association (NYHA) functional class 
II-IV. All patients were symptomatic on stable doses of diuretic therapy prior to the 
study. All patients were admitted to hospital for commencement of ACE inhibitor therapy. 
All had erect systolic blood pressure of > 100 mm Hg, and none had significant 
disturbance of renal or hepatic function, prior to the study.
The diagnosis of CHF was confirmed by clinical history and by physical, 
ectrocardio-graphic and echocardiographic examination in all cases. A number of patients 
had also undergone radionuclide scanning or cardiac catheterisation. Demographic details 
of patients receiving placebo and quinapril are shown in Tables 6.1 and 6.2 respectively.
In all but one patient, all diuretic therapy was withdrawn for 48 hours prior to the study 
day. In this one individual (patient no. 13), diuretic withdrawal was for 24 hours due to 
concerns regarding stability of the clinical condition. All vasodilator (eg oral nitrate, 
calcium channel blocker) or B-blocker (patient 24 only) therapy was witheld on the day of 
the study; digoxin, where prescribed, was continued. On the morning of treatment, the 
individual patient rose, washed and had breakfast as normal. The patient then returned to 
bed where they rested supine. A peripheral venous cannula was inserted in an antecubital 
fossa vein for the purpose of blood sampling.
Following 45-60 minutes supine rest, blood was drawn for estimation of baseline 
drug concentration, ACE activity, plasma renin activity, aldosterone and angiotensin II 
levels. Blood pressure was measured at 2 minute intervals during this period using a semi­
automatic sphygmomanometer (Sentron, Bard, Sunderland, U.K.) to establish baseline 
values. Baseline blood pressure values represent the mean of the recordings at 2 minute
140
Table 6.1
Demographic data 
Placebo
Study No. Age (years) Sex Aetiology NYHA Class
3 56 F IHD n
5 77 M IHD H
8 85 F IHD/HT III
9 60 M IHD/HT HI
12 69 M IHD II
13 55 F IHD/HT n
15 82 F IHD IV
17 68 M IHD n
20 76 F IHD IH
21 73 M IHD/HT IH
23 74 F IHD m
69.1±10.7
4 atrial fibrillation/ 8 sinus rhythm 
Frusemide 70±27 mg/day
IHD Ischaemic heart disease
HT Hypertension
NYHA New York Heart Association functional class
Table 6.2
Demographic data 
Quinapril 2.5 mg
Study No. Age (years) Sex Aetiology NYF
2 79 F IHD/HT n
4 67 M IHD n
6 88 F IHD n
7 81 F HT m
10 75 M IHD/HT n
11 85 F IHD/HT IH
14 68 F IHD n
16 61 F IHD/HT IH
18 76 M IHD n
19 74 M IHD/HT ii
22 83 F IHD/HT n
24 72 M IHD n
75.6±8.2
5 atrial fibrillation/ 7 sinus rhythm 
Frusemide 56.7±27 mg/day (p=0.42)
IHD Ischaemic heart disease
HT Hypertension
NYHA New York Heart Association functional class
intervals during the final 30 minutes of this period. Oral study medication (quinapril 2.5 
mg or matching placebo) was then administered in a double-blind fashion according to the 
randomisation schedule held by the hospital Department of Pharmacy. Blood sampling and 
triplicate determination of blood pressure were carried out at set time points until 10 hours 
after administration of the study drug. Patients remained supine until this time, at the end 
of which they were allowed to resume normal activity. Blood sampling and blood pressure 
measurements were repeated at 24 hours, prior to which the patients again rested supine 
for 45-60 minutes.
At the end of the 24 hour study period the treatment code was broken by the 
Department of Pharmacy. Patients who had received active therapy were continued on 
open ACE inhibitor therapy (mostly enalapril 5 mg b.d.) while those who had received 
placebo were given a standard oral test-dose of captopril 6.25 mg. Patients receiving 
placebo were not included in any other study phase. Vasodilator and diuretic therapies 
were reintroduced as required. Blood sampling for routine haematological and 
biochemical estimation was carried out prior to the commencement of the study and at 
the end of the 24 hour study period.
6.3 RESULTS
6.3.1 General
The patients in each study group were well matched in terms of age, severity of 
CHF and diuretic dosage (Tables 6.1 & 6.2). Pre-treatment haemoglobin concentration 
was higher in the placebo group (p=0.04). None of the biochemical parameters was 
significantly altered 24 hours after initiation of therapy, either active or placebo (Table
6.3). A small fall of approximately lg/dl was seen in haemoglobin concentration and is
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Table 6.3
Laboratory data. Baseline values and change over study period (Mean (1SD))
Quinapril Placebo p-value
Sodium (mmol/L) 
Sodium (change)
140.7 (3.1) 
-3.2 (3.3)
140.5(1.9) 
-0.4 (3.5)
0.91
0.07
Potassium (mmol/L) 
Potassium (change)
4.0 (0.4) 
+0.3 (0.4)
4.4 (0.4) 
+0.2 (0.5)
0.10
0.39
Urea (mmol/L) 
Urea (change)
9.5 (4.4) 
-0.5 (1.6)
8.1 (3.7) 
-0.9 (1.4)
0.39
0.39
Creatinine (jumol/L) 
Creatinine (change)
126.7 (52.4) 
-0.8 (27.3)
114.3 (30.2) 
-10.8(17.3)
0.42
0.3
Haemoglobin (g/dL)
Haemoglobin
(change)
12.8 (1.5) 
-1.0 (0.8)
14.3 (1.8) 
-1.1 90.4)
0.04
0.82
Baseline PRA 
(ng AI/ml/Hour) 
(Mean(95% C.I.))
0.86(1.21-3.39) 1.85 (1.20-6.81) 0.10
Baseline aldosterone 
(pg/ml)
111(66) 155(118) 0.28
Table 6.4
Patient characteristics. Baseline supine blood pressure and heart rate (Mean (1SD))
Quinapril Placebo p-value
Systolic BP (mm Hg) 142(18) 125 (20) 0.055
Diastolic BP (mm Hg) 72 (9) 69 (17) 0.55
Mean BP (mm Hg) 95 (12) 88 (16) 0.21
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Figure 6.1 :
Baseline corrected  ch a n g e  in m ean  arterial blood p ressu re  (Mean±1SD) 
after quinapril 2 .5m g p.o. (A ) o r p laceb o  (□ )  in patients with congestive 
heart failure.
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Figure 6.2:
B aseline corrected  ch a n g e  in systo lic blood p ressu re  (Mean±1 S.D.) 
following quinapril 2 .5m g p .o .(A )o r p lacebo  (□ ) in patients with 
congestive heart failure.
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Figure 6.3:
B aseline corrected  ch an g e  in diastolic blood p ressu re  (Mean±1 S.D.) 
following quinapril 2.5m g p.o.(A ) or p lacebo (□ ) in patients with 
congestive heart failure.
attributable to blood sampling. All patients remained asymptomatic during supervised 
diuretic withdrawal and during the study period. One patient receiving active therapy 
(Subject 18) showed a rise in serum creatinine concentration, from 196pmol/l prior to 
treatment to 242pmol/l 24 hours following acute ACE inhibition. This rise was 
transient and did not necessitate discontinuation of maintenance therapy.
There were three adverse events during the study, none of which was felt to be 
directly related to study medication. One patient who had received placebo therapy 
(Subject 23) was unable to tolerate maintenance ACE inhibitor therapy due to 
symptomatic hypotension following the first dose of oral captopril 6.25 mg. The post­
study ECG of a second patient who had received placebo therapy (Subject 21) showed 
anterolateral ST segment depression without associated symptoms. The patient had known 
stable ischaemic heart disease and no further action was required. One patient who had 
received active therapy (Subject 11) developed a pyrexia during the study period; a urinary 
tract infection was diagnosed clinically and confirmed on urine culture.
6.3.2. Haemodynamic response
Blood pressure and heart responses at each time point are described as change 
from baseline values. Pretreatment baseline MAP was similar in treatment groups (Table
6.4). Systolic blood pressure tended to be higher (p=0.055) in the group receiving 
quinapril (141.8±18 mm Hg) compared to those receiving placebo (125.0±20). Baseline 
heart rate was similar in the two groups (Table 6.4).
Blood pressure
In both active and placebo groups, a transient rise in blood pressure was observed 
during the early part of the study period immediately following administration of the study
142
He
ar
t 
Ra
te 
(C
ha
ng
e 
fro
m 
ba
se
lin
e)
14 -  
12  -  
10  -  
8 -  
6 -  
4 -  
2 
0 
-2 
■4 
-6 
-8 
■10 
-12 
■14
' I 1 I 1 I 'T ■r  \ i r - i- - |  i | i H - i -  i ■
2 3 4 5 6 7 8 9  10
TIME (Hours)
i
24
Figure 6.4 :
C hange in heart ra te  (m ean± 1S D )(change from baseline, bpm) after 
quinapril 2.5m g p.o. ( * )  o r  p laceb o  (□ ) in patien ts with congestive 
heart failure.
drug. There was no statistical difference between the groups in the magnitude of this blood 
pressure change. Following this early rise in MAP, quinapril lowered blood pressure 
compared to placebo. The magnitude of the blood presure fall was greater in absolute 
terms for systolic blood pressure than for diastolic or mean blood pressure. For MAP, the 
change from baseline was significant compared to placebo at 3, 5, 8 and 10 hours (Figure 
6.1). For systolic blood pressure, the change was significant at 5, 5.5, 8 and 10 hours 
(Figure 6.2). For diastolic blood pressure, the change was significant at 1, 3, 3.5, 5, 8 and 
10 hours (Figure 6.3).
The maximum mean fall in MAP compared to baseline was 12.0 (9.8) mm Hg, seen 
at 5 hours post dose. The mean maximum fall in MAP for individual subjects, irrespective 
of its time course, was 19 (8) mm Hg in the quinapril group (range 0 to 27 mmHg) at 5.1 
(2.9) hours and 13 (13) mm Hg at 7.42 (8.10) hours in the placebo group (range 0 to 42 
mmHg) (p=0.20, N.S.)
Heart rate
Supine heart rate showed only minor fluctuations over the period of study. No 
significant change from baseline value was seen at any time point for either active or 
placebo therapy. Heart rate did not change after initiation of therapy with quinapril (Figure
6.4).
6.3.3 Plasma ACE inhibition
Plasma ACE activity was rapidly inhibited in the active treatment group. Inhibition 
reached a statistically significant level by 50 minutes after drug administration. Plasma
ACE inhibition was maximal at 3 hours (87.2 ± 6.2%) although there was no statistical
difference between the degree of inhibition seen at any time point between 2 and 10 hours.
143
The degree of ACE inhibition at 24 hours in the active treatment group remained 
significant (61.3 ± 20.2%) compared to baseline (Figure 6.5).
6.3.4 Plasma drug concentration
Concentrations of both quinapril and the active metabolite quinaprilat were 
determined at frequent intervals during the study day (Figure 6.6). The mean time(SD) to
peak concentration (Tmax) for quinapril was 2.56 (1.15) hours while the mean time to peak
quinaprilat concentration was 3.56 (0.84) hours. The mean maximum concentration (Cmax)
of quinapril was 49.7 (30.9) ng/ml (range 25.2-138.5). The mean maximum concentration
of quinaprilat was 51.0 (22.8) ng/ml (range 29.4-103.5). The active moiety quinaprilat was
detectable in the plasma within 30 minutes, and remained detectable at 24 hours, in all 12
subjects receiving active therapy (mean 4.4±5.2 ng/ml, range 1.5-20.3). Mean quinapril
concentration (n=12) was 1.8 (2.2) ng/ml (range 0.0-7.1) at 24 hours. Quinapril was
undetectable at this time in 3 of 12 subjects.
The half-life (t]/2) estimated by log linear regression analysis of plasma quinaprilat
concentrations at 8, 10 and 24 hours was 6.1 hours. The terminal half-life could not be
estimated in view of the short sampling period.
6.3.5 Plasma renin activity
Plasma renin activity (PRA) at baseline showed wide interindividual variation. 
Baseline PRA was higher in the placebo group (p=0.10) (Table 6.3). Plasma renin activity 
in the active treatment group showed the expected rise compared to placebo.
Plasma renin activity (PRA) at baseline showed wide interindividual variation. 
Baseline PRA was higher in the placebo group (p=0.10) (Table 6.3). Plasma renin activity 
in the active treatment group showed the expected rise compared to placebo (Figure 6.7).
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Figure 6.5:
Plasma ACE inhibition (% baseline activity)(Mean ± 1SD) after quinapril
2.5 mg p.o.(A) or placebo (□ )  in patients with congestive heart failure.
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Figure 6.6:
Plasma concentrations of quinapril (4) and quinaprilat (□ ) following a single dose of 
quinapril 2.5mg po in patients with CHF.
In relative terms placebo therapy was associated with a static diurnal profile of renin 
whereas quinapril clearly produced the expected reactive rise. The mean maximum rise in 
plasma renin activity was significantly higher (p=0.027) in the active treatment group 
(10.23 ± 13.16 ng Al/ml/hr) than for placebo (1.61 ± 2.54 ng Al/ml/hr).
6.3.6 Angiotensin II concentration
Angiotensin II (Angll) concentrations at baseline showed a high degree of inter­
subject variability. Mean Ang II concentrations were similar in the two treatment groups; 
quinapril 21.53 (6.66) finol/ml, placebo 28.84 (15.53) fmol/ml (p=0.148). As expected, 
mean Ang II concentration fell in the active treatment group compared to placebo (Figure 
6.8). There was however no statistically significant differences in Ang II concentration 
between treatment groups at any time point. Mean maximum fall in Ang II was 7.40 (5.84) 
finol/ml for quinapril and 8.75 (8.00) for placebo (p=N.S.).
6.4 DISCUSSION
6.4.1 Haemodynamic response
This is the first reported study in a placebo controlled setting of the haemodynamic 
response to the commencement of the ACE inhibitor quinapril in its recommended starting 
dose, 2.5 mg, in patients with stable CHF. The treatment was well tolerated with no 
episodes of symptomatic hypotension. Considerable inhibition of plasma ACE activity was 
achieved for 24 hours following this relatively small dose of quinapril.
The observed fall in mean arterial pressure was moderate and appears to be of 
a similar magnitude to that seen in previous open studies of quinapril in CHF. The 
observed mean fall of 12 mm Hg in the present study compares with 14 mm Hg seen with 
5mg p.o. (Holt et al 1986), 12 mm Hg with 2.5mg p.o. (Nieminen and Kupari 1990) and
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Figure 6.7:
Plasma renin activity (ng Al/ml/hr) following quinapril 2.5mg p.o. (A)
or placebo (□ ) in patients with con gestive heart failure.
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Figure 6.8:
Plasma angiotensin II concentration (% baseline) following quinapril
2.5m g p.o. (A) or placebo (□ )  in patients with congestive heart failure.
12 mm Hg seen with doses between 2.5-10 mg p.o. (Sedman and Posvar 1989).
The timing of the maximum blood pressure fall seen in the present study is 
somewhat later than previously reported. The maximum blood pressure fall was seen at 5 
hours compared with the 2-2.5 hours to maximal blood pressure response seen in previous 
studies of quinapril in CHF eg 5mg p.o.(Holt et al 1986), 2.5-10mg p.o. (Nieminen & 
Kupari 1990). In addition there would appear to be differences in the duration of effect. 
While the present study recorded a significant fall in blood pressure to 10 hours post dose, 
a previous study in heart failure described haemodynamic changes which were no longer 
different from baseline by 4 hours after a single dose of quinapril 5mg p.o.(Holt et al 
1986). Haemodynamic monitoring was discontinued at 4 hours post dose, and that time 
although not statistically different, mean arterial blood pressure was 93.1 ±4.5 mmHg at 
baseline compared to 77.5±7.5 mmHg at 4 hours. Any continued effect on mean arterial 
pressure after this point would therefore not have been detected and the time to peak 
effect underestimated. Thus, while the time course of the blood-pressure lowering effect of 
quinapril has been compared to that of captopril with a peak effect at 1.5-3 hours (Holt 
et al 1986, Wadworth and Brogden 1991), the present study suggests that in heart failure a 
more accurate comparison may be with enalapril, with which the maximum haemodynamic 
changes are seen at 4-6 hours post dose (Todd & Heel 1986). If the reported greater 
affinity of quinapril for tissue ACE was relevant to the BP response, a relatively greater 
fall in BP than seen here would have been expected. Although a direct comparison 
between the responses to 2.5mg of either enalapril or quinapril in the studies reported in 
this thesis cannot be made, the observations reported do not suggest that BP response 
depends upon inhibition of tissue rather than plasma ACE. The time to peak effect and 
duration of blood pressure response appear to be greater than previously suggested.
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The lack of effect of quinapril on heart rate is is in keeping with other studies of 
acute ACE inhibition, the lack of reflex tachycardia in the face of a fall in blood pressure 
being characteristic of these drugs. Enalapril has been shown to elicit a fall in heart rate 
despite a significant fall in blood pressure in patients with heart failure (MacFadyen et al
1991) and a similar phenomenon has been observed with perindopril p.o. and perindoprilat 
i.v. (Chapter 5).
6.4.2 Pharmacokinetic profile
The present study indicates that peak concentrations of quinapril occur at 2-3 
hours post dose, in agreement with previous studies (Holt et al 1986). Quinaprilat levels 
were not reported in the previous study. The 3-4 hours to peak quinaprilat concentration is 
somewhat longer than the time to peak in normal volunteers of 2 hours (Ferry et al 1987, 
Horvath et al 1990, Elliott et al 1992).
The concentration-time profiles of the parent ester quinapril and the active 
metabolite quinaprilat differ from those seen with other ester prodrug ACE inhibitors in 
this setting. The concentration profiles of enalapril and perindopril show relatively greater 
circulating concentrations of the ester in relation to the subsequent appearance of a 
protracted plateau concentration of the diacid metabolite (Chapter 5). The present study 
shows comparable quantitative profiles for parent ester and diacid metabolite after a single 
dose of quinapril 2.5 mg (Figure 6.6). During chronic dosing, plasma concentrations of 
quinaprilat have been reported to be approximately four-fold higher than those of the 
parent ester (Olson et al 1989). In keeping with the relatively large quantities of potent 
diacid the profile of plasma ACE inhibition with quinapril in the present study is greater 
than that seen following single doses of perindopril 2 mg p.o. and enalapril 2.5 mg p.o. in
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CHF but with a lesser fall in blood pressure (Chapter 5). This may reflect inadequacy of 
the plasma ACE profile as an index of drug effect or may represent differential interactions 
of individual ACE inhibitors with plasma and tissue based renin-angiotensin systems. The 
significance of the atypical pharmacokinetic profile of quinapril is unclear.
Clearance of both quinapril and quinaprilat are directly related to creatinine 
clearance for healthy volunteers (Begg et al 1990) and for normotensive patients 
(Halstenson et al 1992). As with all ACE inhibitors a number of factors are likely to 
contribute to the differing pharmacokinetic profiles of quinapril in elderly patients with 
CHF. It is possible that the delay to peak drug concentration seen in the present study 
reflects a degree of renal impairment, as indicated by the relatively high baseline mean 
urea and creatinine levels. Such renal impairment may be related to age or a consequence 
of heart failure. Changes in drug metabolism secondary to age and as a result of CHF may 
be contributory.
The mean maximum plasma concentration of quinaprilat seen in the present study 
(51 ng/ml) is very similar to that seen in normal volunteers following a single dose of 
2.5mg p.o. (Elliott et al 1992). That quinaprilat remained detectable 24 hours after a single 
2.5mg dose is not surprising given its detection 72 hours after the same dose in normal 
volunteers (Elliot et al 1992). The concentration of drug detectable at 24 hours is higher 
than seen at the same stage in normal volunteers (4.4 ng/ml cf. 2ng/ml). This is likely to 
reflect differences in renal function and drug clearance between healthy volunteers and the 
older patient population of the present study who have concomitant disease.
The elimination half-life of quinaprilat has previously been estimated at 2 hours 
(Wadworth & Brogden 1991), a value which is perhaps inconsistent with the prolonged 
duration of action of quinapril. A previous study (Elliott et al 1992) demonstrated that
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with a more sensitive assay than that used previously and a longer sampling period the 
elimination half-life approximated to 26 hours in normal subjects. The sampling period of 
24 hours in the present study was too short to estimate the terminal t1/2, but over the 
period 8-24 hours plasma concentrations decayed with a calculated t ]/2 of at least 6 hours. 
This is supporting evidence for the value of a sensitive assay in defining the plasma t l/2. 
The pharmacokinetics of all long acting ACE inhibitors are such that estimates of t1/2 are 
heavily dependent upon the sampling period and assay sensitivity. Estimates based on 
insensitive assays are of limited clinical relevance. The limit of detection of our assay is 
approximately 0.1 ng/ml as compared to the 5 ng/ml of the original assay (Olson et al 
1989).
Although maximum quinaprilat concentrations are dose related, persisting low 
levels of drug during the elimination phase have been found with a number of other ACE 
inhibitors and are thought to reflect slow dissociation of the drug from tissue binding sites 
(Lees et al 1989). A formal study using a prolonged sampling period and a sensitive assay 
in patients with CHF would be required to establish the effect of the condition on the 
pharmacokinetics of quinapril, and the impact of the drug on the tissue based system 
derived from the extended pharmacokinetic profile.
The profile of plasma ACE inhibition in the present study is broadly comparable to 
that seen following a single dose of quinapril 2.5 mg p.o. in normal volunteers. Although 
direct comparison is not possible the degree of residual enzyme inhibition at 24 hours 
appears to be somewhat higher in the patients with CHF compared to the volunteers 
studied previously, 63% inhibition in CHF compared to 50% in volunters (Elliott et al 
1992). This is again likely to reflect relatively slower drug clearance in the present 
population.
Although there is a poor correlation between the degree of circulating ACE 
inhibition and the blood pressure response following introduction of ACE inhibitor 
therapy, no dissociation between the two parameters was seen in this study. Quinapril has 
been reported as less often associated with first-dose hypotension (0.4% incidence) than 
either enalapril (1.5%) or captopril (2.2%) (Wadworth & Brogden 1991). These estimates 
do not reflect equivalent drug exposure within the general population and are unlikely to 
reflect the response in CHF. At present, quinapril is indicated for the treatment of CHF in 
doses of 10-20 mg daily in two divided doses. The present study indicates the efficacy of a 
single 2.5mg oral dose in inhibiting plasma ACE over 24 hours in patients with CHF.
The fall in angiotensin II following quinapril iis very much less than would have 
been expected. The relative lack of reduction in angiotensin II may reflect inadequacy in 
sample handling. However large falls were seen in a number of individual patients and is 
reflected in the large standard deviation around the mean fall.
Quinaprilat kinetics are non-linear and characterisation of the concentration-effect 
relationship is dependent upon an Emax model, i.e., a maximum effect model (Elliott et al
1992). The study, in normal volunteers, suggested that 2.5 mg is sufficient to provide near 
maximum ACE inhibition. The present study has confirmed profound ACE inhibition and a 
significant blood pressure fall following 2.5 mg in patients with stable CHF. However the 
relationship between clinical efficacy of ACE inhibitors in heart failure and haemodynamic 
responses such as blood pressure reduction or pharmacokinetic parameters such as plasma 
ACE inhibition is unclear.
Doses of quinapril as low as 0.5 mg p.o. have been shown produce up to 70% 
inhibition of plasma ACE, although the duration of effect is reduced with reduction of
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dose. In hypertension, there appears to be a relationship between antihypertensive effect 
and plasma drug enalaprilat concentration (Donnelly et al 1990). No information is 
available on the haemodynamic response and more importantly the effect on exercise 
tolerance and mortality in CHF in response to chronic therapy with quinapril in a dosage of 
2.5mg once daily. The issue of the dose-response relationship for different ACE inhibitors 
with respect to clinically relevant end points, ie morbidity, exercise capacity and mortality 
has not yet been fully explored. However a greater improvement in exercise capacity has 
been reported with quinapril 10 mg and 20 mg twice daily than with 5 mg twice daily after 
12 weeks of treatment in patients with heart failure (Riegger et al 1990). Further studies 
would be required to identify the minimum effective dose of quinapril in heart failure.
In summary, a single dose of quinapril 2.5 mg administered orally to patients with 
chronic, stable CHF elicited a moderate but significant fall in MAP. The profile of blood 
pressure response was similar to that seen with enalapril in CHF. The pharmacokinetic 
profile showed relatively higher concentrations of the active diacid metabolite than is seen 
with other ACE inhibitors. Changes in neurohormonal parameters were as expected with 
inhibition of ACE which was inhibited to at least 24 hours post dose.
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CHAPTER 7
COMPARATIVE IN-VIVO AND EX-VIVO RAS INHIBITION FOLLOWING 
ACE INHIBITION IN CHF.
7.1 INTRODUCTION
The measured level of plasma ACE inhibition does not correlate well with the 
observed fall in blood pressure following treatment with ACE inhibitors (Unger et al 1986, 
Waeber et al 1980). One possible explanation for this observation is inhibition of tissue 
based renin-angiotensin systems independent of plasma ACE. Alternatively, the degree of 
activation of the renin angiotensin system and the dependence of blood pressure on the 
activity of the system may vary among individuals. This is certainly a factor in patients 
with congestive heart failure in whom the RAS is often activated by the disease process 
itself and by diuretic therapy.
To date the standard method of estimating the activity of the renin angiotensin 
system has been the measurement of plasma ACE activity on synthetic substrates in vitro 
(Piquilloud et al 1970, Ryan et al 1977). However a number of workers have questioned 
the reliability of plasma ACE activity as an indicator of the degree of activity of the RAS. 
The estimate of plasma ACE activity depends to some extent on the substrate used 
(Nussberger et al 1989). The reappearance of increasing levels of angiotensin II during 
ACE inhibition occurs during acute (Morton et al 1980, Swartz et al 1979, Nussberger et 
al 1985) and chronic (Cirillo et al 1988, Hodsman et al 1984, Nussberger et al 1989) 
treatment with a number of ACE inhibitor agents. This phenomenon may have important 
implications during therapy with ACE inhibitors. While plasma ACE appears to be 
inhibited for 24 hours after a sigle dose of lisinopril, the blood pressure response
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better profiles the reduction in circulating angiotensin II concentration; blood pressure 
shows a maximum fall within 6 hours of dosing and then rises steadily without regaining 
pretreatment levels at 24 hours (Cirillo et al 1988). A different and probably more 
complete inhibition of the renin angiotensin system may occur with different treatment 
regimens with alternative agents such as enalapril twice daily (Modina et al 1986). 
Nussberger et al demonstrated that while the degree o f inhibition of plasma ACE produced 
by benazepril was apparently of greater degree and duration than that produced by 
enalapril, the effect on plasma angiotensin II was similar (Nussberger et al 1989). Thus it 
has been suggested that an accurate assessment of the degree of inhibition o f the RAS is 
only given by assay of the relative concentrations of angiotensin I and II rather than in- 
vitro measurement of plasma ACE. Even in the face of complete inhibition o f plasma 
ACE, angiotensin II may be formed from angiotensin I by alternative enzyme activity, e.g., 
chymotrypsin (Thibault & Genest 1981), cathepsin G (Tonnesen et al 1982) and tonin 
(Boucher et al 1972).
The pathophysiological relevance of these alternative pathways of angiotensin II 
generation is unclear. While the measurement of angiotensin peptides may be desirable 
during studies of the renin angiotensin system, there are a number of problems associated 
with the assay of these compounds. Plasma concentrations of active angiotensin II 
(angiotensin-(l-8) octapeptide) lie in the low picomolar range, requiring the use of 
sensitive assays for their quantification. Given the short half life, 10-12 seconds, of 
angiotensin II in plasma of and its in vitro half life of 2-3 minutes, there is potential for 
generation as well as degradation of the peptide between blood sampling and assay 
(Nussberger et al 1986, Nussberger 1988). In addition, a number of metabolite and 
precursor peptides of angiotensin II are present in plasma and are generated in vitro.
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Angiotensin II (Angiotensin-(l-8) octapeptide) coexists with the (1-10) decapeptide, the 
(2-10) nonapeptide and the (4-8) penta-, (3-8) hexa-, and (2-8) heptapeptides. These 
cross-react to varying degrees in the available radioimmunoassays for angiotensin II, 
usually based upon antisera for the amino terminal of the octapeptide. Such antisera are of 
limited specificity and during ACE inhibition; falling concentrations of angiotensin II have 
to be assayed in the presence of concentrations of angiotensin I and metabolites which are 
increased up to 100 times. Previous studies from this department showed differing blood 
pressure responses to orally administered ester ACE inhibitors, no such differences being 
evident with administration of the diacid metabolites of the agents (MacFadyen et al 1991,
1993). In these studies initiation of intravenous ACE inhibitor therapy was associated with 
a small rise in blood pressure, which was postulated to be due to displacement of 
angiotensin II from ACE.
One possible explanation for the difference in blood pressure responses among 
orally administered agents is steric hindrance between the parent ester, a weak but highly 
lipophilic ACE inhibitor, and the diacid metabolite, a potent but highly polar ACE 
inhibitor. The presence of the parent ester perindopril in vitro can alter the degree of 
inhibition of plasma ACE by perindoprilat, the inhibition curve being displaced to the right 
(Harrigan et al 1989).
An alternative explanation for the disparate blood pressure responses seen in the 
face of indistinguishable profiles of plasma ACE inhibition is so-called "slow, tight 
binding". It has been suggested that some ACE inhibitors have the property of a time 
dependent decrease in K, after incubation with ACE (Ryan et al 1986). Thus it is possible 
that ex-vivo measurement of plasma ACE inhibition by an agent showing "slow, tight 
binding" is spuriously high when the assay is carried out weeks or months after the
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blood sample was drawn. Thus, if "slow, tight binding" occurs with perindopril to a 
greater extent than with enalapril, the degree of inhibition of plasma ACE observed with 
perindopril when assays are carried out may be spuriously higher than at the time of 
sampling. Thus the apparently equivalent plasma ACE inhibition may not be an accurate 
representation of inhibition of the RAS at the time of sampling.
Comparison of in-vivo ACE inhibition by measurement of the relative 
concentrations of angiotensin I and angiotensin II, with ex-vivo ACE inhibition by 
measurement of plasma ACE inhibition may reveal any temporal discrepancy between the 
two. In the case of "slow, tight binding" of perindoprilat as the explanation for the 
disparate blood pressure responses to enalapril and perindopril, a temporal dissociation 
between in-vivo and ex-vivo assessments of ACE activity may be expected with 
perindopril administered orally and perindoprilat intravenously, but not with enalapril. In 
the case of steric hindrance, such a temporal dissociation may be expected after 
perindopril p.o. but not after perindoprilat i.v.
This section describes the relative inhibition of the renin angiotensin system seen 
after initiation of ACE inhibitor therapy in heart failure with perindopril 2mg p.o., enalapril 
2.5mg p.o., or perindoprilat 0.167mg i.v. This aspect of the study set out to compare the 
apparent degree of inhibition of the renin angiotensin system as assessed both by in-vitro 
estimation of plasma ACE inhibition and in-vivo estimation of plasma angiotensin I and II 
concentrations.
The aims of the study were to:
1. Compare in-vivo and ex-vivo ACE inhibition following perindopril 2mg p.o and 
perindoprilat 0.167mg i.v. and to compare the results with those obtained for enalapril 
2.5mg p.o. The degree to which in vivo ACE inhibition is delayed or diminished compared
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to ex vivo measurements for each agent will allow us to distinguish between the 
hypotheses of slow, tight binding and steric hindrance discussed above.
2. Establish whether angiotensin I or II concentrations rise at the time o f the 
previously observed rise in blood pressure during infusion of perindoprilat.
7.2 PATIENTS AND METHODS
7.2.1 Patients
Forty eight elderly patients with stable, chronic congestive heart failure were 
recruited to the study. The analyses described here were carried out as part o f the 
observational study described in Chapter 5. The demographic data of the study population 
are described in Chapter 5. The laboratory methods for the measurement of plasma ACE 
activity are described in Chapter 4.
7.2.2 Assay of angiotensin peptides
Angiotensin II (Ang-(l-8) octapeptide) and angiotensin I (Ang-(l-lO) 
decapeptide) were measured using a series of specific and sensitive assays based on the 
methods of Nussberger et al (Nussberger et al 1985) with minor modifications (Devlin
1992). The procedure involves 3 steps: (1) extraction of angiotensin peptides by reversible 
adsorption to bonded phase silica; (2) separation of the angiotensin peptides by isocratic 
reversed phase high performance liquid chromatography (h.p.l.c.) and (3) direct linkage to 
a sensitive radioimmunoassay (r.i.a.).
The treatment of the patients for the purposes of blood sampling was as described 
in chapter 5. All patients rested supine for 45-60 minutes prior to the drawing of blood for 
measurement of baseline angiotensin peptide levels. Patients remained supine until 10 
hours after the administration of study medication, after which they were allowed to rise
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and resume normal activities. They returned to bed and again rested supine for 45-60 
minutes before blood sampling for the determination of angiotensin peptide levels at 24 
hours.
Procedure
Blood samples were drawn into pre-chilled glass collecting tubes on ice. The 
collecting tubes contained 0.5 ml inhibitor solution. The inhibitor solution contained 2% 
ethanol, 125 IS^Ethylene diamine tetra-acetic acid 125 mM, o-phenanthroline 50mM, 
neomycine sulphate 2g/L. To prevent the in vitro generation of angiotensin II, the renin 
inhibitor CGP 38560, lOOpM was added to the peptidase inhibitors of each tube. Samples 
were spun immediately at 4°C at 15000 r.p.m. for 15 minutes. Plasma aliquots were snap 
frozen and stored at -70°C until analysed.
Extraction
Angiotensin I and II were extracted by reversible adsorption to phenylsilyl-silica. 
(Bondelut-PH, Analytichem, Harbor City, California, U.S.A.). Bondelut cartridges each 
containing 100 mg phenylsilyl silica were placed in a vacuum manifold. Consecutive 
aliquots of methanol (1 ml), water (1 ml) and plasma (2 ml) were passed through the 
cartridge by vacuum aspiration in sequence. This procedure allows activation of the silica 
surface and adsorption of angiotensin peptides. Angiotensin peptides were then eluted 
using methanol (0.5 ml) and collected in polypropylene tubes containing albumin buffer 
(0.1 M Tris buffer, pH 7.5, 5 g/L bovine plasma albumin, 0.2 g/L NaN3). The methanol 
was then evaporated under air in a water bath at 40°C.
Chromatography
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Figure 7.1:
Angiotensin converting enzym e inhibition (% baseline , m ean ± 1SD) 
following placebo p.o. (□ ), enalapril 2 .5m g p.o. ( ^ ) ,  perindopril 2mg p.o. (■), 
or perindoprilat 0.167m g i.v. (O) in patien ts with congestive heart failure.
The extraction residue was redissolved 140 pL 0.1 M acetic acid. One hundred 
microlitres of this solution was submitted to isocratic reversed phase h.p.l.c. The system 
used was made up of a Hewlett Packard 1084 B liquid chromatograph with a Gilson 
electronic fraction collector. A 250 x 4.6 mm column containing octadecylsilyl-silica 
(Nucleosil C-18 5p, Innovativ Labor, Adliswil, Switzerland) was used. The mobile phase 
was methanol/0.085% phosphoric acid in a ratio of 33.5 : 66.5 (Nussberger et al 1985). 
The flow rate was 0.5 ml / min and the column compartment was kept at a temperature of 
45°C. At the relevant retention times, previously established using 100 ng of standard 
angiotensin I and angiotensin II, 90 pL fractions were collected into 0.5 ml o f albumin 
buffer.
Radioimmunoassay
Radiolabelled angiotensin II (125I-ANGII, 2200 Ci / mmol, MEM Dupont) in 0.05 
ml of buffer and 0.5 ml antiserum, (kindly provided by Dr. J.J.Morton, Medical Research 
Council Blood Pressure Unit, Western Infirmary, Glasgow) 1:26000 diluted in buffer was 
added to each collected chromatography fraction. Incubation was carried out for 48 hours 
at 4°C. The reaction was terminated by adding 0.3 ml of dextran coated charcoal (2% 
suspension in water). Antibody-bound hormone was separated from free hormone by 
centrifugation followed by decanting (Nussberger et al 1984). A similar procedure was 
used for assay of angiotensin I using radio labelled angiotensin I (125I-ANG I, 2200 Ci / 
mmol, MEM Dupont).
Angiotensin peptide standards
Increasing amounts of of angiotensin I or II (0-20 finol; Peninsula Labs, San 
Carlos, CA, U.S.A.) were added to 0.5 ml buffer and 105 pL of mobile phase. Antiserum
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and radiolabelled angiotensin peptide was added as for the unknown assay samples. 
Standard curves were constructed relating the percentage of bound labelled peptide 
against unlabelled hormone. The concentration of hormone in each h.p.l.c. fraction was 
read from this curve.
7.3 RESULTS
7.3.1 In-vitro plasma ACE inhibition
The profiles of plasma ACE inhibition are shown in Figure 7.1. Plasma ACE 
activity in the placebo group remained stable throughout the study period. Analysis of 
variance revealed a significant main treatment effect with active therapy (p=0.009) and 
significant treatment-time effect (p<0.001).
The profiles of plasma ACE inhibition following enalapril 2.5mg p.o. and 
perindopril 2mg p.o. were similar. There were no statistical differences in the degree of 
plasma ACE inhibition between the two treatments at any time point. Although not 
statistically significantly different from one another, the absolute degree of ACE inhibition 
was greater for enalapril than perindopril until 10 hours post dose, after which perindopril 
displayed greater ACE inhibition. Maximal mean plasma ACE inhibition, as a percentage 
of baseline activity, was observed at 8 hours for enalapril (53.7±24.5%), and at 10 hours 
for perindopril (50.8±21.4%).
For the group receiving oral perindopril, plasma ACE inhibition was significantly 
different from placebo from 4 to 48 hours after initiation of therapy. Plasma ACE 
inhibition was less than in the group receiving perindoprilat i.v. between 5 minutes and 2.5 
hours after initiation of therapy.
Compared to perindopril the onset of plasma ACE inhibition was faster for the 
group receiving enalapril and was different from placebo from 3 to 48 hours after the
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Figure 7.2:
Angiotensin I concentration (fmol/ml, mean ± 1SD) following enalapril
2.5mg p.o. (A) in patients with con gestive heart failure.
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Figure 7.3:
Angiotensin II concentration (fmol/ml, mean ± 1SD) following enalapril
2.5mg p.o. (A) in patients with congestive heart failure.
initiation of therapy. Plasma ACE inhibition was less than the group receiving 
perindoprilat i.v. between 15 minutes and 2 hours after the initiation of therapy.
Plasma ACE inhibition in the group receiving perindoprilat 0.167mg i.v. was 
greater than placebo from 20 minutes to 48 hours after the initiation of therapy, greater 
than after perindopril p.o. from 5 minutes to 2.5 hours and greater than after enalapril 
from 15 minutes to 2 hours after the start of therapy. Maximal mean ACE inhibition was 
seen at the end of the 1 hour infusion period (55.6±21.6%). Following cessation of the 
infusion, plasma ACE activity showed a rapid and substantial return toward baseline 
levels.
Plasma ACE inhibition at 48 hours, i.e., after 2 doses of therapy, in the group 
receiving enalapril was 34.1%, similar to at 24 hours after a single dose (36.3%). In the 
group receiving perindopril p.o. on day 1 and day 2, plasma ACE inhibition at 48 hours 
was 50% compared to 46.7% at 24 hours. In the group receiving perindoprilat i.v. on day 
1 and perindopril p.o. on day 2, plasma ACE inhibition at 48 hours was 43.1% compared 
to 32.8% at 24 hours.
In summary, after the first dose of study medication, i.v. perindoprilat 0.167mg 
produced rapid, profound inhibition of plasma ACE which was significantly different from 
placebo from 20 minutes-24 hours post dose. In addition the degree of plasma ACE 
inhibition produced by this treatment was greater than that produced by perindopril 2mg 
p.o. between 5 minutes and 3 hours post dose. All three active treatments produced 
significant inhibition of plasma ACE between 3 and 24 hours post dose. Plasma ACE 
activity was similar in all three treatment groups from 4-24 hours post dose. The degree 
of inhibition of plasma ACE inhibition increased after 2 consecutive doses of perindopril 
2mg p.o. and also after perindoprilat 0.167mg i.v. on day 1 followed by perindopril 2mg
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Figure 7.4:
Angiotensin I concentration (fmoi/ml, mean ± 1SD) following
perindopril 2mg p.o. (■ )  in patients with congestive heart failure.
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Figure 7.5:
Angiotensin II concentration  (fmol/ml, m ean ± 1SD) following 
perindopril 2m g p.o. (■ )  in p a tien ts  with congestive heart failure.
p.o on day 2. Although the relative increases between 24 and 48 hours were small, no such 
increase was seen with consecutive doses of enalapril 2.5mg p.o.
7.3.2 In-vivo ACE inhibition 
Baseline
The assay for angiotensin I was hindered by relative lack of specificity of the 
antibody to Ang I; this resulted in a constant low level background reading of Ang I. This 
phenomenon was problematic where Ang I levels showed no or little rise after ACE 
inhibition, rendering interpretation of Ang II/Ang I+Ang II ratios difficult. Results showed 
wide variation among patients in terms of both baseline Ang I and Ang II levels and the 
response to initiation of ACE inhibitor therapy. Baseline Ang I levels (p=0.365) and Ang 
II (p=0.541) levels were similar among active treatment groups.
The profiles of Ang II/Ang I+Ang II ratio, as a percentage of baseline activity for 
enalapril 2.5mg p.o. and perindopril 2mg p.o. showed an early rise not seen following 
perindoprilat 0.167mg i.v. In neither case did the rise reach statistical significance.
Placebo p.o.
The profiles of Ang II/Ang I+Ang II ratio, as a percentage of baseline activity, 
showed an early rise with placebo therapy, suggesting increased RAS activity at this time. 
The ratio returned to baseline level by the 2 hour time point. There was no significant 
difference in the ratio of Ang II/Ang I + Ang II from baseline at any time point after 2 
hours in the placebo group. Correction for the response to placebo was made for each 
active therapy.
Enalapril 2.5mg p.o.
Mean baseline Angiotensin I concentration was 133 (212) fmol/ml. Mean baseline
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Figure 7.6:
Angiotensin I concentration (fmol/ml, mean ± 1SD) following perindoprilat
0.167m g iv in patients with con gestive heart failure.
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Figure 7.7:
Angiotensin II concentration (fmol/ml, mean ± 1SD) following
perindoprilat 0.167m g i.v (O) in patients with congestive heart failure.
Angiotensin II concentration (1 S.D.) was 22 (30) fmol/ml. Mean plasma angiotensin I 
concentration showed an early rise and there was a plateau of increased angiotensin I 
concentration between 2 and 8 hours post dose. Maximum concentration (404% of 
baseline) was seen at 5 hours post dose (Figure 7.2). Mean angiotensin II concentration 
fell to 37 (80)% of baseline at 6 hours post dose (Figure 7.3).
Perindopril 2mg p.o.
Mean baseline Angiotensin I concentration was 54 (59) fmol/ml. Mean baseline 
Angiotensin II concentration (1 S.D.) was 11 (12) fmol/ml. Mean plasma angiotensin I 
concentration showed a delayed rise in comparison to that seen following enalapril. In 
addition the relative rise in angiotensin I concentration in relation to baseline was less than 
the rise seen after enalapril. The maximum increase (322% of baseline) was seen at 5 
hours post dose (Figure 7.4). Mean plasma angiotensin II concentration showed an early 
fall to 56 (67)% of baseline at 2 hours and a later fall at 8 hours post dose but there was 
no discernible overall pattern to the change in angiotensin II levels (Figure 7.5).
Perindoprilat 0.167mg p.o.
Mean baseline Angiotensin I concentration was 72 (102) fmol/ml. Mean baseline 
Angiotensin II concentration (1 S.D.) was 21 (30) fmol/ml. Mean plasma angiotensin I 
concentration showed an early rise to reach a maximum (308% of baseline) at 1 hour, i.e., 
the end of the infusion period (Figure 7.6). Mean plasma angiotensin II concentration fell 
to 42 (138)% of baseline at 0.82 hours after the start of the infusion (Figure 7.7).
7.3.3 Comparative in-vivo/ ex-vivo ACE inhibition 
Enalapril 2.5 mg p.o.
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Figure 7.8:
P lacebo corrected renin ang io tensin  sy stem  inhibition (% base line  activity) 
a s  a s s e s s e d  by p lasm a ACE inhibition (±)  and Ang II/Ang I+Ang II ratio 
following enalapril 2.5m g p.o. in p a tien ts  with congestive heart failure.
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Figure 7.9:
P lacebo corrected  renin ang io tensin  sy stem  inhibition (% baseline activity) 
a s  a s s e s s e d  by p lasm a ACE inhibition (□ )  and  Ang ll/Angl+Ang II ratio (■ ) 
following perindopril 2m g p .o  in p a tien ts  with congestive heart failure.
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Figure 7.10:
P lacebo  corrected renin ang io tensin  sy s tem  inhibition (% baseline activity) 
a s  a s s e s s e d  by p lasm a ACE inhibition (O ) and  ANg II/Ang I+Ang II ratio (♦ )  
following perindoprilat 0 .167m g i.v. in patien ts  with congestive heart failure.
Maximum mean ACE inhibition as indicated by minimum Ang II/Ang I+Ang II (86.9% 
inhibition) ratio occurred at 5 hours post dose. Mean maximum ACE inhibition as assessed 
by inhibition of plasma ACE occurred at 8.5 (5.4) hours and as assessed by Angll/Ang I + 
Ang II ratio at 8.8 (8.1) hours (p=0.918) (Figure 7.8).
Perindopril 2mg p.o.
Maximum mean ACE inhibition as indicated by minimum Ang II/Ang I+Ang II 
(45.0% inhibition) ratio occurred at 6 hours. Mean maximum ACE inhibition as assessed 
by inhibition of plasma ACE occurred at 9.3 (5.0) hours and as assessed by Ang II/Ang 
I+Ang II ratio at 6.2 (2.4) hours (p=0.128) (Figure 7.9).
Perindoprilat 0.167mg p.o.
Maximum mean ACE inhibition as indicated by minimum Ang II/Ang I+Ang II 
(81.4% inhibition) ratio occurred at 0.67 hours. Mean maximum ACE inhibition as 
assessed by inhibition of plasma ACE occurred at 0.9 (0.2) hours and as assessed by Ang 
II/Ang I+Ang II ratio at 1.8 (2.4) hours (p=0.178) (Figure 7.10). The patterns of in-vivo 
and in-vitro ACE inhibition were similar, with the nadir in the curve at the end of the 1 
hour infusion period being followed by a partial return toward baseline.
7.3.4 Plasma renin activity
Plasma renin activity (PRA) showed wide variation among patients. Mean PRA 
was similar among treatment groups. Mean baseline values (1 SD) were: placebo 8.59 
(10.54) ng Al/ml/hr; enalapril 10.42 (10.0) ng Al/ml/hr; perindopril 5.89 (9.19) ng Al/ 
ml/hr ; perindoprilat 6.84 (8.02) ng Al/ml/hr (ANOVA p=0.729).
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Figure 7.11:
C hange in p lasm a renin activity (ng Al/ml/hr) following placebo p.o. + 
placebo p.o.(D), enalapril 2 .5m g p.o. + enalapril 2 .5m g p.o.fA), 
perindopril 2mg p.o. + perindopril 2m g p.o. (■ ), or perindoprilat 0.167m g i.v. 
+ perindopril 2m g p.o. in patien ts with congestive  heart failure.
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Figure 7.12:
Theoretical profile of RAS inhibition if steric h indrance w ere to occur.
RAS inhibition with oral ACE inhibitor therapy  (□ ) is significantly reduced 
com pared to that see n  with in travenous therapy (■ ) a t any given time point.
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Figure 7.13:
Theoretical profile of RAS inhibition if "slow, tight binding" were to occur.
There is tem poral d issociation  betw een  RAS inhibition a s  m easured from plasm a 
ACE inhibition (□ ) com pared  to  th a t m easu red  from consideration of 
angiotensin peptide co ncen tra tions (■ ).
There were differences among treatment groups in terms of the mean maximum 
rise in PRA in response to treatment. Mean maximum rise in PRA (1 SD) was: placebo 
6.76 (9.24) ng Al /ml/hr; enalapril 15.64 (17.39) ng Al/ml/hr; perindopril 5.71 (8.69) ng 
Al/ml/hr; perindoprilat 11.06 (14.56) ng Al/ml/hr. The change in PRA was significantly 
greater following enalapril compared to placebo between 5-10 hours post dose (ANOVA 
p<0.05). The change in PRA was significantly greater following enalapril compared to 
perindopril at 6 hours (ANOVA p<0.05) (Figure 7.11).
7.4 DISCUSSION
In-vitro ACE inhibition as assessed by plasma ACE activity was similar following 
perindopril 2mg p.o. and enalapril 2.5mg p.o. The absolute values for ACE inhibition were 
greater following enalapril 2.5mg p.o. In addition the angiotensin I response following 
enalapril 2.5 mg p.o. was of earlier onset, of greater magnitude and more sustained than 
that following perindopril 2 mg p.o. No temporal discrepancy was demonstrated for any 
active therapy between in-vitro and in-vivo ACE activity. The relative degrees of in-vitro 
ACE inhibition following enalapril and perindopril are paralleled by the relative degrees of 
in-vivo ACE inhibition, both being relatively greater for enalapril. However, whereas the 
absolute values for in-vitro ACE inhibition are similar between the two active oral 
treatments, in-vivo ACE inhibition is relatively greater following enalapril 2.5mg p.o.
No rise in blood pressure seen after commencement of perindoprilat i.v. A trend to 
an increase in blood pressure was seen soon after both oral enalapril and perindopril. This 
rise in blood pressure was paralleled by a rise in angiotensin I, a fall in angiotensin II and a 
fall in AII/AI+AII ratio over the same time period with both oral treatments. However 
neither the rise in blood pressure nor the rise in AII/AI+AII ratio was statistically
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significant for either treatment. Only a relatively slight rise in AII/AI+AII ratio was 
observed during or after perindoprilat i.v. infusion but with no concomitant rise in blood 
pressure. The lack of blood pressure rise with intravenous therapy contradicts the findings 
of a previous study (MacFadyen et al 1993).
One theory for the differential blood pressure response to oral perindopril and 
intravenous perindoprilat as compared to placebo was steric hindrance between parent 
ester perindopril and active diacid perindoprilat. This study presents no evidence of 
steric hindrance between perindopril and perindoprilat in a clinical setting. The correlation 
between inhibition of plasma ACE and AII/AI+AII ratio, with no temporal discrepancy, 
does not support the theory and initially suggests that measurement of plasma ACE 
activity represents an accurate assessment of the activity of the circulating RAS. The study 
also fails to support the theory that perindopril shows slow, tight binding to ACE. The 
theoretical profiles of RAS inhibition in the cases of steric hindrance and slow tight 
binding are show in Figures 7.12 and 7.13 respectively.
Although plasma ACE inhibition was more prolonged after perindopril 2mg p.o. 
than after enalapril 2.5mg p.o., and the trend of plasma ACE inhibition was downward at 
24 hours, no greater inhibition of plasma ACE was seen at 48 hours than at 24 hours.
The differing plasma renin activity responses to the active therapies are of note.
The rise in PRA seen after enalapril 2.5mg p.o. was significantly greater than after placebo 
between 4 and 10 hours post dose. No difference from placebo was seen with either 
perindopril 2mg p.o. or perindoprilat 0.167mg i.v. However the rise after perindoprilat 
i.v. was quantitatively greater than with oral perindopril. Qualitatively the pattern of PRA 
response differs between perindopril p.o. and perindoprilat i.v., the rise being earlier, and 
sustained with perindoprilat i.v. While the PRA profile after enalapril may reflect the fall in
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blood pressure seen after this treatment, it may alternatively reflect a greater inhibition of 
the RAS than is seen following perindopril p.o. or perindoprilat i.v. in spite of the 
apparently similar plasma ACE inhibition seen with all three treatments. This hypothesis is 
supported by the greater inhibition of the RAS by enalapril compared to perindopril and 
perindoprilat suggested by AII/AI+AII ratios.
Measurement of angiotensin peptides rather than plasma ACE has been suggested 
to be necessary for true estimation of the state of activity of the RAS (Nussberger et al 
1989). The measurement of angiotensin peptides theoretically allows in-vivo investigation 
of ACE activity whereas plasma ACE may overestimate the degree of enzyme inhibition. 
The current assay for angiotensin peptides proved difficult to apply to a large number of 
patients in a clinical setting, the levels of Ang peptides obtained were rather higher than 
those reported from other groups with expertise in this field (Nussberger et al 1986,
1988). However these elevated values may indicate activation of the RAS in the current 
patient population.
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CHAPTER 8
DETERMINANTS OF THE BLOOD PRESSURE RESPONSE TO THE FIRST 
DOSE OF ACE INHIBITOR IN MILD TO MODERATE CHF.
8.1 INTRODUCTION
In spite of clear evidence of their safety, tolerability and efficacy in all grades of 
chronic CHF (The CONSENSUS Trial Study Group 1987, Pfeffer et al 1992, The 
SOLVD investigators 1991, 1992) and in patients with heart failure following acute 
myocardial infarction (AIRE Study Group 1993, Kober et al 1995), a significant 
proportion of patients who may benefit from treatment are not prescribed an ACE 
inhibitor (Rajfer 1983, Clarke et al 1994) and rates of use vary widely (Philbin et al 1996). 
Concerns regarding first-dose hypotension relate to the risk of organ (renal, myocardial or 
cerebral) hypoperfusion which may result.
The overall incidence of first-dose hypotension remains unclear; however the 
occurrence of first dose hypotension was of sufficient magnitude to warrant a reduction in 
the starting dose of enalapril in one of the early trials of ACE inhibitors in CHF (The 
CONSENSUS Trial Study Group 1987). A number of case reports (Cleland et al 1985), 
and the well-published CONSENSUS II study have highlighted the phenomenon. 
Moreover in the CONSENSUS II study, mortality was higher among those patients who 
developed first-dose hypotension after initiation of therapy with enalapril (Swedberg et al 
1992). On the basis of these reports a variety of anecdotal protocols have been developed 
for the initiation of ACE inhibitor treatment in CHF (McMurray et al 1989). Many of 
these have involved admission to hospital and variable periods of diuretic withdrawal and 
blood pressure observation. The possibility of first-dose hypotension is recognised within 
the data sheets of all ACE inhibitors currently marketed in the U.K. On the basis of the
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possibility of a fall in blood pressure on initiation of therapy, the British National 
Formulary continues to advise both admission to hospital, and temporary diuretic 
withdrawal for certain "high-risk" categories of patient with CHF (British National 
Formulary September 1996). Such procedures have obvious implications for both patient 
and physician in terms of inconvenience and allocation of resources and may contribute to 
the failure to prescribe therapy appropriately.
A number of physiological and biochemical parameters may help to identify 
patients at high risk of significant first-dose hypotension. Hyponatraemia and hypo- 
volaemia associated with high doses of loop diuretic are risk factors in patients with more 
severe CHF (Cleland et al 1985, Hodsman et al 1983, Packer et al 1986). However as the 
patient population for whom ACE inhibition is appropriate therapy has widened, patients 
with these easily identifiable, high risk markers have become the minority of those being 
commenced on therapy. Hyponatraemia and hypovolaemia are seldom found in those with 
mild to moderate CHF, for whom the indicators of the likelihood of a significant fall in 
blood pressure have rarely been investigated.
To date only a single study has investigated in a systematic manner the 
determinants of the blood pressure response to ACE inhibition in mild to moderate CHF 
(Motwani et al 1994). These authors used stepwise regression analysis to study the 
possible determinants of the response to a single oral dose of captopril 25mg in 36 patients 
with mild to moderate CHF. Their results suggested that over 70 % of the variability in 
mean arterial pressure response could be explained on the basis of 3 factors. These were: 
the decrease in serum angiotensin II after initiation of treatment (F ratio =10.3, p<0.01); 
the decrease in serum noradrenaline after initiation of treatment (F ratio = 8, p=0.02); and 
the pre-treatment mean arterial blood pressure (F ratio = 5.6, p=0.04). It is of note that of
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Table 8.1
Design of studies 1-3 
Study 1 72 patients, n=12
Study 2 48 patients, n=12
captopril 6.25mg p.o./ enalapril 2.5mg p.o. / 
perindopril 2mg p.o. / enalaprilat 0.25 mg/hr iv 
(6 hours) / perindoprilat 0.167mg/hr iv (6 hours) /placebo
enalapril 2.5mg p.o. / perindopril 2mg p.o. / 
perindoprilat 0.167 mg/hr iv (1 hour) / placebo
Study 3 24 patients, n=12 quinapril 2.5mg p.o./ placebo
the parameters contained within the model only one, baseline MAP, is a baseline 
parameter, and that this had the weakest association with the blood pressure response.
The analysis described here examines the first-dose blood pressure response in 
patients treated with one of a number of ACE inhibitor formulations or with placebo. The 
aims of the study were firstly, to test whether the variability in pharmacodynamic response 
to acute ACE inhibition, as assessed by the change in systemic blood pressure, was 
determined by pharmacokinetic factors, and if inter-agent differences could be identified in 
this regard. Secondly, to investigate the association between the blood pressure response 
and a variety of physiological variables in an attempt to quantify the magnitude of the 
relationship between routinely available clinical and laboratory parameters and the fall in 
blood pressure in response to a single dose of ACE inhibitor.
8.2 METHODS
8.2.1 Patients
A database was constructed from a number of studies of the haemodynamic 
response to the first dose of ACE inhibitor carried out within the University of Glasgow 
Department of Medicine & Therapeutics (MacFadyen et al 1991, MacFadyen et al 1993, 
Squire et al 1994, Squire et al 1996). The database consisted of 144 patients (51-88 years, 
99 men) with CHF, each of whom was recruited to one of the above double-blind, 
placebo-controlled, parallel group studies. The design of each study is shown in Table 8.1. 
Inclusion and exclusion criteria were identical for each study and are detailed in Chapter 4. 
All studies were approved by the local ethical review committee and each patient gave 
written informed consent to participation. All had stable, chronic CHF, New York Heart 
Association functional class II-IV, and were symptomatic on stable doses of diuretic.
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None had previously been exposed to ACE inhibitor therapy. The procedures for 
commencement of therapy, haemodynamic monitoring and blood sampling were identical 
in each study and are described fully in Chapters 4 and 5.
8.2.2 Haemodynamic observations
The procedure for haemodynamic observation and blood sampling was as 
described in Chapter 4. For each of the 3 studies the mean placebo response was estimated 
by smoothing and averaging the individual baseline corrected placebo blood pressure 
measurements. In the placebo group missing blood pressure measurements were estimated 
by taking the mean of the individual preceding and subsequent measurements. Outliers 
were defined as values < 70 % or > 130 % of the nearer of the preceding or subsequent 
value and were replaced by the mean of the preceding and subsequent measurements. 
Three point averaging was applied to smooth each individual blood pressure profile and an 
average placebo profile constructed for each individual study. For each subject a baseline 
correction was made to mean arterial pressure at each time point by subtracting the 
baseline mean arterial pressure. Baseline corrected mean arterial pressure values in the 
active treatment groups were further corrected by subtracting the appropriate baseline 
corrected average placebo response.
8.2.3 Pharmacokinetic analysis
Patients were randomised to receive one of the following treatments: oral 
perindopril 2mg (n=24); oral enalapril 2.5mg (n=24); oral quinapril 2.5mg (n=12); 
intravenous perindoprilat 0.167mg/hour for 6 hours (n=12); intravenous perindoprilat 
0.167mg/hour for 1 hour (n=12); intravenous enalaprilat 0.25mg/hour for 6 hours (n=12). 
Within each study a control group (n=12) was administered oral and/or intravenous
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placebo as appropriate (Table 8.1). In the setting of a double-blind study, plasma 
concentrations of captopril cannot be determined due to the requirement for special 
preparation of plasma. For this reason the 12 patients who received captopril were not 
included in the present analysis. The pharmacodynamic (PD) effect of each of the orally 
administered ACE inhibitors used in these studies is mediated by the active diacid 
metabolite of the parent ester drug. While it is possible to model the absorption of orally 
administered ACE inhibitor and its conversion to the active diacid metabolite, only the 
formation, disposition and elimination of each active diacid metabolite was modelled. The 
pharmacokinetic (PK) analysis thus included a total of 132 patients: 48 who received 
perindoprilat (24 perindopril p.o., 24 perindoprilat i.v.), 36 patients who received 
enalaprilat (24 enalapril p.o., 12 enalaprilat i.v.) and 12 who received quinaprilat (quinapril 
p.o.). The total number of placebo treated patients was 36. When carrying out PK 
modelling, molar doses and concentration levels were used, with 1 mole of the parent ester 
ACE inhibitor generating 1 mole of the active metabolite.
The pharmacokinetics of each drug were evaluated using a number of 
conventional compartmental models. The fit of each model to the data was assessed by the 
residual sum of squares (RSS), the Akaike Information Criterion (AIC)(Yamaoka et al 
1978) and the Schwarz Information Criterion (SIC). Model fitting was carried out using 
the computer package STATIS (Clydesoft, UK).
8.2.4 Pharmacodynamic modelling
For each individual the area under the baseline and placebo corrected MAP curve 
up to 10 hours after initiation of therapy (MAPio) was calculated using a linear 
trapezoidal method. This estimate was used as a direct measure of the magnitude of the
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8.2.5 Pharmacodynamic/Pharmacokinetic modelling
The parameters estimated for each individual obtained in the above pharmaco­
kinetic analysis were used to determine whether the relationship between pharmacokinetic 
data and the haemodynamic response was best described by a linear (where effect depends 
upon plasma drug concentration) or sigmoid (where a maximum effect is attained) 
concentration/ effect model. Models were again fitted using STATIS and assessed by the 
residual sum of squares and Akaike Information Criterion.
Direct PD/PK modelling was carried out using the software package Minitab 
(Minitab Inc, PA, USA). A number of the assessed parameters were not normally 
distributed and non-parametric methods have been used to describe results. All confidence 
intervals (C.I.) are at the 95 % level. Thus a result is significant at the 5 % level if the Cl 
does not contain 0.
Three kinetic models of the pharmacodynamic effect were compared. In the first a 
linear relationship was proposed to relate the mean arterial blood pressure response (E) to 
the measured drug concentration [c];
E = A.[c] + B,
where A and B are the slope and the baseline effect respectively. Two non-linear models 
were proposed: 
a Langmuir model
E = [c].Emax + B ,
[c] + [c50]
and the more general Hill model E = [c]A .Emax + B ,
[c]a + [ c50]a
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Figure 8.1:
Individual drug (enalaprilat) and MAP time profiles following intravenous infusion of 
enalaprilat at a constant rate of 0.25mg/hr for 6 hour in patients with mild to moderate 
CHF.
MAP=mean arterial blood pressure
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Figure 8.2:
Individual drug (perindoprilat) and MAP time profiles following intravenous infusion 
o f perindoprilat at a constant rate o f 0.167mg/hr for 1 hour in patients with mild to 
moderate CHF.
MAP=mean arterial blood pressure
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Figure 8.3:
Individual drug (perindoprilat) and MAP time profiles following intravenous infusion 
of perindoprilat at a constant rate of 0.167mg/hr for 6 hours in patients with mild to 
moderate CHF.
MAP=mean arterial blood pressure
where Emax is the maximum effect, c50 is the concentration at which 50 % Emax occurs,
B is the baseline effect and A is constant.
8.2.6 Influence of physiological variables
The relationship was investigated between a number of baseline physiological 
variables and the magnitude of the blood pressure response, as assessed directly by the 
AUClO and indirectly by the slope of the PD/PK relationship (vide infra). For the 
categorical variables gender (male/female), cardiac rhythm (sinus rhythm, other rhythm), 
aetiology of CHF (ischaemic heart disease/hypertensive heart disease/alcohol related/ 
valvular heart disease/idiopathic) and NYHA class (II/ III+IV), the mean arterial pressure 
responses were compared and 95% confidence intervals calculated for the differences in 
medians between groups for each variable. Patients with NYHA class III and IV CHF 
were considered together in view of the small number of patients with class IV disease.
The strength of association with the MAP response for the baseline value of each 
continuous variable (age, baseline values of mean arterial pressure, diuretic dose, ACE 
activity, plasma renin activity, and each of serum sodium, potassium and creatinine 
concentrations) was quantified using the Spearman rank correlation coefficient. In addition 
stepwise linear regression analysis and best-subsets regression analysis were used to 
determine whether the pharmacodynamic response could be predicted from some subset of 
the above information. Statistical analysis was carried out using Minitab.
8.3 RESULTS
8.3.1 General
Summary statistics for baseline clinical and laboratory features of each treatment 
group are shown in Table 8.2. Initiation of study therapy was in no case associated with
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symptomatic hypotension. In 10 patients randomised to receive 6 hour infusions, study 
treatment was stopped prematurely due to a fall in mean arterial pressure of > 30% of 
baseline, as was stipulated in the study protocol. All remained in the study and 
haemodynamic data were analysed on an 'intention to treat' basis. One patient, a 74 year 
old female who had received oral placebo as study treatment, was unable to tolerate 
subsequent open ACE inhibitor therapy due to symptomatic hypotension after the first 
dose. Plots of plasma drug concentration (diacid metabolite) against time, together with 
placebo- and baseline-corrected change in MAP against time for each treatment are shown 
in Figure 8.1 - 8.6.
8.3.2 Pharmacokinetic analysis
8.3.2.1 Intravenous dosing
Twelve patients received intravenous enalaprilat, 0.25 mg/hr for 6 hours; 5 of the 
infusions were terminated prematurely at between 2 and 5 hours due to excessive falls in 
MAP of > 30 % of baseline (Appendix 1.1). A total of 24 patients were given intravenous 
perindoprilat: 12 received 0.167 mg/hr for 1 hour and 7 received 0.167 mg/hr for 6 
hours. Five further 6-hour infusions were terminated at between 2.5 and 5 hours due to 
excessive falls in mean arterial pressure of > 30 % of baseline (Appendix 1.1).
Pharmacokinetic analysis was carried out for each subject on the basis of the total 
dose of drug administered in each individual. One and two compartment models with first 
order elimination were fitted to the intravenous infusion data using the computer package 
STATIS. In the case of intravenous enalaprilat the data was adequately described by the 
one compartment model (Figure 8.1). Analysis of the residual (observed-predicted vs. 
predicted data) concentration plots suggested that in some cases a 2 compartment model
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Figure 8.4:
Individual drug (enalaprilat) and MAP time profiles following a single dose of enalapril
2.5mg p.o. in patients with mild to moderate CHF.
MAP=mean arterial blood pressure
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Figure 8.5:
Individual drug (perindoprilat) and MAP time profiles following a single dose of
perindopril 2mg p.o. in patients with mild to moderate CHF.
MAP=mean arterial blood pressure
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Figure 8.6:
Individual drug (quinaprilat) and MAP time profiles following a single dose of 
quinapril 2.5mg p.o. in patients with mild to moderate CHF.
MAP=mean arterial blood pressure
was more valid. With only 3 data points after the end of the 6-hour infusion, the 
parameters of the model could not be estimated and superiority of the 2 compartment 
model could not be assumed.
In contrast it was clear from the 1-hour infusion data that the pharmacokinetics of 
perindoprilat were better described by a 2 compartment model (Figure 8.2) and the formal 
analysis confirmed this. Data from the 6-hour infusions again suggested that in some cases 
a 2 compartment model was more valid. Once again there were insufficient data points 
after the end of the infusion to estimate the parameters of the 2 compartment model 
(Figure 8.3).
The estimated individual values for the elimination rate constant (Ke) and volume 
of distribution (Vd) together with the RSS, AIC and SIC for intravenous dosing with 
enalaprilat and perindoprilat are shown in Appendix 1.2 and 1.3 respectively.
8.3.2.2 Oral dosing
The formation, disposition and elimination of each active diacid metabolite ACE 
inhibitor was modelled using a one-compartment model and first-order elimination. From 
the profiles of concentration against time it was evident that it was appropriate to fit a lag 
phase to model formation of the metabolite. Zero-order and first-order methods were 
compared when modelling drug absorption and conversion to the active metabolite. In the 
case of enalapril (Figure 8.4) and quinapril (Figure 8.6) a zero-order process was more 
appropriate in the majority of cases. Residual plots again suggested that a 2-compartment 
model may be more appropriate in a number of individuals but there were insufficient data 
points after the end of the phase of drug absorption and conversion to estimate the model 
parameters. For oral enalapril, individual parameter estimates of Ke and Vd, together with
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Perindoprilat Enalaprilat Quinaprilat
100 -
0
-100
-200
Oral iv 6h Oral
95% CI for median -37 to 23 -55 to 14 -116 to -31 -120 to -60 -174 to -49 -92 to -11
Figure 8.7:
Summary plots showing median, quartiles and range of the pharmacodynamic 
response, as assessed directly from the AUClO o f the pharmacodynamic/ 
pharmacokinetic relationship, following a single dose of ACE inhibitor in patients with 
mild to moderate CHF.
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Figure 8.8:
Summary plots showing median, quartiles and range of the pharmacodynamic 
response, as assessed indirectly from the slope (p-coefficient) of the pharmacodynamic 
/ pharmacokinetic relationship, following a single dose of ACE inhibitor in patients 
with mild to moderate CHF.
RSS, AIC and SIC values are shown in Appendix 2.1 and 2.2 for a 1-compartment model 
with zero-order absorption and a 1-compartment model with 1st order absorption 
respectively. Corresponding results for oral quinapril are shown in Appendix 3.1 and 3.2 
respectively.
There was much greater variation in the data as regards oral perindopril (Figure 
8.5). In only 13 of the 24 individuals could a 1-compartment model with first order 
elimination be fitted to the data. In two patients, drug concentration was still increasing at 
10 hours. Individual pharmacokinetic parameter estimates for oral perindopril are shown 
in Appendix 4.1 and 4.2 for a 1 compartment model with zero-order and first order 
absorption respectively.
8.3.3 Pharmacodynamic analysis
Summary plots showing the median, quartiles and range for the AUClO are shown 
for each drug treatment in Figure 8.7. Enalaprilat oral (95% C.I. for median -120 to -60 
mmHg.h), enalaprilat i.v. (95% C.I. for median -174 to -49 mmHg.h), perindoprilat 1 mg 
i.v. over 6 hours (95% C.I. for median -116 to -31 mmHg.h) and quinaprilat (95% C.I. for 
median -92 to -11) produced a significant fall in mean arterial pressure as estimated by 
AUClO. With perindoprilat given as 0.167 mg i.v. over 1 hour (95% C.I. for median -55 
to 14 mmHg.h) or as oral perindopril (95% C.I. for median -37 to 23 mmHg.h), the 
median AUClO could not be shown to be different from zero.
8.3.4 Pharmacodynamic/pharmacokinetic modelling
Where the plot of pharmacodynamic effect of a drug against time lags behind that 
of plasma drug concentration against time, the plot of drug concentration against effect 
will show an anti-clockwise hysteresis loop. If the data showcompartment requires to be
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Table 8.3
Relationship between categorical variables (gender (male/female), New York Heart Association (NYHA) 
functional class (II/IIHTV), and cardiac rhythm (sinus/other)) and MAP response as assessed by 13- 
coefficient (mmHg/ nmol.l'1) of pharmacodynamic/pharmacokinetic relationship.
Enalaprilat Perindoprilat Quinaprilat All
treatments
Gender (1) Male
(2) Female 
(1) - (2)
95% Cl 
p-value
(Mann-Whitney)
-0.31
-0.23
-0.04
-0.20-0.20
0.72
-0.28
-0.43
0.03
-0.38-0.47
0.92
-0.06
0.01
-0.07
-0.13-0.01
0.10
-0.25
-0.18
-0.04
-0.18-0.14
0.58
NYHA m  + iv  
n
(m  + iv )  - n
95% Cl 
p-value
(Mann-Whitney)
-0.23
-0.38
0.17
-0.01-0.34
0.07
-0.39
-0.32
0.06
-0.36-0.51
0.73
-0.03
-0.04
0.00
-0.10-0.10
0.93
-0.22
-0.24
0.04
-0.12-0.21
0.69
Cardiac rhythm (1) Sinus
(2) Other 
(1) - (2)
95% Cl 
p-value
(Mann-Whitney)
-0.24
-0.33
0.09
-0.07-0.28
0.26
-0.16
-0.61
0.47
0.06-0.95
0.02
0
-0.06
0.04
-0.05-0.10
0.38
-0.16
-0.35
0.17
0.02-0.39
0.03
included in the model to accomodate the delay between profiles. The modelling approach 
detailed in section 8.2.5 showed that the s such a loop then an effect 
pharmacodynamic/pharmacokinetic (PD/PK) relationship was best described by a simple 
linear model with a baseline error term, without the need to fit an effect compartment.
This was confirmed by the formal analysis. Thus a direct linear relationship between the 
pharmacodynamic effect and plasma drug concentration was derived:
MAP/y = a / + (3/ cij ,
where MAP// and cij are mean arterial pressure (baseline and placebo corrected) and 
plasma drug concentration for individual / at time j, and ai and p/ are estimated intercept 
and slope of the fitted line for individual /. The estimated slope (i.e. the P-coefficient) of 
the relationship was taken as an indirect measure of the magnitude of the relationship 
between the pharmacodynamic response and observed drug concentration, ie the PD/PK 
relationship.
Individual values for the estimated slope and intercept of the regression line 
relating fall in MAP to plasma drug concentration are shown in Appendix 5.1. Summary 
plots showing the median, quartiles, range and outliers (>1.5 interquartile range from the 
quartiles) for the p-coefficient of the PD/PK relationship, together with 95% confidence 
intervals for the median, are are shown in Figure 8.8. It is clear from the plots that for 
enalaprilat oral (95 % Cl for median slope -0.52 to -0.29 mmHg/ nmol.1'1) and enalaprilat 
i.v. (95 % Cl for median slope -0.25 to -0.07 mmHg/ nmol.1'1) there was a negative 
estimate of slope, indicating a direct relationship between enalaprilat concentration and fall 
in MAP. In keeping with the pharmacokinetic data the relationship of plasma drug 
concentration to blood pressure response with perindoprilat was more variable. There was 
a direct relationship between concentration and effect for i.v. administration of
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Table 8.4
Relationship between categorical variables ((gender (male/female), New York Heart Association 
(NYHA) functional class (E/III+IV), and cardiac rhythm (sinus/other)) and MAP response as assessed by 
AUCio (mm Hg.h) of MAP/time profile.
Enalaprilat Perindoprilat Quinaprilat All
treatments
Gender (1) Male
(2) Female
(D -(2 )
95% Cl 
p-value
(Mann-Whitney)
-71.4
-100.9
38.8
27.2-83.5
0.26
-13.7
-59.2
37.8
3.8-69.4
0.04
-95.8
-28.7
-50.3
-160.9-274
0.19
-43.4
-75.6
27.6
-5.2-58.1
0.09
NYHA m  + rv 
n
(m  + iv )  - n
95% Cl 
p-value
(Mann-Whitney)
-97.7
-0.90
-7.7
-70.4-53.2
0.88
-27.4
-19.4
-4.2
-40.8-35.3
0.81
-47.0
”-70.7
17.4
-110.6-104.5
0.67
-63.2
-50.2
-3.12
-34.6-29.1
0.86
Cardiac rhythm (1) Sinus
(2) Other 
(1) - (2)
95% Cl 
p-value
(Mann-Whitney)
-65.9
-105.9
41.7
-10.7-94.5
0.12
-27.4
-7.9
1.5
-43.6-40.7
0.93
-67
-64.6
-29.6
-108.8-67.2
0.69
-36.1
-75.6
29.2
0.02-0.39
0.07
perindoprilat over both 6 hours and 1 hour (95% C.I. for median slope -0.39 to -0.1 and 
-1.1 to -0.27 mmHg/ nmol.1'1 respectively). In contrast for perindoprilat given as oral 
perindopril there was no evidence of a direct relationship between concentration and effect 
(95% C.I. for median slope -0.69 to 0.08 mmHg/ nmol.1'1). There was however no 
difference between the oral perindopril and intravenous perindoprilat preparations, the 
95% confidence intervals for a difference between medians (oral-intravenous) being -0.30 
to 0.61 mmHg/ nmol.1'1.
Relatively higher plasma drug concentrations in the face of broadly similar mean 
blood pressure responses were achieved with oral quinapril than with other treatments. 
Thus the estimated slopes defining the PD/PK relationship were smaller in magnitude than 
with other preparations. The 95% C.I. for the median slope were -0.08 to 0.01 mmHg/ 
nmol.1'1.
It is evident from the results that the response to intravenous administration of 
ACE inhibitor is more consistent than to oral therapy. Although for treatments other than 
enalapril (oral or intravenous) no consistent relationship was observed between plasma 
drug concentration and effect, within each treatment group a close relationship between 
plasma drug concentration and blood pressure response was observed for a number of 
individual patients including those receiving oral therapy.
8.3.5 Influence of physiological covariates
Both the direct pharmacodynamic response, as measured by the AUClO, and the 
indirect PD/PK response, as measured by the slope of the linear model, were considered 
when determining which factors may be related to the blood pressure response. As the 
distribution of values for some of the variables was skewed, the Spearman rank correlation
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Table 8.5
Spearman rank correlation coefficient (RCC) for the relationship between the value of continuous 
physiological variables and fall in MAP after a single dose of ACE inhibitor. Results for enalaprilat 
and perindoprilat represent combined results of individual studies.
Physiological variable
Treatment Na+ K+ Cr MAP ACE PRA Age Diuretic
Quinaprilat AUC10
P-coeff
-0 .494
-0.653
-0 .549
-0 .452
-0 .2 6 6
-0 .1 6 8
-0.011
0 .074
0.231
0 .025
-0.017
0.009
-0 .210
-0.021
-0 .052
-0 .190
Enalaprilat AUCio
p-coeff
-0 .042
0.183
0.014
-0.337
-0 .0 0 5
0 .0 4 6
-0 .380
0 .064
-0 .200
0 .036
-0 .276
-0 .294
-0 .010
-0 .020
-0.305
-0 .078
Perindoprilat AUCio
P-coeff
0.011
0.122
0.074
0.082
0 .3 7 0
0 .0 7 8
0.115
-0 .354
0.093
-0 .098
-0 .090
0.050
-0.188
-0.145
-0.051
0.212
All treatments AUCio
p-coeff
-0.125
0.041
-0 .038
0.160
0 .0 0 9
-0 .0 7 0
0 .158
0.068
-0 .177
-0 .143
-0.025
-0 .009
-0.123
-0.112
-0 .164
0.019
coefficient was used to assess the strength of the association of each variable with the 
MAP response. When categorical variables were considered, patients with abnormal 
cardiac rhythm had a greater fall in MAP as assessed by the P-coefficient of the PD/PK 
relationship (95% C.I. for difference between medians, 0.02 - 0.39, p=0.03). Neither 
gender (95% C.I. -0.18 to -0.14, p=0.58), nor NYHA class (95% C.I. -0.12 to 0.21, p= 
0.69) showed any correlation with blood pressure response (Table 8.3).
When AUClO was considered, no categorical variable could be shown to be 
associated with the fall in MAP (Table 8.4). The statistically strongest relationship was 
again with abnormal cardiac rhythm (95% C.I. for difference between medians, -3.87 to 
58.0, p=0.07). Spearman rank correlation coefficient values for p-coefficient and AUClO 
for each continuous variable for each ACE inhibitor drug considered alone and for 
treatments combined are given in Table 8.5. There was no consistent relationship between 
any single covariate and either measure of blood pressure response. Although in each 
study significant correlations between covariates and slope were identified, a number of 
such results can be expected by chance and were not reproduced when studies were 
considered together.
To determine whether the blood pressure response can be predicted from a 
combination of baseline variables, forward stepwise regression analysis was carried out 
using age, gender, cardiac rhythm, New York Heart Association functional class, diuretic 
dose, serum ACE activity, plasma renin activity, and serum sodium, potassium and 
creatinine concentrations as predictor variables with AUClO and p-coefficient as response 
variables. Where the data were skewed, logarithmic and reciprocal transformations were 
also considered. The regression analysis was performed using all active treatments 
considered together and also for each drug treatment individually. The proportion of
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Table 8.6
Stepwise forward regression analysis for MAP response as assessed by AUCio and 
p-coefficient of pharmacodynamic/pharmacokinetic relationship.
AUCiO p-coefficient
Variables 
in model
Adjusted
R2
F P Variables 
in model
Adjusted
R2
F P
MAP 5.8 6.68 0.02 cardiac rhythm 5.8 6.69 0.02
MAP
+PRA
10.6 5.88 0.03 cardiac rhythm 
+PRA
6.7 1.92 0.34
MAP 
+PRA 
+ 1/Cr
13. 6 4.17 0.09 cardiac rhythm 
+PRA
+diuretic dose
7.9 2.19 0.28
MAP
+PRA
+1/Cr
+Age
14.4 1.79 0.37 cardiac rhythm 
+PRA
+diuretic dose
8.8 1.96 0.33
MAP
+PRA
+1/Cr
+Age
+Drug 23.6 6.32 <0.01
cardiac rhythm 
+ PRA
+diuretic dose 
+MAP 
+ Drug 14.2 7.35 <0.01
R2 = percentage variability in response explained by the value predictor variable(s). The R2 
value will increase as more predictor variables are added to the model. Adjusted R2 takes 
account of the number of variables in the model.
ACE = Angiotensin converting enzyme activity; CR = serum creatinine concentration; diuretic 
= daily diuretic dose (mg frusemide or equivalent); MAP = mean arterial pressure; PRA = 
plasma renin activity.
variability (R2) in mean arterial pressure response explained by each predictor variable was 
used to compare contending models.
The results for each individual treatment were similar to the overall analysis and 
are not presented. The subsets of predictors containing between 1 and 4 variables are 
shown in Table 8.6. In no case did the inclusion of a fifth variable other than the nature of 
the ACE inhibitor increase the value of the adjusted R2. The results show that less than 
15% of the variability in mean arterial pressure response can be explained on the basis of 
the considered baseline factors. When the ACE inhibitor agent is also considered, the 
adjusted R2 values increase to 23.6% and 14.2% for AUClO and P- coefficient 
respectively. The models including drug as a variable gave an improved fit (F=6.32, 
p<0.01) but still left over 75% of the variability in response unexplained. Best subsets 
regression analysis gave similar results.
Baseline physiological variables were compared within the population of 24 
patients who received 6-hour intravenous infusion therapy. When the 10 patients in whom 
infusion was terminated prematurely due to the magnitude of the blood pressure fall were 
compared to the remaining 14 who received intravenous treatment, an association 
emerged between the magnitude of the blood pressure response and high baseline plasma 
renin activity (p=0.03, Mann-Whitney U-test, Table 8.7).
8.4 DISCUSSION
This analysis represents the most systematic analysis to date of the first-dose 
blood pressure response on initiation of ACE inhibitor therapy in patients with mild to 
moderate CHF. All patients were studied using a standard protocol of drug administration, 
blood sampling and supine haemodynamic monitoring. Current clinical practice was
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reflected in that, for oral therapy, each agent was administered in its recommended starting 
dose in CHF and on a background of 24-48 hours diuretic withdrawal. The parameters 
studied represent the easily identifiable clinical and physiological variables which are 
routinely available to physicians prior to starting ACE inhibitor therapy. No consistent 
relationship could be established between any pre-treatment parameter and the blood 
pressure response. Even when using the best combination of predictive physiological 
variables (baseline values of mean arterial pressure, plasma renin activity, creatinine 
concentration, age and the ACE inhibitor agent), less than 25% of the variability in blood 
pressure fall could be explained on the basis of baseline information. The results indicate 
that the first-dose hypotensive response cannot be predicted from baseline clinical or 
physiological variables in patients with mild to moderate CHF.
A much more consistent pharmacodynamic response was seen where inter­
individual pharmacokinetic differences are minimised by intravenous dosing. For oral 
therapy, interindividual differences in drug metabolism appear to explain 
pharmacodynamic differences, the blood pressure response largely reflecting the plasma 
concentration of active diacid achieved.
While various parameters have been suggested to predict the likelihood of first- 
dose hypotension on initiation of ACE inhibitor therapy, such assertions are based largely 
on evidence from studies in patients with severe CHF (Cleland et al 1985, Hodsman et al 
1983, Packer et al 1986, Packer 1989). While hyponatraemia and high doses of loop 
diuretic are associated with first-dose hypotension in severe heart failure (Packer 1989), 
studies of the determinants of the blood pressure response in patients with mild to 
moderate CHF are lacking. In a study of the acute effects of oral captopril in 36 patients 
with mild to moderate CHF, neither plasma sodium nor diuretic dose were predictive of
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the blood pressure response (Motwani et al 1994). The present analysis extends these 
results to include oral perindopril and quinapril, and to enalaprilat and perindoprilat given 
intravenously. In spite of a high average daily diuretic dose and wide range of dose in the 
present population, there was no clear relationship to the blood pressure response.
In the study of Motwani et al, the fall in plasma noradrenaline and angiotensin II 
levels in response to initiation of ACE inhibitor therapy correlated with the fall in blood 
pressure (Motwani et al 1994). It is perhaps a limitation of the present study that no 
attempt was made to relate the blood pressure response to baseline levels of atrial 
natriuretic factor, noradrenaline or angiotensin II. However in the study of Motwani none 
of these was predictive of the blood pressure response to initiation of therapy. Moreover, 
information on the level of these neurohormones is not available to the majority of 
physicians in routine practice, and the present study was designed to assess the predictive 
value of routinely available parameters. For similar reasons no attempt was made to relate 
blood pressure response to left ventricular ejection fraction. In the absence of information 
on ejection fraction, the identification of abnormal cardiac rhythm as a predictor of the 
blood pressure response may indicate a subgroup of patients with more severe CHF at 
greater risk of a fall in blood pressure. Similarly the identification of baseline plasma renin 
activity as a predictor of MAP response in those patients receiving intravenous therapy 
suggests an important role for activation of the renin-angiotensin system in the magnitude 
of the blood pressure response in patients with mild to moderate CHF. This is in keeping 
with the correlation between the magnitude of the fall in angiotensin II concentration and 
blood pressure response seen in the study of Motwani.
In the present analysis the extent of the blood pressure fall with acute ACE 
inhibition was related to the level of pre-treatment blood pressure, larger falls being seen
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Table 8.7
Comparison of of baseline physiological values (Mann-Whitney U-test for comparison of medians) in 
patients receiving 6-hour infusion therapy. Patients were divided according to a fall in MAP of > 30% 
(M s, n=10) or < 30% (Mns, n=14) from baseline.
Variable Median
(M ns)
Median
(Ms)
Estimated
(M ns-M s)
95 % C.I. M Ns-M s p-value
PRA 0.965 5.090 -2.905 -5.37 to -0.73 0.03
ACE 22.45 21.35 1.7 -4.3 to 6.6 0.64
MAP 97.5 89.0 5.0 -8.0 to 18.0 0.40
Age 68.5 70.5 -2.0 -8.0 to 4.0 0.70
Na+ 140 139.5 1.5 0.0 to 4.0 0.07
K+ 4.4 4.05 0.1 -0.3 to 0.6 0.77 .
Cr 104.5 95.0 4.0 -17.0 to 25.0 0.70
Diuretic (mg 
frusemide/day
80 80 0 -40 to 40 0.75
ACE = Angiotensin converting enzyme activity; Cr = plasma creatinine concentration; MAP = mean 
arterial pressure; PRA = plasma renin activity.
with higher pre-treatment levels. Although baseline mean arterial pressure was the 
strongest single determinant of the blood pressure response, only a small fraction, 6-7%, 
of the variability in response could be explained on this basis. Further to this, during 
stepwise regression analysis the best subset of baseline variables could explain around only 
25% of the variability in blood pressure response. While Motwani was able to explain 74% 
of the variability in blood pressure response to captopril, mean arterial pressure was the 
only baseline parameter in the predictive model, the others being the magnitude of the falls 
in plasma noradrenaline and angiotensin II levels after initiation of treatment. Pre­
treatment mean arterial pressure is a well recognised determinant of the blood pressure 
response to ACE inhibition in hypertension (Hodsman et al 1983), as is the case for all 
agents which lower blood pressure.
The incidence of first-dose hypotension varies according to patient populations 
and reporting procedures, some suggesting 10-15% (Hodsman et al 1983), others 30- 
40% (Packer et al 1986). In patients with CHF the incidence of symptomatic hypotension 
has been reported as approximately 5-10% (The CONSENSUS Trial Study Group 1987, 
AIRE Study Group 1993); between 2 % and 5% withdraw from treatment as a result. The 
occurrence of first dose hypotension was considered a sufficient problem to warrant 
reduction of the starting dose of enalapril in an early trial of ACE inhibition in CHF (The 
CONSENSUS Trial Study Group 1987). In addition, mortality was higher among those 
patients who developed first-dose hypotension after initiation of therapy with enalapril in 
the CONSENSUS II study (Swedberg et al 1992). However the latter study differs from 
others in that administration of ACE inhibitor was by intravenous infusion and within three 
days of acute myocardial infarction.
On the basis of the above evidence a variety of protocols have been developed for
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the initiation of ACE inhibitor treatment in CHF (McMurray et al 1989). Such procedures 
have implications for the patient in terms of time and inconvenience, and for the individual 
physician and health services as a whole in terms of allocation of resources. Moreover, 
many physicians remain reluctant to start ACE inhibition on the basis of concerns 
regarding first-dose hypotension. A recent postal survey of General Practitioners revealed 
that 46% expressed some degree of concern regarding potential adverse effects of ACE 
inhibition (Houghton & Cowley 1996). Of these, 86% identified hypotension, particularly 
on the first dose, as the adverse effect of most concern. This compared to 45% expressing 
concerns regarding renal impairment and 9% regarding electrolyte disturbance. Moreover, 
GPs expressing such concerns were less likely to have initiated ACE inhibitor therapy for 
CHF. Reluctance to implement the findings of the major trials of ACE inihibitors in CHF is 
not confined to the primary care setting. Marked variation in the prescription of ACE 
inhibition in CHF exists between hospitals (Philben et al 1996). This applies to both 
patients with chronic heart failure (Missouris & MacGregor 1996) and those with heart 
failure after acute myocardial infarction (Sapsford et al 1996). The latter study surveyed 
235 patients with heart failure after MI. In only 20% was ACE inhibitor initiated prior to 
discharge from hospital. Again a proportion of physicians identified the possibility of 
hypotension as a factor in the non-prescription of ACE inhibitors.
From the above, it is evident that identification of individual patients at high risk of 
first-dose hypotension would have therapeutic and economic implications. Moreover, 
identification of those at low risk would perhaps allow more widespread prescription of 
appropriate therapy. In this context it is perhaps surprising that studies of possible agent- 
or dose-related differences in response are rare. Within the dose ranges currently available 
there is good evidence that in any individual patient, there is no difference in the
184
magnitude of blood pressure response to a single dose of either 6.25mg or 25mg of 
captopril (McLay et al 1992). While it has been suggested that the determinants of the 
response to chronic ACE inhibition may differ from those determining the acute response 
(Cleland et al 1987), the available evidence indicates that in patients with CHF the blood 
pressure response to the first dose of ACE inhibitor is the same as that seen after chronic 
treatment (Packer et al 1986, McLay et al 1992). In this context, the occurrence of only a 
single episode of symptomatic hypotension on initiation of therapy in the population of 
144 patients studied here with mild to moderate CHF is reassuring.
In summary, the present study indicates that the blood pressure response to the 
initiation of ACE inhibitor therapy in patients with chronic, stable CHF cannot be 
predicted from baseline pathophysiological variables. The present lack of consensus on 
both the factors which constitute a patient at high risk of significant first-dose hypotension 
and the optimum protocol for the avoidance of the phenomenon in CHF indicate that this 
is the situation as presently perceived in clinical practice. While the magnitude of blood 
pressure response is in general related to plasma drug concentration, inter-individual 
variation in the magnitude and duration of response is high.
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CHAPTER 9
CONCLUDING REMARKS
The studies described here demonstrate differences among prodrug ester ACE 
inhibitor agents in terms of the haemodynamic response to initiation of therapy in patients 
with CHF. However although the average blood pressure response differs from one agent 
to another, there is wide inter-individual variability in the response to any one agent. The 
ranges of responses observed are thus very similar among ACE inhibitor agents.
The apparent transient pressor response to initiation of therapy previously 
observed was inconsistent in the current studies and indeed was observed with placebo. 
This phenomenon is likely to be a manifestation of an alerting response associated with 
the activity of study initiation rather than to the displacement of angiotensin peptides from 
binding sites. No evidence was found for the putative inter-agent pharmacokinetic 
differences of steric hindrance on the one hand and "slow, tight binding" on the other. 
Differences among ACE inhibitors in terms of their binding to plasma and to tissue ACE 
may explain differences in blood pressure response.
The assay of angiotensin peptide concentrations offered no additional information 
over and above that provided by assay of plasma ACE in terms of defining the state of 
activity of the circulating RAS. This may be due to the limitations of the assay in our 
laboratory including those associated with its application to a large number of samples 
from patients in a clinical setting. The assay is unlikely to have advantages over assay of 
plasma ACE activity in standard clinical studies.
The observed inter-individual differences in response to oral therapy appear to be 
related largely to inter-individual pharmacokinetic differences. These findings do not prove
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that plasma ACE inhibition is the mechanism by which ACE inhibitors lower blood 
pressure. However these studies offer no evidence for inhibition of tissue ACE as the 
defining action in this regard. The blood pressure response in the current studies was on 
the whole related to the concentration of ACE inhibitor agent achieved in the plasma.
The analysis described in Chapter 8 represents the largest and most systematic 
investigation of the relationship of baseline clinical and laboratory variables to the blood 
pressure response to initiation of ACE inhibitor therapy. The study shows that the blood 
pressure response can not be accurately predicted using readily available criteria. However 
the correlation of blood pressure response with baseline plasma renin activity, particularly 
where interindividual pharmacokinetic differences were minimised by intravenous 
administration of ACE inhibitor, suggests the importance of activation of the renin 
angiotensin system in the response.
The ACE inhibitors are currently one of the cornerstones of the treatment of 
congestive heart failure. However in spite of their proven benefits, their administration to 
patients for whom they are undoubtedly indicated remains inconsistent. Prescription is 
limited, to some extent at least, by physicians' concerns regarding the possibility of 
symptomatic hypotension on initiation of therapy. However the available literature 
suggests that the phenomenon is infrequent. Moreover, the blood pressure response to the 
first dose of ACE inhibitor is very similar to that seen with later doses. A symptomatic fall 
in blood pressure is an infrequent phenomenon in patients with mild to moderate CHF. 
Although the extent of blood pressure fall can not be predicted with any accuracy, the 
observed differences among agents may provide alternatives for initiation of therapy in 
selected patient groups perceived to be at high risk.
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Appendix 1.1
Infusion time and total dose given by constant rate intravenous 
infusion in Study 1.
A. Perindoprilat (proposed total dose of lmg given by 
constant rate intravenous infusion over 6 hours)
Patient Infusion duration Total dose gr
(hours) (mg)
1 6 1
2 2.5 0.417
3 6 1
4 6 1
5 6 1
6 5 0.833
7 6 1
8 5 0.833
9 5 0.833
10 4 0.667
11 6 1
12 6 0.833
B. Enalaprilat (proposed total dose of 1.5mg given by 
constant rate intravenous infusion over 6 hours)
Patient Infusion duration Total dose given
(hours) (mg)
1 6 1.5
i 6 1.5
3 6 1.5
4 6 1.5
5 2 0.5
6 -> 0.5
7 6 1.5
8 6 1.5
9 J 0.75
10 4 1.0
11 6 1.5
12 > 1.25
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Appendix 1.2
Pharmacokinetic parameters (1 compartment model) for enalaprilat given as constant rate intravenous
infusion, 0.25mg / hr (718nmol / hr) for up to 6 hours.
Patient A Cl VI Ke AUC f 1/2 RSS SIC AIC Time
1 0.229 4.36 19.0 0.229 988 3.02 3457 177 175 6
2 0.440 2.27 11.5 0.198 1893 3.50 23210 217 215 6
3 0.396 2.52 24.1 0.105 1706 6.63 4620 183 181 6
4 0.213 4.70 19.5 0.241 917 2.87 5774 188 186 6
5 0.211 4.74 20.8 0.228 303 3.04 1051 152 150 2
6 0.233 4.30 16.2 0.265 334 2.61 1168 154 152 2
7 0.139 7.21 29.6 0.243 597 2.85 1102 153 151 6
8 0.623 1.60 16.1 0.100 2683 6.95 7014 192 190 6
9 0.267 3.75 12.1 0.310 575 2.24 4430 182 180 3
10 0.170 5.89 22.3 0.265 487 2.62 1184 155 153 4
11 0.133 7.50 27.3 0.275 574 2.52 880 148 146 6
12 0.253 3.96 20.2 0.195 907 3.55 1519 160 158 5
where
A coefficient for exponential term
Ke Elimination rate constant (h r '!)
Cl Clearance (1 / hr)
tl/2 Elimination half-life (hours)
V Volume of distribution (1)
AUC Area under the plasma concentration time curve (nmol.I"1.hour)
RSS Residual sum of squares
SIC Schwarz Information Criterion
AIC Akaike Information Criterion
Time Infusion duration (hours)
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Appendix 1.3
Pharmacokinetic parameters (1 compartment model) for perindoprilat given as constant rate
intravenous infusion, 0.167mg / hr (489nmol /  hour) for up to 6 hours.
Patient A Ke Cl V Cmax tl/2 AUC RSS AIC SIC Time
1 0.179 0.169 5.57 33.1 66 4.1 527 582 138 140 6
2 0.166 0.352 6.03 17.1 55 2 203 405 130 132 2.5
3 0.412 0.109 2.43 22.3 94 6.4 1006 1083 151 153 5
4 0.152 0.233 6.57 28.2 67 3 447 607 139 141 6
5 0.551 0.121 1.81 15.0 108 5.7 675 3310 174 176 2.5
6 0.080 0.233 12.5 53.6 32.3 3 235 227 118 120 6
7 0.016 0.292 9.4 32.1 47.9 2.4 312 445 132 134 6
8 0.277 0.214 3.62 16.9 117.5 3.2 810 2402 167 170 6
9 0.088 0.317 11.3 35.7 36.7 2.2 216 261- 121 123 5
10 0.155 1.1 6.45 58.6 38 0.6 303 336 126 128 4
11 0.162 0.178 6.18 34.7 56.4 3.9 475 142 108 HO- 6
12 0.308 0.169 3.24 19.2 117.5 4.1 906 2357 167 169 6
where
A coefficient for exponential term
Ke Elimination rate constant (hr'1)
Cl Clearance (1 / hr)
V Volume of distribution (1)
Cmax Peak drug concentration (nmol/1)
11/2 Elimination half-life (hours)
AUC Area under the plasma concentration time curve (nmol. I’1.hour)
RSS Residual sum of squares
SIC Schwarz Information Criterion
AIC Akaike Information Criterion
Time Infusion duration (hours)
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Appendix 1.4
Pharmacokinetic parameters (1 compartment model) for perindoprilat given as constant rate
intravenous infusion, 0.167mg / hr (489nmol / hr) for 1 hour.
Patient A Ke Cl VI Cmax f 1/2 AUC RSS SIC AIC
37 0.071 0.333 14.1 42.3 11.16 2.1 34.7 82.2 94.2 92.2
38 0.064 0.767 15.6 20.4 17.03 0.9 31.3 106 99.3 97.3
39 4.699
40 0.131 0.376 7.64 20.3 26.73 1.8 64 204 112 110
41 0.0294 0.554 34.1 61.5 7.34 1.3 14.3 25.8 67.6 65.8
42 0.0303 0.289 32.9 114 4.699 2.4 14.9 16.3 61.8 59.9
43 0.0469 1.93 20.9 10.4 20.26 0.4 23.4 165 108 106
44 0.0758 0.108 13.2 122 4.405 6.4 37 6.22 40.6 38.7
45 0.0372 1.23 26.9 21.8 13.22 0.6 18.2 -98 97.5 95.7
46 0.15 0.278 6.68 24 29 2.5 73.2 38.7 125 123
47 0.0266 0.922 37.6 40.8 8.22 0.8 13 38.9 79.2 77.2
48 0.0245 0.883 39.3 44.5 9.4 0.8 12.4 31.7 71.5 69.7
where
A coefficient for exponential term
Ke Elimination rate constant (hr'1)
Cl Clearance (1 / hr)
V Volume of distribution (1)
Cmax Peak drug concentration (nmol/1) 
tj/2 Elimination half-life (hours)
AUC Area under the plasma concentration time curve (nmol.f 1.hour])
RSS Residual sum of squares
SIC Schwarz Information Criterion
AIC Akaike Information Criterion
Note:
Patient 39: No fit - Cmax at 50 minutes (4.99u), 60mins = 4.7u, 75mins = .29u, 90mins = 2.64u,
105 mins = 1.45u, 120mins = 1.18u, 180mins = 4.7u
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Appendix 1.5
Pharmacokinetic parameters (2 compartment model) for perindoprilat given as constant rate intravenous
infusion, 0.167mg / hr (489nmol / hr) for 1 hour.
Patient A
xlOO
alpha B beta
xlOO
AUC tl/2
alpha
t|/2
beta
klO Cl Vdss RSS AIC SIC
37 0 .922 9 .30 0.142 8.82 74 0 0 7 4 7 .86 0 .65 6.61 70.4 16.3 63.8 67.8
38 1.70 4 .12 0123 14.9 68.7 0 .168 4 .66 0.65 7.12 42.3 19.2 67.1 71.1
39
40 5.33 0 .929 1.12 0.987 572 0 .746 70 .2 0 .052 0.855 82.7 121 104 108
41 0.668 5.45 0.093 6.73 48 .6 0 .127 10.3 0 .429 10.1 140 4.27 35.6 39 .4
42 0.451 4 .26 0.060 7.06 31 .7 0.163 9.82 0 .362 15.4 204 5.36 41 .6 45 .6
43 2.79 4 .75 0 .180 7.36 102 0 .146 9.41 0.7 4.8 56.6 22.5 70.3 74.3
44 0 .396 2 .00 0.211 2.56 105 0 .346 27.1 0 .062 4 .64 178 1.62 17.2 21
45 1.92 2 .78 0.380 2.08 195 0 .249 33.3 0.153 2.5 4 1 4 22.8 70.5 74.5
46 2.43 .997 0.169 14.1 94 .6 0 .695 4 .92 0 .249 5.17 32.7 368 126 130
47 0.968 3 .72 0.149 4.29 77 .6 0 .186 16.2 0 .267 6.3 138 2.8 28.6 32.6
48 0.541 10.1 0.058 16.6 30.8 0 .068 4 .19 1.02 15.9 87.8 13.5 57.4 61.2
where
A, B Coefficients for exponential term
alpha, beta Macroscopic rate contstants (hr*1)
ti/2 -alpha Half life of drug during distribution phase
ti/2 -beta Half life of drug during elimination phase
Cl Clearance (1 / hr)
Vdss Volume of distribution at steady state (1)
Time Infusion duration (hours)
AUC Area under the plasma concentration time curve (nmol.I'1.hour)
( AUC = Dose / Cl)
klO Elimination rate constant from compartment 1 to 0
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Appendix 2.1
Pharmacokinetic parameters for enalaprilat (1 compartment, zero order absorption) given as a
single dose of enalapril 2.5mg p.o.
Patient A Ke Tabs Tlag RSS AIC SIC Cmax AUC ti/2 Cl/F V/F
13 0.0265 0.3610 4.19 1.820 183.00 117.0 122.0 33.010 136 1.92 37.6912 104.408
14 0.0697 0.0862 3.79 0.626 42.20 86.6 90.8 24.400 357 8.04 14.3585 166.572
15 0.0712 0.1560 5.19 1.700 27.90 77.9 82.1 34.440 365 4.44 14.0438 90.025
16 0.3510 0.0432 4.77 1.220 307.00 128.0 132.0 71.760 1798 16.00 2.8509 65.994
17 0.1250 0.0665 4.72 0.435 66.80 96.2 100.0 39.040 641 10.40 7.9969 120.254
18 0.0840 0.0650 9.70 0.302 121.00 109.0 113.0 17.220 430 -10.70 11.9209 183.399
19 0.0952 0.0458 7.71 1.600 10.80 57.9 62.1 18.940 488 15.10 10.5041 229.347
20 0.1150 0.0821 5.51 1.330 13.30 62.4 66.6 34.440 588 8.45 8.7177 106.184
21 0.1280 0.0857 4.32 1.970 52.70 91.2 95.4 44.490 656 8.08 7.8140 91.179
22 0.0749 0.0172 2.57 0.657 4.94 41.5 45.5 6.315 384 40.30 13.3490 776.102
23 0.0781 0.1100 3.88 0.623 4.48 39.5 43.7 34.440 400 6.31 12.8150 116.500
24 0.0811 0.0856 4.78 1.180 17.70 68.3 72.5 28.700 415 8.10 12.3518 144.297
25 0.1220 0.0656 6.38 0.791 21.00 72.0 72.6 32.430 627 10.60 8.1754 124.626
26 0.1140 0.0826 4.02 0.779 42.80 86.9 91.0 38.460 585 8.39 8.7624 106.082
27 0.0645 0.1000 3.33 1.220 177.00 117.0 121.0 26.690 330 6.91 15.5333 155.333
28 0.0622 0.0838 4.46 1.140 23.60 74.4 78.5 21.810 319 8.26 16.0690 191.754
29 0.1450 0.0492 5.31 1.200 21.10 72.0 76.2 31.290 744 14.10 6.8898 140.036
30 0.0681 0.0876 3.28 2.450 2.82 29.8 34.0 25.830 349 7.91 14.6877 167.668
31 0.6340 0.0208 4.79 0.878 67.50 96.5 101.0 65.440 3252 33.20 1.5763 75.782
32 0.0380 0.0910 7.32 1.920 19.20 70.0 74.2 12.060 195 7.61 26.2872 288.870
33 0.0839 0.1180 4.05 0.323 168.00 116.0 120.0 38.170 430 5.88 11.9209 101.025
34 0.1080 0.0884 5.55 1.810 49.70 90.0 94.2 34.440 554 7.84 9.2527 104.669
35 0.0402 0.0271 8.72 1.660 1.31 13.7 17.9 4.880 206 25.50 24.8835 918.210
36 0.1730 0.0730 6.61 1.080 275.00 126.0 130.0 53.390 888 9.49 5.7725 79.076
Abbreviations as per previous Tables.
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Appendix 2.2
Pharmacokinetic parameters for enalaprilat (1 compartment, 1st order absorption) given as single dose of 
enalapril 2.5mg p.o.
Patient A Ke Ka Tlag RSS AIC SIC Cmax
13 147 0.322 0.478 2.40 347 131 135 33.01
14 92.4 0.0963 0.48 0.954 10.8 57.9 62.1 24.4
15 169 0.180 0.305 2.28 71 97.5 102 34.44
16 1570 0.123 0.139 1.46 39.1 85 89.2 71.76
17 120 0.111 0.238 0.862 170 116 120 39.04
18 478 0.0972 0.109 1.03 179 117 121 17.22
19 195 0.0924 0.117 0.695 13.9 63.3 67.5 18.94
20 728 0.145 0.164 1.62 27.9 77.9 82.1 34.44
21 141 0.130 0.296 2.38 84.4 101 105 44.49
22 7.6 0.0201 0.794 0.925 2.57 27.8 32 6.315
23 141 0.175 0.317 0.934 63.9 95.3 99.5 34.44
24 827 0.166 0.180 1.44 56.5 92.7 " 96.9 28.7
25 557 0.119 0.138 1.18 77.5 99.4 104 32.43
26 169 0.152 0.276 1.11 93.2 103 107 38.46
27 549 0.136 0.517 1.63 197 119 123 26.69
28 69.0 124 0.271 1.43 54.6 92 96.2 21.81
29 52.6 0.0586 0.301 1.53 17.9 68.6 72.8 31.29
30 43.1 0.104 0.538 2.75 20.9 71.9 76.1 25.83
31 94.7 0.0346 0.303 1.26 199 119 123 65.44
32 115 0.134 0.175 2.83 17.2 67.7 71.9 12.06
33 121 0.159 0.343 0.585 207 120 124 38.17
34 718 0.154 0.176 2.37 59.4 93.8 98 34.44
35 314 33.8 0.0737 0.107 2.5 1.65 18.5 4.88
36 597 0.121 0.149 1.54 276 126 130 58.39
where
A coefficient for exponential term
Ke elimination rate constant (hr*1)
Ka Absorption rate constant
Tlag Lag phase (absorption)
RSS Residual sum of squares
AIC Akaike information criterion
SIC Schwarz information criterion
where
A= coefficient for exponential term; Ke= elimination rate constant in hr*1 
Ka= absorption rate constant in hr'1; Tlag=Lag phase time in hours 
AUC=Area under the plasma concentration time curve in nmol / (1/ hour) 
Other abbreviations as per previous Tables.
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Appendix 3.1
Pharmacokinetic parameters for quinaprilat (1 compartment, zero order absorption) givena s a
single dose o f quinapril 2.5mg p.o.
Patient A Ke Tabs Tlag RSS AIC SIC AUC ti/2 Cmax Cl/F V/F
1 0.2120 0.168 2.53 0.890 244 123 128 1210 4.11 149.30 4.7107 28.0401
2 0.1120 0.202 1.31 1.380 241 123 127 641 3.43 103.80 8.8924 44.0216
3 0.2520 0.252 1.59 1.920 734 147 151 1435 2.75 252.10 3.9721 15.7624
4 0.1080 0.189 2.36 1.300 263 125 129 617 3.68 86.24 9.2382 48.8796
5 0.1170 0.167 1.31 0.406 759 147 151 669 4.14 94.76 8.5202 51.0190
6 0.6540 0.061 2.16 0.315 2874 175 179 3726 11.4 197.80 1.5298 25.0785
7 0.0638 0.371 1.99 1.420 321 129 133 364 1.87 83.07 15.6593 42.2085
8 0.0907 0.269 1.88 0.788 714 146 150 517 2.58 100.60 11.0251 40.9857
9 0.1390 0.164 1.19 2.810 1000 153 157 793 4.23 123.50 7.1879 43.8286
10 0.0907 0.272 4.95 0.571 863 150 154 517 2.55 72.11 11.0251 40.5336
11 0.1850 0.184 2.71 1.010 854 143 147 1054 3.77 157.40 5.4080 29.3911
12 0.0655 0.279 3.24 0.899 282 121 125 373 2.48 71.62 15.2815 54.7724
A Coefficient for exponential term
Ke Elimination rate constant (hr'1)
Tabs Absorption time (hours)
Tlag Lag time (hours)
RSS residual sum of squares
SIC Schwartz Information criterion
AIC Akaike Information Criterion
AUC Area under plasma concentration time curve (nmol/[l/hour])
Cmax Peak plasma drug concentration
Cl Clearance (1/hr)
F Bioavailability
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Appendix 3.2
Pharmacokinetic parameters for quinaprilat (1 compartment, first order absorption) given as a
single dose o f quinapril 2.5mg p.o.
Patient A Ke Ka Tlag RSS AIC SIC AUC ti/2 Cmax
1 496 0.253 0.562 1.140 467 137 141 1078 2.74 149.30
2 202 0.260 1.08 1.470 421 135 139 588 2.66 103.80
3 1750 0.433 0.639 1.950 109 107 111 1301 1.60 252.10
4 230 0.262 0.721 1.600 412 134 139 559 2.65 86.24
5 175 0.234 1.190 0.580 797 148 152 602 2.96 94.76
6 281 0.0779 0.765 0.537 3228 178 182 3243 -8 .90 197.80
7 304 0.450 0.943 1.660 602 142 147 354 1.54 83.07
8 210 0.308 1.110 1.120 1187 157 161 491 2.25 100.60
9 145 0.174 9.570 2.980 981 153 157 820 3.99 123.50
10 1390 0.286 0.325 0.933 755 147 151 579 2.42 72.11
11 374 0.234 0.626 1.310 1964 160 164 1000 2.96 157.40
12 9390 0.408 0.415 1.180 629 137 141 377 1.70 71.62
A Coefficient for exponential term
Ke Elimination rate constant (hr'1)
Ka Absorption rate constant (hr-1)
Tlag Lag time (hours)
RSS residual sum of squares
SIC Schwartz Information criterion
AIC Akaike Information Criterion
AUC Area under plasma concentration time curve (nmol/[l/hour])
Cmax Peak plasma drug concentration
Cl Clearance (1/hr)
F Bioavailability
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Appendix 4.1
Pharmacokinetic parameters (1 compartment, zero order absorption) for perindoprilat
given as single dose o f perindopril 2mg p.o.
Patient A Ke Tabs Tlag R SS A IC SIC Cmax A U C Cl/F V/F
13
14
8.5
21.15
15 0 .0 8 2 4 0.165 1.46 0 .577 172 116 120 32.31 224 12.1 73.4
16
17
0 .0895 0 .0640 2.81 0 .809 7.11 4 9 .2 53 .4 14.68
11.16
243 11.2 1755
18 0 .1 3 4 0 .0553 6 .54 0 .228 42 .3 86 .7 9 0 .8 17.62 365 7.4 134
19 0.121 0.0373 .510 0 .625 13.2 6 2 .2 6 6 .4 12.34 329 8.2 221
20 0 .0 8 8 9 0 .0416 1.08 0.661 9.63 55 .6 59 .7 9.98 241 11.3 271
21
22
23
0 .1 0 6 0.0281 4.11 1.34 5.08 42.1 46 .3 7 .34
7.34  
17.62
287 9.5 337
24
25
0 .117 0 .0229 2.89 0.963 2.53 27 .5 31 .7 7.34
10.28
319 8.51 372
26
27
0 .0417 0.205 4.44 0.27 54 .8 88.1 92 12.92
10.87
113 24.0 117
28 0 .089 0.0521 3.71 0 .549 7 .2 4 7 .5 51 .5 10.57 241 11.3 216
29
30
31
0 .0 9 4 6 0 .0315 3.53 0.52 3.43 3 2 .7 3 6 .6 8.57
6.17
22.61
257 10.6 335
32 0 .0 6 0 4 0 .0418 .384 1.19 8 .42 4 8 .5 52.3 7.93 164 16.5 396
33 0 .0358 0 .0126 1.03 0.782 21 .5 6 9 .4 73 .7 12.63 97.3 27.9 2214
34
35
36
0 .169 0 .0519 4.18 0.832 43 .7 83 .5 87.5 20 .26
12.04
10.0
458 5.9 114
13 No fit - cones still increasing at 10 hours - absn not 0 order
14 No fit - double peak at 3h (12u) and 8h (21u)
17 No fit - reached 9.4u by 4h then all cones > 8u
19 No fit - double peaks at 1.75h (12.34u) and 6h (12.34u)
20 No fit - double peaks at 2-3h (lOu) and 6h (8.7u)
22 No fit - double peaks at 6h (7u) and lOh (7.3u)
23 No fit - double peaks at 6h (17.6u) and lOh (17u)
25 No fit - double peaks at 4h (9.7u) and 8h (10.3u)
27 No fit - double peaks at 4h (9.7u) and 8h (10.3u)
30 No fit - double peaks at 4-5h (6.2u) and 8h (5.6u)
31 No fit - still in absorption phase at 1 Oh
34 1st order absorption may be better
35 No fit - double peaks at 3h (9.7u) and 6h (12.04u)
36 No fit - double peaks at .83 (lOu) and 4h (5u)
where
A= coefficient for exponential term; Ke= elimination rate constant in hr'1 
Tabs=Absorption time in hours; Tlag=Lag phase time in hours 
AUC=Area under the plasma concentration time curve in nmol / (1/ hour) 
Cl/F=Clearance/Bioavailability; WF=Volume of distribution /Bioavailability 
Other abreviations as per previous Tables.
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Appendix 4.2
Pharmacokinetic parameters for perindoprilat (1 compartment, 1st order absorption) given as single dose
o f perindopril 2mg p.o.
Patient A Ke Ka Tlag RSS AIC SIC Cmax AUC tl/2
13 8.5
14 21.15
15 43 .5 0.167 1.52 0 .762 232 122 127 32.31 218 3.93
16 17.2 0 .0647 0.795 1.17 12.3 6 0 .7 64.9 14.68 244 10.7
17 11.16
18 47 .3 0 .0769 0.183 0.550 49 .4 89 .9 94.1 17.62 357 9.02
19 12.8 0.0413 3.47 0.658 12.2 6 0 .6 64.8 12.34 307 16.8
20 10.7 0 .0469 2.04 0.800 9 .49 55 .3 59.4 9.98 223 14.8
21 9 .3 4 0 .0335 0.511 1.85 2 .68 2 8 .7 32.9 7.34 261 20.7
22 7.34
23 17.62
24 7 .86 0 .0252 0.716 1.25 2 .5 2 2 7 .4 31.5 7.34 301 27.5
25 10.28
26 146 0.264 0.335 0.637 3 8 .9 81 .2 85.2 12.92 117 2.63
27 10.-87
28 16.6 0 .0640 0.459 0.833 1.01 8.13 12.1 10.57 224 10.8
29 9 .3 4 0 .0362 0.532 0.868 9.3 52 .6 56.6 8.57 241 19.2
30 6.17
31 22.61
32 6 .98 0 .0433 6.21 1.22 8.81 49 .3 53.1 7.93 160 16
33 13.9 0.145 2.41 0.975 32 .5 7 7 .6 81.6 12.63 90.2 4.79
34 40 .3 0 .0778 0.336 1.14 10.5 55.1 59.1 20.26 398 8.91
35 12.04
36 10.0
13 No fit - cones still increasing at 10 hours - absn not 0 order
14 No fit - double peak at 3h (12u) and 8h (21u)
17 No fit - reached 9.4u by 4h then all cones > 8u
19 No fit - double peaks at 1.75h (12.34u) and 6h (12.34u)
20 No fit - double peaks at 2-3h (lOu) and 6h (8.7u)
22 No fit - double peaks at 6h (7u) and lOh (7.3u)
23 No fit - double peaks at 6h (17.6u) and lOh (17u)
25 No fit - double peaks at 4h (9.7u) and 8h (10.3u)
27 No fit - double peaks at 4h (9.7u) and 8h (10.3u)
30 No fit - double peaks at 4-5h (6.2u) and 8h (5.6u)
31 No fit - still in absorption phase at lOh
34 1 st order absorption may be better
35 No fit - double peaks at 3h (9.7u) and 6h (12.04u)
36 No fit - double peaks at .83 (lOu) and 4h (5u)
where
A= coefficient for exponential term; Ke= elimination rate constant in hr'1 
Ka= absorption rate constant in hr'1; Tlag=Lag phase time in hours 
AUC=Area under the plasma concentration time curve in nmol / (1/ hour) 
Other abbreviations as per previous Tables.
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Appendix 5.1
Estimated individual P-coefficient and intercept of regression line relating fall in MAP to 
plasma drug concentration.
(3-coefficient (mm He.nmol'1.!)
Patient
Quinaprilat 
Oral Study 3
Enalaprilat 
I.V. Study 1
Enalaprilat 
Oral Study 1
Enalaprilat 
Oral Study 2
Perindorilat 
I. V. Study 1
Perindoprilat 
Oral Study 1
Perindoprilat 
Oral Study 2
Perindoprilat 
I.V. Study2
1 -0.02 0.04 -1.03 -0.64 0.00 -1.78 -0.80 -0.88
2 -0.10 -0.05 -0.14 -0.82 -0.47 -0.22 -1.14 0.03
3 -0.06 -0.03 -0.23 -0.40 -0.11 0.08 -0.53 0.60
4 -0.10 -0.15 -0.14 -0.26 -0.39 -0.91 -1.52 -0.48
5 -0.01 -0.34 -0.22 -0.56 -0.20 0.85 -1.80 -1.59
6 0.03 -0.25 -0.62 -0.31 -0.32 -1.10 -0.70 -1.75
7 0.03 -0.24 -1.33 -0.19 -0.1 -0.25 ’ 0.07 -0.86
8 0.01 -0.09 -0.28 -0.45 -0.13 0.57 0.78 -1.21
9 -0.13 -0.17 -0.4 -0.23 -0.46 0.46 1.21 -0.61
10 -0.06 -0.46 -0.31 -0.62 -0.67 1.02 -0.77 -0.06
11 0.03 -0.05 -0.52 0.92 -0.07 -0.83 -0.16 -0.60
12 -0.06 -0.15 -0.35 -0.48 -0.15 -0.12 0.31 -0.50
Intercept (mm Hg)
Patient
Quinaprilat 
Oral Study 3
Enalaprilat 
I.V. Study 1
Enalaprilat 
Oral Study 1
Enalaprilat 
Oral Study 2
Perindoprilat 
I. V. Study 1
Perindoprilat 
Oral Study 1
Perindoprilat 
Oral Study 2
Perindoprilat 
I.V. Study2
1 -1.43 -2.68 -9.73 4.13 1.95 5.96 4.2 1.38
2 -2.31 -2.5 -1.96 7.02 0 -6.24 11.05 -4.07
3 -4.26 -0.34 -6.42 2.12 -6.3 -2.31 9.57 1
4 -2.39 5.5 -4.24 10.04 7.68 0.05 12.21 -0.26
5 -9.86 4.56 -5.13 -1.75 -9.54 -8.2 2.04 10.2
6 -2.21 1.8 -0.15 3.84 3.62 10.56 12.45 0.75
7 -1.46 -5.07 -6.15 1.26 1.83 2.11 -2.11 -2.88
8 -1.73 -13.63 -1.47 1.07 5.4 -5.41 -2.41 -3.83
9 -2.36 -2.34 -5.29 -6.76 -3.1 8.6 2.45 6.9
10 -7.3 3.88 0.95 ' 2.97 6.85 4.91 4.47 -6.49
11 9.77 0.06 3.43 1.37 -2.4 0.44 4.97 4.53
12 -2.79 -12.87 -8.07 2.27 1.44 o -8.17 4.24
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Appendix 6.1
Demographic data for patients receiving enalaprilat
Patients l-12=0.25mg/hr i.v. enalaprilat for 6 hours; 13-36=2.5mg oral enalapril 2.5mg
Patient Study Age Sex Aetiology NYHA Cardiac
Rhythm
+
Na
+
K Creatinine InitialMAP
Initial
ACE
Initial
PRA
1 1 72 2 1 3 1 146 3.6 87 102 17.9 0.09
2 1 71 2 2+3 3 1 140 3.6 94 121 31.4 0.28
o 1 74 2 2 3 2 140 4.5 101 116 27.2 0.97
4 1 60 1 3 3 2 141 4.7 117 79 19.9 3.16
5 1 73 1 1 3 -> 137 3.7 182 80 24.3 4.53
6 1 76 2 2 3 2 140 3.9 82 75 13.9 5.65
7 1 60 1 3+4 2 1 138 4.4 117 99 28.9 12.24
8 1 77 2 4 3 1 143 3.5 132 112 25.6 9.09
9 1 77 2 2 3 2 143 3.3 76 91 16.8 4.28
10 1 70 1 2+3 3 2 139 4.5 97 110 19.4 5.79
11 1 66 1 2 2 2 140 4.0 108 102 22.2 1.50
12 1 63 1 3+4 3 2 140 4.2 106 102 22.9 2.23
13 1 63 2 2+1 2 1 141 4.1 8 5 - 133 26 0.74
14 1 63 1 2 3 1 142 3.8 107 101 46 1.66
15 1 82 2 2 3 1 139 4.9 84 94 17 1.80
16 1 66 2 2 3 1 138 3.0 180 116 16 6.05
17 1 58 1 ->j 3 1 145 4.3 111 107 20 0.47
18 1 78 1 3 3 1 136 4.1 77 97 20 1.12
19 1 60 2 1+3 3 1 137 5.2 93 120 23 45.00
20 1 60 1 2+3 j 5 139 3.6 120 101 22 7.53
21 1 66 1 2 3 1 141 4.6 117 91 20
22 1 62 1 2 2 1 142 4.8 75 112 15 0.52
23 1 64 2 2 2 1 140 3.7 83 99 29 0.69
24 1 69 2 J 2 1 144 3.8 89 103 21 0.47
25 2 75 2 2+4 3 1 135 4.1 89 76 17.5 25.34
26 2 75 1 2 2 n4m 141 4.1 120 92 19.6 3.64
27 2 70 1 2+4 2 1 141 4.7 113 100 19.2 0.75
28 2 55 1 2 3 2 138 4.4 118 74 8.9 4.03
29 2 71 1 1 4 1 135 4.0 121 86 35.7 14.64
30 2 76 1 2 2 2 139 4.1 122 83 27.9 3.71
31 2 66 2 4 2 125 3.3 177 69 30.5 33.30
32 2 72 1 T 2 2 139 4.1 100 80 17.9 3.36
33 2 66 1 2 2 2 130 3.4 101 102 26.4
34 2 69 2 2 2 143 4.9 126 104 22.8 9.44
35 2 75 1 2 3 2 135 4.3 98 83 22.4 3.19
36 2 77 1 3 1 138 4.7 192 106 27.7 13.30
Age years Aetiology (Sum of all present) Cardiac rhythm (Sum of all present)
Sex l=Male; 2=Female 1 Alcohol related cardiomyopathy 1 Atrial fibrillarion
Na* mmol/L 2 Ischaemic heart disease 2 Sinus rhythm
KT mmol/L 3 Hypertensive heart disease 4 Sinus rhythm -  Frequent ventricular
Cr pmol/L 4 Valvular heart disease premature complexes
MAP mm Hg
PRA Plasma Renin activity in ng A l ml/hr
ACE Angiotensin Converting Enzyme activity 
(ng Ang I/ml/Hour)
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Appendix 6.2
Demographic data for patients receiving perindoprilat. Patients 1-12=0.167mg/hr iv 6hr; 13-36=2mg oral; 
37-48=0.167mg/hr iv lhr______________________________________________________________
Patient Study Age Sex Aetiology NYHA Cardiac
Rhythm Na
+
K Creatinine InitialMAP
Initial
ACE
Initial
PRA
1 1 64 1 3 3 2 143 4.5 130 96 15.3 0.72
2 1 84 2 2 2 1 132 4.3 83 97 23.5 2.11
3 1 87 2 2 3 1 145 4.6 122 92 22.7 0.35
4 1 62 2 2 3 1 140 4.6 68 83 29.7 0.96
5 1 65 1 2 2 2 140 4.4 80 100 14.1 0.33
6 1 68 1 2 2 2 141 3.7 129 110 26.2 1.96
7 1 64 1 2+3 2 2 138 4.6 87 80 13.9 0.54
8 1 71 2 2+3 3 2 139 4.8 118 83 15.6 13.05
9 1 63 1 2+3 3 2 136 4.6 83 78 26.9 10.2
10 1 60 2 3 3 2 140 3.9 93 87 19.8 9.77
11 1 71 1 3+2 2 2 141 3.6 81 80 12.5 8.7
12 1 73 1 3+2 3 4 140 3.8 142 83 29.8 5.7
13 1 59 1 2+3 -J 4 136 3.9 121 118 29 1.4
14 1 72 2 3 2 1 140 3.6 62 83 12 10.93
15 1 85 2 1+3 J 1 141 5.2 11L 87 33 4.76
16 1 74 2 2 3 2 140 3.9 89* 98 18 1.21
17 1 66 1 2+3 J 2 140 3.5 124 113 24 4.3
18 1 64 2 2 2 2 143 4.4 87 102 37 1.4
19 1 60 1 2 0 2 143 3 159 96 20 11.9
20 1 69 1 3 3 1 144 3.6 143 84 20 2.15
21 1 73 1 2+3 ;> 2 143 3.8 169 98 21 0.2
22 1 61 1 2 j 2 138 4 179 88 26 10.2
23 1 79 2 3 *■> 2 143 3.1 117 101 17 3.07
24 1 69 2 3+2 2 2 139 4.4 98 111 29 0.79
25 2 71 1 2 3 2 136 5.3 162 85 14.8 1.49
26 2 66 1 2 3 1 140 4 118 84 20.1 3.8
27 2 79 2 2+3 2 1 141 4.1 114 85 17 2.77
28 2 75 1 2 2 2 145 4.2 112 94 17 3.12
29 2 78 1 2 3 1 143 4.4 83 95 24.5 1.63
30 2 69 1 1 3 1 135 4.4 99 103 32 0.66
31 2 73 2 2 3 2 135 4.7 287 93 18.9 2.81
32 2 52 1 2+1 3 2 139 4 102 75 34.3 3.14
33 2 56 1 2 2 2 145 4.8 101 101 18.6 9.25
34 2 71 2 2 2 2 135 4.2 99 102 25.7 34.24
35 2 64 1 2 2 2 136 4.7 96 82 34 2.22
36 2 81 2 2 3 2 141 3.5 123 76 24.4 8.87
37 2 67 *> 4+3 2 1 140 4.3 97 108 33.5 4.81
38 2 54 2 2 2 2 141 4.2 87 71 17.4 2.24
39 2 62 1 2 3 2 137 4.8 94 82 10 2.96
40 2 61 2 2 3 2 137 3.2 107 84 21.9 27.7
41 2 76 1 2 j 1 144 4.4 115 110 15.6 0.34
42 2 53 1 1 3 1 139 3.9 140 83 29.2 6.83
43 2 77 1 2 3 1 134 3.3 131 94 35.8 19.6
44 2 69 1 2 2 2 141 5 172 102 16.2 2.76
45 2 71 1 2 3 1 136 4.1 127 87 30 4.58
46 2 69 1 2 J 2 144 4.9 109 80 25.6 0.62
47 2 71 1 2 3 2 133 4.1 140 95 18 1.45
48 2 60 1 2 2 2 135 3.3 121 92 21 8.21
Abbreviations as per Appendix 6.1
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Appendix 6.3
Demographic data for patients receiving quinaprilat. 
Patients l-12=oral quinapril 2.5mg
Patient Study Age Sex Aetiology NYHA Cardiac
Rhythm
+
Na
+
K Creatinine InitialMAP
Initial
ACE
Initial
PRA
1 1 79 2 3+2 3 1 146 3.6 87 102 17.9 0.09
2 1 67 1 2 3 1 140 3.6 94 121 31 .4 0.28
3 1 88 2 2 3 2 140 4.5 101 116 27.2 0.97
4 1 81 2 3 3 1 141 4.7 117 79 19.9 3.16
5 1 75 1 2 3 2 137 3.7 182 80 24.3 4.53
6 1 85 2 2+3 3 2 140 3.9 82 75 13.9 5.65
7 1 68 2 3 2 2 138 4 .4 117 99 28 .9 12.24
8 1 61 2 2+3 3 2 143 3.5 132 112 25 .6 9.09
9 1 76 1 2 3 2 143 3.3 76 91 16.8 4.28
10 1 74 1 2 3 1 139 4.5 97 110 19.4 5.79
11 1 83 2 2 2 1 140 4.0 108 102 22 .2 1.50
12 1 72 1 24 3 1 140 4 .2 106 102 22 .9 2.23
Age years Aetiology (Sum of all present) Cardiac rhythm (Sum of all present)
Sex l=Male; 2=Female 1 Alcohol related cardiomyopathy 1 Atrial fibrillation
Na" mmol/L 2 Ischaemic heart disease 2 Sinus rhythm
KT mmol/L 3 Hypertensive heart disease 4 Sinus rhythm + Frequent ventricular
Cr pmol/L 4 Valvular heart disease premature complexes •
MAP mm Hg
PRA Plasma Renin activity in ng Al ml/hr
ACE Angiotensin Converting Enzyme activity 
(ng Ang I/ml/Hour)
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Appendix 7.1
Spearman rank correlation coefficient for the relationship between p-coefficient of regression line 
relating fall in MAP to plasma drug concentration, and baseline continuous variables.
Drug Form Study N a+ K+ Cr Initial
M A P
Initial
A C E
Initial
PRA
A ge Diuretic
dose
Quinaprilat oral 3 -0.653 -0 .452 -0 .1 6 8 0 .0 7 4 0 .025 0.009 -0.021 -0 .190
Enalaprilat i.v . 1 0.607 -0 .144 -0 .1 0 2 0 .493 0.231 -0.755 0.035
Enalaprilat oral 1 0.355 -0 .34 0.441 -0 .133 -0 .268 -0.024 -0 .032
Enalaprilat oral 2 -0.524 -0 .225 -0 .0 8 4 -0 .3 2 2 0 .168 -0.193 -0 .349
Enalaprilat oral/i. v. 1+2 0.183 -0 .337 0 .0 4 6 0 .0 6 4 0 .036 -0.294 -0 .020 -0.078
Perindoprilat i.v . 1 0.513 0.085 0 .2 9 8 -0 .166 -0 .573 -0.329 0 .298
Perindoprilat oral 1 0.036 -0 .046 0 .573 -0.371 -0.011 0.228 0 .088
Perindoprilat oral 2 -0 .074 -0.011 0 .165 -0 .312 0 .235 0.364 -0 .354
Perindoprilat i.v. 2 -0.116 0.021 -0 .651 -0 .685 -0 .273 -0.049 -0 .26
Perindoprilat oral/i.v. 1+2 0.122 0 .082 0 .0 7 8 -0 .354 -0 .098 0.050 -0 .145 0.212
A ll treatments oral/i.v. 1+2+3 0.041 0 .160 -0 .0 7 0 0 .068 -0 .143 -0 .009 -0 .112 0.019
Age years
Sex l=Male; 2=Female
Na" mmol/L
K" mmol/L
Cr pjnol/L
MAP mm Hg
PRA Plasma Renin activity in ng Al ml/hr
ACE Angiotensin Converting Enzyme activity
(ng Ang I/ml/Hour)
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Appendix 7.2
Spearman rank correlation coefficient for relationship between AUC 10 (Area under mean arterial 
pressure curve to 10 hours after initiation of therapy) and baseline continuous variables.
D rug Form Study N a+ K+ Cr Initial
M A P
Initial
ACE
Initial
PRA
A ge Diuretic
dose
Quinaprilat oral J -0 .494 -0 .549 -0 .2 6 6 -0.011 0.231 -0 .017 -0.21 -0 .052
Enalaprilat i.v. 1 0 .102 0.081 -0 .1 2 6 -0 .162 -0.175 -0.643 -0.021
Enalaprilat oral 1 0.158 -0.253 -0 .2 3 8 -0 .2 8 4 -0 .07 -0 .138 -0 .176
Enalaprilat oral 2 0.028 0.271 -0 .2 9 4 -0 .5 8 8 -0 .42 -0 .382 -0.109
Enalaprilat oral/i.v 1+2 -0 .042 0.014 -0 .0 0 5 -0 .380 -0 .200 -0 .276 -0.010 -0.305
Perindoprilat i.v. 1 0.271 -0 .157 0.441 -0 .0 8 5 -0 .294 0 .028 -0.07
Perindoprilat oral 1 0 .176 0.475 0 .5 2 4 -0 .207 0.589 -0 .126 -0.161
Perindoprilat oral 2 0.028 0.197 -0 .021 0 .0 0 4 -0 .014 -0 .098 -0.469
Perindoprilat i.v. 2 -0 .134 -0.011 0 .1 1 2 0 .462 -0 .28 -0 .315 0.063
Perindoprilat oral/i.v. 1+2 0.011 0.074 0 .3 7 0 0 .115 0.093 -0 .090 -0.188 -0.051
A ll treatments oral/i.v. 1+2+3 -0.125 -0.038 0 .0 0 9 0 .158 -0 .177 -0 .025 -0.123 -0 .164
Age years
Sex l=Male; 2=Female
Na' mmol/L
IC mmol/L
Cr |imol/L
MAP mm Hg
PRA Plasma Renin activity in ng A l ml/hr
ACE Angiotensin Converting Enzyme activity
(ng Ang I/ml/Hour)
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